Scleroderma Lung Study III (SLS III ): 
Combining the anti -fibrotic effects of pi[INVESTIGATOR_7735] (PFD) 
with mycophenolate (MMF) for treating scleroderma -
related interstitial lung disease  
Protocol Identifying Number: UCLA -SLS3  
 
Principal Investigator   
[INVESTIGATOR_68020] D. Roth, M.D.  
Division of Pulmonary & Critical Care  
Department of Medicine, 43-229 CHS 
David Geffen School of Medicine/UCLA  
Los Angeles, CA [ZIP_CODE]- 1690 
Tel: ([PHONE_13518]  
Fax: ([PHONE_13519] 
[EMAIL_12385]  Co-Principal Investigator   
[INVESTIGATOR_256492], M.D., M.Sc.  
Division of Rheumatology  
Dept. of Internal Medicine, Suite 7C27  
Univ. of Michigan School of Medicine  
[ADDRESS_876207] , SPC 5422 
Ann Arbor, MI  [ZIP_CODE]  
Tel: (734) 232- 2104   
Fax: (734) 763- 5761 
[EMAIL_1861]  
 
Data Coordinating Center Director / Principal Statistician  
Cathie Spi[INVESTIGATOR_8614], D.Sc  
Department of Biostatistics  
School of Public Health II  
University of Michigan  
1415 Washington Heights, Rm M4507  
Ann Arbor, MI [ZIP_CODE] -2029  
Tel: (734) 615- 5469  
Fax: (734) 647- 3711 
[EMAIL_7094] 
  
IND:   IND# 135848 
Michael D. Roth, M.D.  
   David Geffen School of Medicine/UCLA  
 
Financial support for an Investigator -Initiated Study provided by :    
[CONTACT_8229], Inc.  
[ADDRESS_876208]  
South San Francisco, CA [ZIP_CODE]  
 
Protocol Version Number:  v.2.5 
Protocol Version Date: 11/ 17/[ADDRESS_876209] of Participating  Clinical Sites as of June 30 , 2020 : 
(15 to 25 participating sites anticipated)  
Site #  Institution  Location  
1 [LOCATION_011] University, School of Medicine  [LOCATION_011], MA  
2 David Geffen School of Medicine at UCLA*  Los Angeles, CA  
[ADDRESS_876210] Medical School, Brigham & Wom en’s Hospi[INVESTIGATOR_111465], MA  
5 Hospi[INVESTIGATOR_23176], [LOCATION_001] [LOCATION_001] , NY 
6 Johns Hopkins University School of Medicine  Baltimore, MD  
7 Medical University of South Carolina  Charleston, SC  
8 Northwestern University Feinberg School of Medicine  Chicago, IL  
9 Rutgers Robert Wood Johnson Medical School  New Brunswick, NJ  
10 University of [LOCATION_004], San Francisco, School of Medicine  San Francisco, CA 
11 University of Colorado  Denver  Denver, CO 
12 University of Michigan Medical School**  Ann Arbor, MI   
13 University of Minnesota Medical School  Minneapolis, MN  
14 University of Pi[INVESTIGATOR_645446], PA  
15 University of [LOCATION_007] Medical School at Houston  Houston, TX  
16 University  of Utah School of Medicine  Salt Lake City, UT  
17 University of Washington School of Medicine  Seattle, WA  
20 University of Indiana Heatlh  Indianapolis, IN  
 
*Also serves as Clinical Coordinating Center  
**Also serves as Data Coordinating Center  
 
 
ii 
 Table of Contents  
LIST OF ABBREVIATIONS  .............................................................................................................................. 1  
STATEMENT OF COMPLIANCE  ................................................................................................................................. 4  
PROTOCOL SUMMARY  .............................................................................................................................................. 5  
SUMMARY SCHEMATIC OF STUDY DESIGN  ......................................................................................................... 10 
SUMMARY TABLE OF STUDY VISITS AND ASSESSMENTS  ................................................................................. 11 
1 KEY ROLES  ......................................................................................................................................................... 12 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE .................................... 16 
2.1  Background Information  ............................................................................................................... 16 
2.1.1  Prevalence & Course of SSC -ILD & the Need for New Treatments  .......................................... 16 
2.1.2  Effectiveness of Immune Suppression for the Treatment of SSc -ILD ...................................... 17 
2.1.3  The Importance of Addressing Fibrosis in Addition to Inflammation  ...................................... 20 
2.1.4  Pi[INVESTIGATOR_7735]: a Drug of Interest for Treating the Fibrotic Aspect of SSc -ILD ............................ 22 
2.1.5  The Documented Efficacy of Pi[INVESTIGATOR_652587]  ........................................ 23 
2.1.6  The Feasibility of Combining PFD with MMF for the Treatment of SSc -ILD ............................ 25 
2.2  Rationale and Study Approach  ...................................................................................................... 26 
2.3  Potential Risks and Benefits  .......................................................................................................... 28 
2.3.1  Known Potential Risks  .............................................................................................................. 28 
2.3.2  Known Potential Benefits  ........................................................................................................ 41 
3 STUDY OBJECTIVES AND PURPOSE  ............................................................................................................... 41 
4 STUDY DESIGN AND ENDPOINTS  .................................................................................................................. 42 
4.1  Description of the Study Design  .................................................................................................... 42 
4.2.1  Primary Endpoint  ……………..  ............................................................................................... 42 
4.2.2  Secondary Endpoints  …… ......................................................................................................... 42 
4.2.3 Other Important Endpoints  ..................................................................................................... 43 
4.2.4  Exploratory Endpoints  .............................................................................................................. 44 
5 STUD Y ENROLLMENT AND WITHDRAWAL  .................................................................................................. 44 
5.1  Participant Inclusion Criteria ......................................................................................................... 44 
5.2  Participant Exclusion Criteria ........................................................................................................ 45 
5.3  D iscontinuing Drug Treatment  or Complete  Withdrawal from the Study  .................................... 48 
5.3.1  Reasons for Discontinuing Drug Treatment or Withdrawing from Study  ............................... 48 
5.3.2  Definition and Handling of Treatment Failures  ....................................................................... 48 
5.3.3  Handling of Premature Participant Withdrawals  ..................................................................... 49 
5.4  Premature Termination or Suspension of Study  ........................................................................... 49 
6 STUDY AGENT  ................................................................................................................................................... 50 
6.1  Study Agent(s) and Control Description  ........................................................................................ [ADDRESS_876211] Storage & Stability  ...................................................................................................... 52 
6.1.4  Route, Administration, Titration Schedule and Target Dose  ................................................... 52 
iii 
 6.1.5  Pre-specified Dose Adjustment & Modifications  ..................................................................... 53 
6.1.6  Duration of Therapy  …………..  .................................................................................................. 58 
6.1.7  Tracking of Dose and Drug Compliance  ................................................................................... 58 
6.2  Study agent Accountability Procedures  ........................................................................................ 59 
6.2.1  Responsibilities of the Central Pharmacy Core  ........................................................................ 59 
6.2.2  Responsibilities of the Clinical Site Pharmacy .......................................................................... 59 
6.2.3  Site Investigator Responsibility  ................................................................................................ 59 
6.2.4  Monitoring & Compliance Oversight by [CONTACT_36909]  .................................. 59 
7 STUDY PROCEDURES AND SCHEDULE  .......................................................................................................... 59 
7.1  Study Procedures/Evaluations  ...................................................................................................... [ADDRESS_876212] of Care Study Procedures  ......................................................................................... 64 
7.2  Study Schedule  .............................................................................................................................. 65 
7.2.1  Screening Visits (Study Day -90 through 0; Screening Visit #1&2)  .......................................... 65 
7.2.2  Enrollment/Baseline Visit (Study Day 0; Visit #1)  .................................................................... 66 
7.2.3  Follow -up Visits (Months 0.5 -18, Study Visits #2 -21) .............................................................. 67 
7.2.4  Final Phone Follow -up Visit / Early Termination Final Phone Visit  .......................................... 68 
7.2.5  Follow -up for Participants who Prematurely Discontinue  Study Drug Treatment or who 
Completely Withdraw from the Study  ..................................................................................... 68 
7.2.6  Unscheduled Visits for Additional Safety Monitoring  ............................................................. 69 
7.2.7  Long- term Follow -up ….. .......................................................................................................... 69 
7.3  Summary of Study Schedule and Assessments  ............................................................................. 69 
7.4  Concomitant Medications & Treatments During the Study  .......................................................... 71 
7.5  Prohibited Medications and Treatments During the Study  .......................................................... 71 
7.5.1  Prohibited Medications & Treatments with DMARD Activity .................................................. 71 
7.5.2  Prohibited Medications & Treatments that may Increase Immune Suppression Risk  ............ 71 
7.5.3  Prohibited Medications that may Interfere with Study Drug Absorption/Metabolism .......... 72 
7.5.3  Restrictions on Medications with Other Adverse Interactions  ................................................ 72 
7.6  P
rophylactic Medications, Treatments, and Procedures  .............................................................. 73 
8 ASSESSMENT OF SAFETY  ................................................................................................................................ 73 
8.1  Specification of Safety Parameters  ............................................................................................... 73 
8.1.1  Definition of Adverse Events (AEs)  .......................................................................................... 73 
8.1.2  Definition of Serious Adverse Events (SAEs)  ............................................................................ 74 
8.1.3  Definition of Unanticipated Problems (UP – unexpected AEs & Problems)  ............................ 74 
8.2  Classification of an Adverse Event  ................................................................................................ 75 
8.2.1  Severity of Event  …. ........................................................................................................... 75 
8.2.2  Relationship to Study Drug  .................................................................................................... 755 
8.2.3  Expectedness  … ............................................................................................................ [ADDRESS_876213]  …… ......................................................................................................... 76 
8.3  Adverse Event Reporting  ............................................................................................................... 76 
8.3.1  Adverse Event Reporting  ......................................................................................................... 77 
iv 
 8.3.2  Serious Adverse Event Reporting  ............................................................................................. 77 
8.3.3  Unexpected Adverse Event/Problem (UP) Reporting  .............................................................. [ADDRESS_876214] -Study Adverse Events  ................................................................................. 79 
8.4  Study Halting Rules  ........................................................................................................................ 79 
8.5  Safety Oversight  ............................................................................................................................ 79 
8.5.1  Morbidity and Mortality Committee  ....................................................................................... 79 
9 CLINICAL MONI TORING  .................................................................................................................................. 80 
10 STATISTICAL CONSIDERATIONS  .................................................................................................................... 81 
10.1  Statistical and Analytical Plans  ....................................................................................................... 81 
10.2  Statistical Hypotheses  .................................................................................................................... 81 
10.3  Analysis Datasets  ............................................................................................................................ 81 
10.4  Description of Statistical Methods  ................................................................................................. 82 
10.4.1  General Approach  …. ........................................................................................................... 82 
10.4.2  Analysis of the Primary Efficacy Endpoint  ............................................................................... 82 
10.4.3  Analysis of the Secondary Endpoints and Exploratory Outcomes  ........................................... 83 
10.4.4  Safety Analyses  …. ........................................................................................................... 84 
10.4.5  Adherence & Retention Analyses  ............................................................................................ 84 
10.4.6  Baseline Descriptive Statistics  .................................................................................................. 84 
10.4.7  Planned Interim Analyses  ........................................................................................................ 84 
10.4.8  Additional Sub -Group Analyses  ............................................................................................... 85 
10.4.9  Multiple Comparison/Multiplicity Analyses  ............................................................................ 85 
10.4.10   Tabulation of Individual Response Data  ................................................................................ 85 
10.4.11    Exploratory Analyses  ............................................................................................................. 85 
10.5  Sample Size ..................................................................................................................................... 85 
10.5.1  Introduction & Background to Sample Size Determination  .................................................... 85 
10.5. 2 A
ssumptions  …. ........................................................................................................... 86 
10.5.3  Defining the Primary Study Outcome  ...................................................................................... 87 
10.5.4  Clinical Trial Scenarios & Simulations to Estimate Study Power in Treatment Naïve P atients  [ADDRESS_876215] of a Mixed Population of Treatment Naïve and Previously -treated Patients on the 
Estimate of Study Power  .......................................................................................................... 89 
10.6  Measures to Minimize Bias  ............................................................................................................ 93 
10.6.1  Enrollment/Randomization/Masking Procedures  ................................................................... 93 
10.6.2  Evaluation of Success of Blinding  ............................................................................................. 93 
10.6.3  Breaking the Study Blind/Participant Code  ............................................................................. 93 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .................................................. 94 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ......................................................................................... 95 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  .............................................................................................. [ADDRESS_876216] KEEPI[INVESTIGATOR_1645]  ................................................................................................. 112 
14.1  Data Collection and Management Responsibilities  ..................................................................... 112 
14.2  Study Records Retention  .............................................................................................................. 113 
14.3  Protocol Deviations  ...................................................................................................................... 113 
14.4  Publication and Data Sharing Policy  ............................................................................................. 113 
15 STUDY ADMINISTRATION AND OVERSIGHT  ............................................................................................. 114 
15.1  Study Leadership  .......................................................................................................................... 114 
15.1.1  UCLA Administrative & Contracting Core  .................................................................................. 115 
15.1.2  Data Coordinating Center (DCC)  ............................................................................................ 116 
15.1.3  Executive Committee  ………………………………………………………………………………………………………. 116 
15.1.4  Steering Committee ………………….  .......................................................................................... 117 
15.1.5  Data & Safety Monitoring Board (DSMB)  .............................................................................. 117 
15.1.6  Study Cores  …………………………………………………………………………………………………………………….. [ADDRESS_876217] POLICY  ................................................................................................................... 119 
16.1  Compliance with 21 CFR part 54  .................................................................................................. 119 
16.1.1  Disclosable Financial Interests & Arrangements under 21 CFR part 54  ................................ 119 
16.1.2  Completion of Forms FDA 3455 & 3454 under 21 CFR part 54 ............................................. 120 
16.2  Compliance with Local State and University Regulations & Policy  .............................................. 121 
17  EMERGENCY DISASTER/ PANDEMIC MANAGEMENT  PLAN  ........................................................................ [ADDRESS_876218]  ........................................................................................................................................................ 125 
 
 
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876219] Aspartate Aminotransferase  
ATS American Thoracic Society  
AUC  Area under the curve  
BID Twice daily  
BDI Baseline Mahler Modified Dyspnea Index  
BAL Bronchoalveolar lavage  
BUN  Blood Urea Nitrogen  
CDC Center for Disease Control  
CFR Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
Cmax  Maximum concentration  
CMP  Clinical monitoring plan  
CMV  Cytolomegalovirus  
COVID -19 Coronavirus Disease  2019  
Cr Creatinine  
CRF  Case Report Form  
CRISS  Combined Response index in Systemic Sclerosis  
CTCAE  Common Terminology Criteria for Adverse Events V4.03 -2010  
CYC Cyclophosphamide  
CYP Cytochrome P450  
DCC  Data Coordinating Center  
DLCO  Single -Breath Diffusing Capacity of the Lung for Carbon Monoxide  
DLCO -Hb-% DLCO, adjusted for age, height, gender and hemoglobin  
DMARD  Disease -modifying antirheumatic drug  
DSMB  Data Safety Monitoring Board  
ECG Electrocardiogram  
eCRF  Electronic Case Report Forms  
ERS European Respi[INVESTIGATOR_652588]1  Forced Expi[INVESTIGATOR_652589]-% Forced vital capacity as a percentage of the age -, height -, gender - and race -adjusted 
predicted value  
GERD  Gastroesophageal reflux disease  
GCP Good Clinical Practice  
GGO  Ground glass opacification  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   2 GLP  Good Laboratory Practices  
GMP  Good Manufacturing Practices  
H&P  History and physical  
HBV  Hepatitis B virus  
HCV  Hepatitis C virus  
Hgb Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act  
HRCT  High resolution computerized tomography  
HRCT -TLC HRCT -measured total lung capacity at maximum inspi[INVESTIGATOR_652590] -related quality of life  
IB Investigator’s Brochure  
IFN-γ Interferon -gamma  
ILD Interstitial lung disease  
IND  Investigational New Drug Application  
IPF Idiopathic pulmonary fibrosis  
IRB  Investigational Review Board  
JC Polyomavirus JC  
LCQ Leicester Cough Questionnaire  
LFTs  Liver function test  
MCP -1 Macrophage chemotactic protein -1 
MCTM  Markov Chain Transition Matrix  
mITT  Modified intention to treat  
MPA  Mycophenolic acid  
MPAG  phenolic glucuronide metabolite of MPA  
MMF  Mycophenolate mofetil ; same as CellCept  
MMP  Matrix metalloproteinase  
MOP  Manual of Procedures  
mRSS  Modified Rodnan Skin Score  
NIH  National Institutes of Health  
NSIP  Non-specific interstitial pneumonia  
OHRP  Office for Human Research Protections  
PAH  Pulmonary arterial hypertension  
PDGF  Platelet derived growth factor  
PFD Pi[INVESTIGATOR_7735] ; same as Esbriet  
PFT Pulmonary function test  
PI  [INVESTIGATOR_652591] -29 Patient -reported outcomes measurement information system 29 -item health profile  
PVAN  Polyomavirus associated nephropathy  
QA Quality Assurance  
QC Quality Control  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876220]. George's Respi[INVESTIGATOR_652592] (same as Systemic Sclerosis)  
SSc-lc Scleroderma with limited cutaneous features  
SSc-dc Scleroderma with diffuse cutaneous features  
SSc-ILD Scleroderma -related interstitial lung disease  
TDI Transitional Mahler Modified Dyspnea Index  
TEAE  Treatment -emergent adverse event  
TGF-β1 Transforming growth factor beta -[ADDRESS_876221]  Upper limit of normal  
UP  Unanticipated  Problem  
US  [LOCATION_002]  
WBC  White blood cell  
 
  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   4 STATEMENT OF COMPLIA NCE  
 
This trial will be conducted with Good Clinical Practice (GCP) and in accordance with the Code 
of Federal Regulations on the Protection of Human Subjects ( 21 CFR Part 50). The Principal 
Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without documented approval from the applicable Institutional Review Board s (IRBs), except 
where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.   
 
I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments.  
Principal Investigator:  
[INVESTIGATOR_68020] D. Roth, M.D.   ( Print/Type Name )  
Signed:  
 
 
__________________________________________________________________________ 
(Signature )  
 
Date:   11/17/2021   (version 2.5)    

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   5   
PROTOCOL SUMMARY  
Title:  SCLERODERMA LUNG STUDY III (SLS III)  
Précis:  A Phase II multi -center, double -blind, parallel group, randomized and 
placebo -controlled clinical trial addressing the treatment of patients with 
active and symptomatic Scleroderma-related interstitial lung disease (SSc -
ILD). 150 patients who are either treatment naïve or only recently started 
treatment  (<6 mo of prior treat ment with a potentially disease -modifying 
therapy) will be randomized in a 1:1 assignment to receive either oral 
mycophenolate mofetil (MMF) and a placebo (Plac ) or a combination of 
oral MMF and oral pi[INVESTIGATOR_7735] (PFD), with both regimens administered for 
18 months. The primary assessment will be the change from baseline over 
the 18 month treatment period , as measured at 3 -month intervals,  in the 
course of the For ced Vital Capacity measured as a percentage of the age- , 
height -, gender - and race -adjusted predicted value ( FVC-%). Key secondary 
outcomes will include changes over time in dyspnea, skin score , diffusing 
capacity  and high resolution computerized tomograph y (HRCT) measures 
of interstitial lung disease  ILD). Tolerability and t oxicity of the two 
treatment s will also be assessed .  
Objectives:  
 Primary Hypothesis:  
The primary hypothesis is that the rapid onset and anti -fibrotic effects 
of PFD, which have been observed in the treatment of Idiopathic Pulmonary Fibrosis (IPF), will complement the delayed anti-inflammatory and immunosuppressive effects of MMF, to produce a significantly more rapid and/or greater impr ovement in lung function 
over time than occurs in patients receiving control therapy with MMF and Plac.  
A secondary objective is to demonstrate that combination therapy with PFD and MMF is well tolerated, in comparison to MMF alone, and 
not associated with  limiting toxicity that impacts on the overall 
treatment effect.  
Endpoint s Primary Endpoint : 
The primary endpoint  is the change from baseline, measured at 3 -
month intervals, in the mean forced vital capacity (represented as the 
percentage of the age- , height -, gender - and race -adjusted predicted 
value,  i.e. FVC -%) over the course of the 18 -month double -blind 
treatme nt period.   
Pre-specified Secondary Endpoints : 
1. The change from baseline to 18 months, measured at 3 -month 
intervals, in the following disease measures:  
• Single -breath diffusing capacity for carbon monoxide (DLCO), 
calculated as a percent of the age -, heigh t-, gender -, race - and 
hemoglobin -adjusted predicted value ( DLCOHb -%).  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   6 • Modified Rodnan Skin Score (mRSS).  
• Transitional Mahler Modified Dyspnea Index (TDI).  
• Patient Reported Outcomes (PROs), which provide subjective 
measures of dyspnea and quality of life  based on patient 
responses to standardized patient questionnaires.  
2. The change from baseline to [ADDRESS_876222] measures of SSc -
ILD: 
• Quantitative lung fibrosis score in the whole lung (QLF -WL).  
• Quantitative lung fibrosis  score in the lobe of maximal 
involvement (QLF -LM).  
• Quantitative interstitial lung disease score in the whole lung 
(QILD -WL).  
• Quantitative interstitial lung disease score in the lobe of 
maximal involvement (QILD -LM).  
• Total lung capacity at maximum inspi[INVESTIGATOR_1516] (HRCT -TLC)  
3. Differences in the frequency distribution of individual patient 
responses when grouped into defined intervals of improvement or 
worsening (defined by [CONTACT_652674] 18 months) for the following outcome me asures:  
• Forced vital capacity (represented as the percentage of the age-, height -, gender - and race -adjusted predicted value,  i.e. 
FVC-%) 
• Single -breath diffusing capacity for carbon monoxide (DLCO), 
calculated as a percent of the age, height, gender and 
hemoglobin adjusted predicted value ( DLCOHb -%).  
• Modified Rodnan Skin Score (mRSS).  
• Transitional Mahler Modified Dyspnea Index (TDI)  
4. The time (in months) required for each treatment arm to achieve a 
3.0% or greater improvement from baseline in the FVC-% over the 
18-month treatment period . 
5. A threshold analysis based on the percentage of subjects in each treatment arm achieving greater than a 5% improvement in FVC -% 
over the 18 -month treatment period . 
6. Tolerability and toxicity of MMF+Plac  versus MMF+PFD over the 
course of 18 months.  
Population: 150 randomized participants from recruitment sites in the [LOCATION_002], 
including both male and femal e patients  of an age >18 years, diagnosed 
with  systemic scleroderma  (SSc)  as defined by [CONTACT_941] 201 3 American College 
of Rheumatology ( ACR)/European League Against Rheumatism ( EULAR ) 
classification criteria, who demonstrate evidence of active restrictive lung 
disease by [CONTACT_580086], symptomatic dyspnea and any 
evidence of ground glass opa cification (GGO) on baseline thoracic HRCT , 
and who meet the study definition of being either treatment naïve or 
recently started on treatment (<6 mo of prior treatment with a potentially 
disease -modifying therapy ) and all other inclusion & exclusion criteria as 
detailed below. 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   7 Phase: Phase II  
Number of Sites 
enrolling participants : Between [ADDRESS_876223] of participating sites  
Description of Study  
Agents : 1. Mycophenolate Mofetil (MMF) 
Manufactured by: [CONTACT_164428], Inc  (Generic ) 
Oral Route  
250 mg capsules  
Target Dose:  
1500 mg  twice daily as tolerated with a 4 -step titration at monthly 
intervals   
a) 500 mg (two capsules) twice daily  (BID) for 4 weeks  
b) 1000 mg (four capsules) BID  for 4 weeks  
c) 1250 mg (five capsules) BID  for 4 weeks  
d) 1500 mg (six capsules) BID  for remainder of study as 
tolerated . 
2. Pi[INVESTIGATOR_7735] (PFD), same as Esbriet®  
Manufactured by:  [CONTACT_8229], Inc.  
Oral Route  
267 mg capsules.  
Target Dose:  
801 mg three times daily as tolerated with a 3 -step titration  at 2 
week intervals:  
a) 267 mg ( one capsule) three times daily (TID) for 2 weeks 
b) 534 mg (two capsules) TID for 2 weeks  
c) 801 mg (three capsules)  TID for remainder of st udy as 
tolerated . 
3. Placebo (Plac), matching to the PFD capsules  
Manufactured by:  [CONTACT_8229], Inc.  
Oral Route  
267 mg capsules.  
Target Dose:  
801 mg three times daily as tolerated with a 3 -step titration  at 2 
week intervals:  
a) 267 mg ( one capsule) three times daily (TID) for 2 weeks  
b) 534 mg (two capsules) TID for 2 weeks  
c) 801 mg (three capsules)  TID for remainder of study as 
tolerated . 
Study Duration: Approximately 4 years total study duration , sub -divided into the following 
components : 
a. 24 month enrollment period  
b. 18-month randomized, double -blind treatment period per patient  
c. 1 month follow -up period after completion of drug therapy  
d. 6 month primary analysis period  
Participa nt Duration: 20-[ADDRESS_876224] participation period  made up of the following 
components:  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   8 - screening = 1 -3 month s 
- randomized, double -blind treatment period = 18 months  
- final follow -up period after completion of drug therapy = 1 month  
Inclusion Criteria : 1.  Age >18 yrs 
2.  Scleroderma as determined by  [CONTACT_941] 2013 ACR/EULAR classification 
criteria.  
3.  Grade ≥2 on the Magnitude of Task component of the Mahler Modified 
Dyspnea Index   
(Becomes short of breath with moderate or average tasks such as 
walking up a gradual hill, climbing less than three flights of stairs, or carrying a light load on the level.  
4.  FVC -% of  ≤85% at screening . 
5.  Onset of the first non- Raynaud manifestation of SSc within the prior [ADDRESS_876225]  
7.   Repeat FVC -% at the baseline visit within 10% of the FVC-% value 
measured at screening. If these criteria are not met, a repeat FVC-% 
may be obtained within [ADDRESS_876226] may qualify for 
randomization if the repeat FVC -% agrees within 10% of the FVC -% 
obtaine d at screening. 
Exclusion Criteria : 1.   Disease features supporting the primary diagnosis of another 
connective tissue disease such as rheumatoid arthritis, systemic lupus erythematosus or mixed connective tissue disease (Features consistent 
with a secondary Sjogren syndrome or scleroderma-associated myopathy will be allowed).  
2.   FVC -% of  <45% at either screening or baseline.  
3.   FEV1/FVC ratio <0. 65 at either screening or baseline.  
4.   DLCOHb -% of <30%  at screening or  <25% at baseline .  
a)  A ll participants with a DLCOHb-% between 30 to 40% must have 
pulmonary artery pressures documented by [CONTACT_652675], right heart catheterization or magnetic resonance imaging in order to be considered for inclusion.  
5.   D iagnosis of clinically significant resting pulmonary hypertension 
requiring treatment or mild pulmonary hypertension requiring treatment with more than one oral medication as ascertained prior to 
study evaluation or as part of a standard of care clinical assessment performed outside of the study protocol.  
6.   Evidence of uncontrolled congestive heart failure, unstable ischemic 
heart disease, history of complicated  pulmonary embolism  impacting 
on heart or  lung function , or unstable cardiac arrhythmia requiring 
chronic anticoagulation.  
7.   Clinically significant abnormalities on HRCT not attributable to SSc  
8.   Hematologic abnormality at screening including:  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   9 a) Leukopenia (white blood cells [WBC] <4.0x103/µl)  
b) Thrombocytopenia (platelet count <1 20.0x103/µl) 
c) Clinically significant anemia [Hemoglobin (Hgb) <10.0 g/dl]   
Participants with an identified and correctable etiology may be eligible 
if repeat testing within the maximal [ADDRESS_876227] (LFTs) or total bilirubin that are >2.0 x upper normal limit  
10.  Serum creatinine >2.0mg/dl  
11. History of recurrent aspi[INVESTIGATOR_1516], uncontrolled heartburn, or 
gastroesophageal reflux disease (GERD) with  a reflux scale score of 
>1.00 as determined by a UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC GIT), Version 2.0.   
Participants with uncontrolled heartburn or GERD that is amenable to 
medical management may be eligible if repeat testing within the maximal 90 -day screening period meets this criteria.  
12. Known achalasia, esophageal stricture or esophageal dysfunction 
sufficient to limit the ability to swallow medication.  
13. Pregnancy (documented by [CONTACT_652676]) and/or breast 
feeding 
14. If of child bearing potential (a female participant < 55 years of age who 
has not been postmenopausal for ≥ 5 years or who has not had a bilate ral salpi[INVESTIGATOR_1656], hysterectomy and/or oophorectomy), failure 
to employ two reliable means of contraception which may include surgical sterilization, barrier methods, spermicidals, intrauterine devices, and/or hormonal contraception, unless the participant  
chooses abstinence (to avoid heterosexual intercourse completely.) If a subject chooses abstinence, then a second reliable means of contraception is not needed.   
15. Prior use  of potential disease modifying antirheumatic drugs (DMARDs) 
according to the f ollowing exposure rules : 
a)  Use of oral cyclophosphamide (CYC), MMF, azathioprine or other 
oral or short half-life DMARDs (as detailed in Section 7.5.1a) for 
more than [ADDRESS_876228] year  as determined at the time of 
the initial screening visit . 
b)  Treatment with more than three intravenous doses of CYC, one 
treatment course of Rituximab or other intravenous or injectable DMARDs  (as detailed in Section 7.5.1b) in the past year.  
c)  More distant h/o  treatment with a DMARD is allowed as long as the 
patient has a new diagnosis/new epi[INVESTIGATOR_652593] -ILD since 
stoppi[INVESTIGATOR_652594] 15a or 15b .  
16. Use of CYC, MMF, azathioprine, Rituximab or other DMARD  (as 
detailed in Section 7.5.1 a&b) in the 30 days prior to the bas eline visit  
S c l e r o d e rm a  L u n g  S t u d y  I I I                                            [ C o n f i d e n t i a l ]  V e r s i o n  2 . 5  
P r o t o c o l  # U C L A -S L S 3  1 1 / 1 7 / 2 1  
F D A  I N D  # :  1 3 5 8 4 8   1 0  u n l e s s  t h e  p a t i e n t  i s  o n  MM F  a n d  t h e  r e s p o n s i b l e  p h y s i c i a n  i n d i c a t e s  
t h a t  c o n t i n u e d  u s e  i s  i n  t h e  b e s t  c l i n i c a l  i n t e r e s t  o f  t h e  p a t i e n t .  
1 7 .  A c t i v e  i n f e c t i o n  ( l u n g ,  u l c e r s  o r  e l s e w h e r e )  w h o s e  m a n a g em e n t  w o u l d  
b e  c om p r om i s e d  b y  imm u n o s u p p r e s s i o n .  
1 8 .  O t h e r  s e r i o u s  c o n c om i t a n t  m e d i c a l  i l l n e s s  ( e . g . ,  a c t i v e  m a l i g n a n c y  
w i t h i n  t h e  p a s t  5  y e a r s  o t h e r  t h a n  s u r g i c a l l y -r em o v e d  l o c a l  s k i n  c a n c e r  
s u c h  a s  a  b a s a l  c e l l  c a r c i n om a ) ,  c h r o n i c  d e b i l i t a t i n g  i l l n e s s  ( o t h e r  t h a n  
S S c ) ,  u n r e l i a b i l i t y  o r  d r u g  a b u s e  t h a t  m i g h t  c om p r om i s e  t h e  p a t i e n t ’ s  
p a r t i c i p a t i o n  i n  t h e  t r i a l .  
1 9 .  C u r r e n t  u s e ,  o r  u s e  w i t h i n  t h e  3 0  d a y s  p r i o r  t o  t h e i r  b a s e l i n e  v i s i t ,  o f  
p r e d n i s o n e  ( o r  e q u i v a l e n t )  i n  d o s e s  > 1 0  m g / d a y .  
2 0 .  Sm o k i n g  o f  c i g a r s ,  p i p e s ,  o r  c i g a r e t t e s  d u r i n g  t h e  p a s t  6  m o n t h s .  
2 1 .  U s e  o f  c o n t r a i n d i c a t e d  m e d i c a t i o n s ,  i n c l u d i n g  m e d i c a t i o n s  w i t h  
p u t a t i v e  d i s e a s e -m o d i f y i n g  p r o p e r t i e s  t h a t  d o  n o t  m e e t  t h e  e x p o s u r e  
l im i t s  d e s c r i b e d  i n  E x c l u s i o n  C r i t e r i a  # 1 5  a n d  # 1 6 ,  m o d e r a t e  o r  s t r o n g  
i n h i b i t o r s  o f  c y t o c h r om e  P 4 5 0  ( C Y P )  i s o z ym e  1 A 2  ( C Y P 1 A 2 )  ( n o t e  
c i p r o f l o x a c i n  a l l o w e d  u p  t o  a  d o s e  o f  5 0 0  m g  t w i c e  d a i l y ) ,  a n d  
m o d e r a t e  i n d u c e r s  o f  C Y P 1 A 2  ( s u c h  a s  t o b a c c o  sm o k e ,  o r  p h e n y t o i n ) .  
S e e  S e c t i o n  7 . 5  f o r  c om p l e t e  l i s t .  
 
 
S UMM A R Y  S C H EM A T I C  O F  S T U D Y  D E S I G N  
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   11 SUMMARY TABLE OF STUDY VISITS AND ASSESSMENTS ** 
  Screen   Randomized Double -blind Phase   Exit visit*  
Visit #   
S1 S2  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18 V19 V20 V21  
V22 
Month on Study  
(Month = 28 days)   
Sc-1 Sc-2  0 
 0.5 (14 
days)  
±7d 1 (28 
days)  
±7d 1.5 (42 
days)  
±7d 2 (56 
days)  
±10d  3 (84 
days)  
±10d  4 (112 
days)  
±10d  5 (140 
days)  
±10d  6 (168 
days)  
±10d  7 (196 
days)  
±10d  8 (224 
days)  
±10d  9 (252 
days)  
±10d  10 (280 
days)  
±10d  11 (308 
days)  
±10d  12 (336 
days)  
±14d  13 (364 
days)  
±10d  14 (392 
days)  
±10d  15 (420 
days)  
±14d  16 (448 
days)  
±10d  17 (476 
days)  
±10d  18 (504 
days)  
±14d   Month 19  (532 
days)   
±10d  
                            
Phone conta ct      X  X      X X  X X  X X  X X   X 
On-Site Vi sit  X X  X  X  X X X X X   X   X   X   X   
       
Complete H&P   X                 X         
F/u SSc -H&P      X  X  X X X X X   X      X   X   
Vital signs   
X   X  X  X X X X X   X   X   X   X   
mRSS   
   X     X   X   X   X   X   X   
Study Consent   
X                          
Adverse events   
    X X X X X X X X X X X X X X X X X X X X  X 
Concomitant 
Medications   
X   X X X X X X X X X X X X X X X X X X X X X  X 
Dispense meds      X  X  X X X X X   X   X   X      
Drug reconciliation      X  X  X X X X X   X   X   X   X   
Mahler BDI/TDI      X     X   X   X   X   X   X   
SGRQ      X     X   X   X   X   X   X   
SHAQ, PROMIS -29, 
UCLA SCTC GIT, 
CRISS, LCQ , Global 
Assessments   
UCLA 
SCTC 
GIT   X 
(except 
CRISS )        X      X      X   
LABS:                             
  - CBC, diff, plat   X     X  X X X X X   X   X   X   X   
  - Metabolic/liver   X     X  X X X X X   X   X   X   X   
  - Serum Preg+  X                          
  - Urine Preg+     X  X  X X X X X   X   X   X   X   
HRCT    X                      X   
Spi[INVESTIGATOR_2152]/DLCO   X   X‡     X   X   X   X   X   X   
Biorepository      X              X      X   
‡Screen and Baseline FVC value must be within an absolute difference in percent -predicted of 10% - may repeat within 7 days if not and proceed to enroll if criteria met  
+For women of childbearing potential, initial serum pregnancy testing will be carried out with subsequent urine testing at each visit  using test kits provided by [CONTACT_1758].  
*Exit visit will also be carried out within 30 days (±10d) of early termination/withdrawal from the protocol. All subjects who terminate/withdraw early will be encouraged to return for the outcome 
assessments as deta iled above for the 12 month (V15) and 18 month (V21) visits.  
**Refer to Protocol Section 17.0 (EMERGENCY DISASTER/ PANDEMIC MANAGEMENT PLAN)  for allowed adjustments in the event of a disaster/pandemic  that disrupts pat ient or institutional access .  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   12 1 KEY ROLES  
Study Roles and Participating Sites as of February 18 , 2020  
Administrative  Coordinating 
Center  
David Geffen School of Medicine  
at UCLA  
Los Angeles, CA [ZIP_CODE] -1690   
  Study Principal Investigator  
[INVESTIGATOR_68020] D. Roth, M.D.  
Professor , Pulmonary and Critical Care  
Vice -Chair for Clinical Research Compliance  
Department of Medicine, 43-229 CHS 
David Geffen School of Medicine at UCLA  
Los Angeles, CA [ZIP_CODE]- 1690  
Tel: ([PHONE_13518] ;  Fax: (310) 206 -5088  
[EMAIL_12385] 
 Director , HRCT  Quantitative Image Analysis (QIA) Core  
Jonathan G. Goldin, M.D., Ph.D . 
Professor of Radiology & Biomedical Physics Program  
Executive Chief of Clinical Care, Dept . of Radiology  
David Geffen School of Medicine at UCLA  
Los Angeles, CA [ZIP_CODE]- 1690  
Tel: (424 ) 259-8719 ;  Fax : ([PHONE_13520] 
[EMAIL_12386] 
 Director, UCLA Research Pharmacy Core  
Christina S. Shin , Pharm.D.  
Investigational Drug Pharmacist  
Investigational Drug Section  
Ronald Reagan -UCLA Medical C enter Pharmaceu tical Serv ices 
757 Westwood Plaza Room, Room# B- 504G  
Tel: ([PHONE_4481] ;  Fax : ([PHONE_13521] 
[EMAIL_12387] 
 Director, UCLA Pulmonary Function Quality Assurance Core  
Eric Kleerup, M.D.  
Clinical Prof essor of Pulmonary & Critical Care  
Department of Medicine, 37 -131 CHS  
David Geffen School of Medicine at UCLA  
Los Angeles, CA [ZIP_CODE]- 1690  
Tel: ([PHONE_13522]  
[EMAIL_12388] 
Data Coordinating Center  
University of Michigan  
Ann Arbor, MI [ZIP_CODE] -2029   Principal Statistician & Director of Data Coordinating Center  
Cathie Spi[INVESTIGATOR_8614], D.Sc . 
Associate Research Professor of Biostatistics   
Director, Statistical Analysis of Biomedical  
and Educational Research (SABER) Unit  
School of Public Health  
University of Michigan  
1415 Washington Heights, Rm M4507  
Ann Arbor, MI [ZIP_CODE] -2029  
Tel: (734) 615 -5469 ;  Fax: (734) 647 -3711  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   13 [EMAIL_7094]  
 Co-Principal Investigator  
[INVESTIGATOR_256492], MD, MSc  
Division of Rheumatology  
University of Michigan School of Medicine  
[ADDRESS_876229], SPC 5422  
Ann Arbor, MI  [ZIP_CODE]  
Tel: (734) 232- 2104 ;  Fax: (734) 763- 5761 
[EMAIL_1861] 
17 Participating Clinical Sites  1. [LOCATION_011] University, School of Medicine  
Marcin Trojanowski , MD  
Principal Investigator  
[INVESTIGATOR_652595]: (617 ) 638-7460  
[EMAIL_12389]  
 2. David Geffen School of Medicine at UCLA  
S. Samuel Weigt, M.D.  
Principal Investigator  
[CONTACT_341416] & Critical Care  
Department of Medicine   
Tel: ([PHONE_13523]  
[EMAIL_12390] 
 3. Georgetown University School of Medicine  
Virginia Steen, M.D.  
Principal Investigator  
[INVESTIGATOR_652596]: ([PHONE_13524]  
[EMAIL_12391] 
 4. Harvard / Brigham and Women’s Hospi[INVESTIGATOR_652597], M.D.   
Principal Investigator  
[INVESTIGATOR_652598], Immunology and Allergy Department of Medicine   
Tel: (617 ) 732-5548  
[EMAIL_12392]  
 5. Hospi[INVESTIGATOR_652599], M.D.  
Principal Investigator  
[INVESTIGATOR_652596]: (212 ) 606-1351  
[EMAIL_12393] 
 6. Johns Hopkins University School of Medicine  
Laura Hummers, M.D.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   14 Principal Investigator  
[INVESTIGATOR_652596]: (410 ) 550-6819  
[EMAIL_12394]  
 7. Medical University of South Carolina  
Richard Silver, M.D.  
Principal Investigator  
[INVESTIGATOR_652596]: (843 ) 792-3484  
[EMAIL_12395]  
 8. Northwestern University Feinberg School of Medicine  
Jane Dematte -D’Amico, M .D.  
Principal Investigator  
[CONTACT_341416] & Critical Care  
Department of Medicine   
Tel: (31 2) 695-1879  
[EMAIL_12396] 
 9. Rutgers Robert Wood Johnson Medical School  
Vivien Hsu, M .D.   
Principal Investigator  
[INVESTIGATOR_652596]: (732 ) 418-8484  
[EMAIL_12397]  
 10. University of [LOCATION_004] San Francisco  
Jeffrey Golden, M.D.   
Principal Investigator  
[CONTACT_341416] & Critical Care  
Department of Medicine  
Tel: ([PHONE_13525]  
[EMAIL_12398]  
 11. University of Colorado Denver  
Joyce S. Lee, M.D.  
Principal Investigator  
[INVESTIGATOR_652600]: ([PHONE_13526]; 
[EMAIL_12399]   
 12. University of Michigan Medical School  
Vivek  Nagaraja, MBBS  
Principal Investigator  
[INVESTIGATOR_652596]: ( [PHONE_13527]  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   15 [EMAIL_12400]  
 13. University of Minnesota Medical School  
Hyun Kim , M.D.  
Principal Investigator  
[CONTACT_341416] & Critical Care  
Department of Medicine   
Tel: (612 ) 626-6127  
[EMAIL_12401]  
 14. University of Pi[INVESTIGATOR_652601] T Domsic, M. D.  
Principal Investigator  
[INVESTIGATOR_652596]: (412 ) 648-4814  
[EMAIL_2051]  
 15. University of [LOCATION_007] Medical School at Houston  
Maureen Mayes, M.D.  
Principal Investigator  
[INVESTIGATOR_652595]: (713 ) 500-6905  
[EMAIL_12402]  
 16. University of Utah School of Medicine  
Mary Beth Scholand, M.D.  
Principal Investigator  
[CONTACT_341416] & Critical Care  
Department of Medicine  
Tel: (801 ) 581-7806  
[EMAIL_12403] 
 17. University of Washington School of Medicine  
Ganesh Raghu, MD  Principal Investigator  
[CONTACT_341416] & Critical Care  
Department of Medicine  
Tel: (206 ) 598-6190  
[EMAIL_12404] 
 20. University of  Indiana Health  
Ryan Boente , MD  
Principal Investigator  
[CONTACT_341416] & Critical Care  
Department of Medicine  
Tel: (317 ) 278 -0064  
[EMAIL_12405]  
 
  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   16 2 INTRODUCTION: BACKGR OUND INFORMATION AND  SCIENTIFIC RATIONAL E  
 
2.1  BACKGROUND INFORMATION  
 
2.1.1  Prevalence & Course of SSC -ILD & the Need for New Treatments  
Systemic scleroderma (Systemic Sclerosis, SSc) is an autoimmune rheumatologic disorder 
characterized by [CONTACT_652677] -antibodies, tissue inflammation with small vessel 
vasculopathy, activation of tissue fibroblasts , and the deposition of extra cellular matrix within skin 
and other defined organ sites including the lungs ( 55). It falls within the Food and Drug 
Administration's (FDA) designation of a rare disease, with estimates of the prevalence in the [LOCATION_002] ranging between 40,000 to 165,000 overall  cases  (3). Although relatively rare, its impact is 
magnified by [CONTACT_652678] -age, produces debilitating morbidity 
that can involve many organ systems,  and is associated with significant mortality . Ten -year survival 
rates have recently been estimated at 65 -70% ( 48).  
Of patients with SSc , up to 74% have some evidence of interstitial fibrosis at the time of autopsy ( 9) 
and progr essive interstitial lung disease (ILD) occurs in approximately 40% of patients . SSc-related 
ILD (SSc -ILD) has emerged as a leading overall cause of disease -related deaths as summarized in a 
report by [CONTACT_652679] ( Table 2.1.1a; 38,54). 
 
Table 2.1.1a.  Causes of death in SSc: results from the University of Pi[INVESTIGATOR_106735] h SSc cohort (5 4) and 
the EUSTAR registry (4 8) as reproduced from the report by [CONTACT_652680] & Baron , 2014 (38) 
 
ILD, interstitial lung disease; PAH, pulmonary arterial hypertension, SSc, systemic sclerosis  
aCause of death not assigned at the time of publication  
bAmong 5860 patients at risk; although there were 283 deaths, death questionnaires were completed in 234 
patients for whom data are summarized in this table  
cAmong 221 patients at risk  
dAmong 1508 patients at risk  
SSc-ILD usually emerges early during the inflammatory phase of the disease and rapi[INVESTIGATOR_652602] ( 40,57). In fact, when the average 
annual decline in lung function was mapped out over time in a large cohort of 889 SSc patients, the 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876230] few years after 
diagnosis, after which time further decline was rather limited ( Figure 2.1.1a/b; 46). The median 
survival for patients with SSc -ILD is in the range of 5 -8 years and the extent of pulmonary 
involve ment has repeatedly been found to correlate in an independent manner as a risk factor 
predicting time to dea th (16,35 ,38,46-47 ).  
 
Figure 2.1.1a (above, left). Mean loss of percent vital capacity occurring over 2 -year time periods in 55 
patients whose initial pulmonary function tests (PFTs) were performed during the first 5 years of 
scleroderma symptom s. (adapted from ref 46). 
Figure 1 b. (above, right) Percent cumulative survival rate from onset of disease in patients grouped 
according to their lowest forced vital capacity. Those with severe restrictive lung disease had the worst prognosis (p<0.01). ( adapted from ref 46). 
 
Based on such information, a strong argument can be made that the identification of SSc -ILD and 
targeted early intervention s that reduce or reverse the impact of lung inflammatory and fibro sis 
have the potential to significantly reduce patient morbidity and mortality.  
 
2.1.2  Effectiveness of I mmune Suppression for the Treatment of SSc -ILD 
SSc-ILD is characterized by a combination of interstitial and alveolar inflammation, vascular injury 
with endothelial activation/apoptosis, and evidence of activation of fibroblasts and pro -fibrotic 
signaling cascade s (56). Based on the proposed linkage between inflammation and fibrosis, 
immunosuppression was initially investigated as the treatment of choice in Scleroderma Lung Study I (SLS I; 51 ). One -hundred fifty -eight (158) patients with SSc- ILD w ere randomized into a placebo -
controlled double -blind trial to evaluate a 1 -year treatment with  oral cyclophosphamide  (CYC) on 
the course of forced vital capacity as a percentage of the age- , height -, gender - and race -adjusted 
predicted value (FVC -%) and s everal secondary outcomes. There was a modest but statistically -
significant difference between the treatment arms at the 12 -month primary outcome ( 51) which 
continued to increase over time until a maximal treatment effect was observed at 18 months; 6 month s after stoppi[INVESTIGATOR_652603] ( 50, Figure 2 .1.2a ). At this point, using a 
longitudinal statistical model and a modified intention to treat ( m-ITT) approach to take into 
account all available data, the average improvement in absolute FVC -% was 2.67% comparing the 
lung function in the active treatment arm to that in the placebo (Plac) group (p=0.0107). SLS I was 
the first randomized controlled trial to demonstrate that SSc -ILD responds to immunosuppression 
with placebo -adjusted improvements i n pulmonary function as well as associated improvements in 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   18 the patient's perception of dyspnea, objective measurements of skin disease, and health- related 
quality of life ( HRQoL ) when compared to an untreated contr ol arm ( 26,50-51 ). 
Figure 2 .1.2a  (below). Time course from 6 to 24 months of mean values ( +SE) for the FVC -% of 
participants in the Plac and CYC treatment groups of the SLS I study determined using a longitudinal 
model that adjusted for baseline % predicted values, maximal high- resolution computed tomography–
scored fibrosis, and non- ignorable missing data. Numbers of patients in each treatment group at each visit 
are shown, along with the P values for the between -treatment differences obtained from Huber’s robust 
regression analysis with multiple imputation  
. 
Similar results were observed with the use of intravenous CYC in the Fibrosing Alveolitis in 
Scleroderma Trial (FAST  study ) carried out in the United Kingdo m (19). While the overall magnitude 
of the response to CYC has been considered modest in these studies, a subset analysis of the SLS I 
patients suggested that distinct subsets of “responders” and “non -responders” might be 
prospectively identified based on  the extent of interstitial disease on chest high resolution 
computerized tomography (HR CT) imaging and/or the extent of skin disease (44 ). When results from 
SLS I were retrospectively stratified based on these criteria, the average treatment effect in the responder population was approximately a [ADDRESS_876231] to the FVC-% (Figure 2.1.2b ). Approximately one -half of the 
overall treatment effect in this responder population could be attributed to the ongoing deterioration that occurs in subjects treated with placebo, while the other one- half of the treatment 
response appeared to represent a significant improvement over time in subjects who were on active CYC therapy. In contrast, subjects identified as non- responders by [CONTACT_652681], if any, benefit from CYC ( Figure 2.1.2c ). 
Figure 2.1.2b (left) and 2c (right) . Time -trend curves. The changes in FVC -% from baseline to 18 months 
(adjusted for baseline FVC -%) are plotted for the cyclophosphamide  (CYC) and placebo (Plac) arms (mean 
+SEM). The number of subjects (N) at each time -point and the p- value comparing groups is presented. (A) 
There was a small but significant difference between the treatment arms at 18 months when results were plotted for all patients. (B) Dividing the study population into Responder and Non- responder subsets 
resulted in two distinct plots with a highly -significant treatment effect from 9 to 18 months occurring only 
in the Responder population.  

S c l e r o d e rm a  L u n g  S t u d y  I I I                                            [ C o n f i d e n t i a l ]  V e r s i o n  2 . 5  
P r o t o c o l  # U C L A -S L S 3  1 1 / 1 7 / 2 1  
F D A  I N D  # :  1 3 5 8 4 8   1 9   
I n  S c l e r o d e rm a  L u n g  S t u d y  I I ,  a  t w o  y e a r  c o u r s e  o f  d a i l y  o r a l  m y c o p h e n o l a t e  mo f e t i l  ( MM F )  w a s  
e v a l u a t e d  a s  a n  a l t e r n a t i v e  t o  o n e  y e a r  o f  d a i l y  o r a l  C Y C  ( f o l l o w e d  b y  p l a c e b o  i n  t h e  s e c o n d  y e a r ) .  
T h e  g o a l s  w e r e  t o  e v a l u a t e  w h e t h e r  MM F ,  a n  a l t e r n a t i v e  imm u n o s u p p r e s s a n t ,  w o u l d  i n d u c e  c l i n i c a l  
r e s p o n s e s ,  e x t e n d  t h e  d u r a t i o n  o f  t h e  t r e a tm e n t  e f f e c t ,  a n d  p r o d u c e  a  l o n g e r  l a s t i n g  o u t c om e  w i t h  
l e s s  t o x i c i t y  ( b o n e  m a r r o w  s u p p r e s s i o n ,  h em o r r h a g i c  c y s t i t i s  o r  m a l i g n a n c i e s )  t h a n  C Y C  ( 1 4 , 4 2 ) .  T h e  
p r im a r y  o u t c om e  f r om  t h e  S L S  I I  t r i a l  c o n f i rm e d  t h a t  b o t h  MM F  a n d  C Y C  s i g n i f i c a n t l y  im p r o v e d  l u n g  
f u n c t i o n  c om p a r e d  t o  t h a t  a t  b a s e l i n e  w i t h  n o  d i f f e r e n c e  b e t w e e n  t h e  s t u d y  a rm s  ( 5 2 ,  Fi g u r e  
2 . 1 . 2 d / e ) .  
  
F i g u r e  2 . 1 . 2 d  ( l e f t ) .   A b s o l u t e  c h a n g e  i n  F V C -%  
f r om  b a s e l i n e  b y  t r e a tm e n t  a rm .  E s t im a t e s  o f  t h e  
a b s o l u t e  c h a n g e s  i n  m e a n  F V C - %  i n  t h e  t w o  
t r e a tm e n t  a rm s  a t  t h r e e  m o n t h  i n t e r v a l s  f r om  
b a s e l i n e  t o  2 4  m o n t h s  w e r e  c a l c u l a t e d  u s i n g  a  
p r e -s p e c i f i e d  j o i n t  l o n g i t u d i n a l  m o d e l  t h a t  l i n k e d  
a  l i n e a r  m i x e d -e f f e c t s  m o d e l  w i t h  a  c a u s e -s p e c i f i c  
h a z a r d s  m o d e l  a n d  t o o k  i n t o  a c c o u n t  t h e  t im e  t o  
c a u s e -s p e c i f i c  d r o p -o u t ,  t r e a tm e n t  f a i l u r e  a n d / o r  
d e a t h .  9 5 %  c o n f i d e n c e  i n t e r v a l s  f o r  t h e  e s t im a t e s  
a r e  s h o w n  f o r  t h e  d a t a  a t  6 ,  1 2 ,  1 8  a n d  2 4  
m o n t h s .  F i g u r e  2 . 1 . 2 e   ( r i g h t ) .  A  n um b e r  o f  p a t i e n t s  w h o  
r e c e i v e d  a t  l e a s t  o n e  d o s e  o f  s t u d y  m e d i c a t i o n  
p r em a t u r e l y  w i t h d r e w  o r  w e r e  w i t h d r a w n  f r om  
s t u d y  t r e a tm e n t  a t  v a r i o u s  t im e s  d u r i n g  t h e  s t u d y  
d u e  t o  a d v e r s e  e v e n t s ,  n o n c om p l i a n c e ,  l o s s  t o  
f o l l o w -u p  o r  h a v i n g  m e t  t h e  p r o t o c o l -  d e f i n i t i o n  
o f  t r e a tm e n t  f a i l u r e .  A s  a n  o v e r a l l  m e a s u r e  o f  
t o l e r a b i l i t y ,  t im e  t o  w i t h d r a w a l  f r om  t h e  s t u d y  
m e d i c a t i o n  o r  t r e a tm e n t  f a i l u r e  w a s  s i g n i f i c a n t l y  
s h o r t e r  i n  t h e  C Y C  a rm  ( p = 0 . 0 1 9 ;  l o g  r a n k  t e s t )  
a n d  c o n s i s t e n t  w i t h  t h e  h y p o t h e s i s  t h a t  MM F  i s  
b e t t e r  t o l e r a t e d  a n d  a s s o c i a t e d  w i t h  l e s s  d o s e -
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876232] to the time to treatment failure or 
drug discontinuation (p=0.019; log rant test ; Figure 2.1.2e ) and its use was associated with fewer 
epi[INVESTIGATOR_190816] -defined levels of anemia (CYC = 26; MMF = 18), leukopenia (CYC = 51; MMF = 
5), neutropenia (CYC = 7;  MMF = 3) and thrombocytopenia (CYC = 7; MMF = 0).  
In order to better understand the modeled outcomes, frequency distribution histograms were prepared from the un -modeled outcome data in which the subject -by-subject change in FVC -% from 
baseline to 24 mon ths were plotted for the two treatment arms in increments of a 5% improvement 
or worsening from baseline ( Figure 2.1.2f ). Very similar to outcomes portrayed by [CONTACT_652682], 
the overall change ( +SE) in FVC-% averaged 3.0+1.2 for the CYC arm and 3.3+1.1 for the MMF arm. 
The majority of subjects in both arms had improving FVC-% values over time (64.7% for CYC, 71.7% 
for MMF) and no significant difference was identified between treatments (p=0.55; Fisher’s exact 
test). Of the 34 patients in the CYC arm and the 38 patients in the MMF arm with a positive change 
over time, the average (±SE) improvement was a 7.1±0.7 and 7.5± 0.9 change in FVC -%, respectively. 
Of the 17 patients in the CYC arm and the 15 patients in t he MMF arm whose FVC -% declined over 
24 months, the average (±SE) decrement was a 6.0±1.6 and 6.4±1.6 change in FVC- %, respectively. 
We noted that the majority of subjects who experienced decrements in lung function belonged to the subset in either arm tha t had stopped drug treatment prematurely.  Similar to the observations 
from the SLS I study, values for the mRSS decreased (i.e. improved) in 73.6 % of subjects on CYC and 71.7 % of subjects on MMF, with most of these improvements being by ≥5 units. Mahler’s 
Transitional Dyspnea Index ( TDI) values increased (i.e. improved) by [CONTACT_2669] 1 unit in 59 % of 
subjects on CYC and 47.5% % of subjects on MMF, with most of these improvements being by ≥[ADDRESS_876233] been described for both of these endpoints ( 22,25,52 ). 
Figure 2.1.2f .  Raw 
unmodeled data from all 
subjects completing the [ADDRESS_876234] a frequency 
distribution of changes from 
baseline in FVC -% at 24 
months , by [CONTACT_2939].  
 
 
The relatively equivalent efficacy and improved tolerability of MMF, as compared to CYC, make a 
strong clinical argument for its use as the preferred immunosuppressive medication for SSc -ILD 
(10,52). 
 
2.1.3  The Importance of Addressing Fibrosis in Addition to Inflammation  
In addition to confirming the important role of inflammation and auto -immunity in driving SSc -ILD, 
the Scleroderma Lung Study also identified the extent of fibrotic interstitial lung changes on baseline 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876235], i.e. linear reticular marki ngs, as an important predictor of progressive lung destruction and 
treatment- related improvement in SSc -ILD ( 44). The important role of lung fibrotic changes on 
disease progression and mortality has also been observed in a number or retrospective and 
longitud inal studies ( 35,58).  These observations prompted us to examine HR CT-based evidence of 
disease progression in patients who participated in the SLS I study. Quantitative computer aided HRCT measurements of fibrosis, ground glass c hanges and honeycomb changes were compared at 
baseline to scans performed after 12 months in the patients assigned to the Plac Arm ( Figure 2.1.3a ; 
28). By [CONTACT_187237], the most frequently observed transition from one type of lung involvement to another 
related to the development of fibrotic reticulatio n and honeycomb changes (cumulative probability 
0.29) while the progression to a ground glass appearance, usually associated with worsening inflammation, was infrequent (cumulative probability 0.04).  
 Figure 2.1.3a.  A Markov Chain Transition Matrix 
(MCTM) was prepared for the patients participating 
in the Placebo Arm of the SLS I study based on 
quantitative computer aided image analysis of HRCT scans obtained on the same patients at baseline and again at [ADDRESS_876236] deviations of the probability of 
transitioning from one pattern to another (straight arrows) or of remaining the same pattern (curved arrows near a circle) are shown for the most severe 
zone of disease involvement in each patient. Note 
that the most common transition from one type of disease finding to another related to the transition of both existing ground glass changes into fibrotic 
and honeycomb changes or the change from what appeared to be normal lung to fibrotic and 
honeycomb changes.  
These observations further strengthen the linkage between fibrosis and progressive SSc -ILD. While 
SSc-ILD is most often thought of as a form of non -specific interstitial pneumonia (NSIP), 
differentiating it from the usual interstitial pneumonia (UIP) that occurs in Idiopathic Pulmonary 
Fibrosis (IPF), the work of Bouros et a l. (6, Table 2.1.3a/b ) makes a convincing argument that it is 
best characterized as fibrotic rather than cellular NSIP. In contrast to other rheumatologic diseases associated with ILD wh ere cellular NSIP and lymphocytic infiltration appear to predominate, SSc -ILD 
demonstrates significant fibrosis combined with infiltration by [CONTACT_652683].  
Table 2.1.3a.  Histopathologic diagnosis, according to type of scleroderma and duration of 
exertional dyspnea. ( adapted from ref 6) 
 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   22  
Table 2.1.3 b. Bronchoalveolar lavage cell (BAL) differential (median, range) in usual interstitial 
pneumonia/end- stage lung disease, non -specific interstitial pneumonia, with data given 
separately for cellular and fibrotic non -specific interstitial pneumonia . (adapted from ref 6) 
 
In addition to this pathologic and CT evidence of fibrosis, there has been considerable effort at 
mappi[INVESTIGATOR_652604] -ILD through the study of serum, 
plasma, peripheral blood, BAL fluid and lung tissue obtained from patients and in animal models. A 
number of these findings support the role of a pro -fibrotic environment. In some of the earliest 
studies, BAL obtained from the lungs of SSc -ILD patients were noted to have significantly higher 
levels of platelet derived growth factor (PDGF) and transforming growth factor beta- 1 (TGF -β1) than 
BAL obtained from controls and these factors stimulated the proliferation of myofibroblasts ( 32). 
Baroni et al ( 4), identified autoantibodies from the serum of scleroderma patients that targeted and 
activated the PDGF receptor, resulting in collagen production and the generation of a myofibroblast phenotype. Thrombin levels are also increased in BAL fluid from patients with SSc -ILD and can 
induce profibrotic cytokines, growth factors, and extracellular matrix production associated with a myofibroblast phenotype, a key feature of fibrotic lung disease (1 ,14). Increased numbers of 
circulating fibrocytes – bone marrow -derived fibroblast precursors that have been reported in the 
circulation of patients with IPF, especially in the setting of acute exacerbation, are also observed in patients with SSc (4).  Similarly, gene arrays and cytokine profiling have repeatedly identified the activation of related pro -fibrotic pathways in SSc -ILD patie nts including TGF -β1, collagens, 
interferon -gamma (IFN -γ) receptor, matrix metalloproteinase - 7 (MMP -7), macrophage chemotactic 
protein -1 (MCP -1), and others as recently reviewed by [CONTACT_652684]  (13).  
Collectively, there is strong and clear evidence  of the important role of pro -fibrotic signaling and 
active fibrosis in the pathogenesis of SSc -ILD. 
 
2.1.4 Pi[INVESTIGATOR_7735]: a Drug of Interest for Treating  the Fibrotic Aspect of SSc -ILD 
PFD, currently marketed under the trade name [CONTACT_652806]®, is an anti-inflam matory and anti -fibrotic 
drug that was approved by [CONTACT_34033] 2014 for the treatment of IPF. PFD is a low molecular weight 
non-peptide molecule and biologically active when taken by [CONTACT_149260] ( 12). In vitro, PFD inhibits 
release of pro fibrotic factors by [CONTACT_652685] -inflammatory factors. It reduces lung damage in animal models of 
pulmonary fibrosis and in human clinical trials it significantly reduces the rate of decline of lun g 
function in patients with I PF (29,49 ). 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876237] to the slow onset of activity observed when CYC and MMF are used to treat SSc -ILD (50-
52), PFD exhibits a relatively rapid onset of anti- fibrotic activity in patients with IPF  (29) . In IPF , the 
course of disease progres sion in patients on PFD and those on placebo begin to separate within the 
first few months and follow divergent trajectories over time  (see Figure 2.1.4a).  
Figure 2.1. 4a: Time course of the response to 
PFD in patients with IPF . The mean change 
from baseline in FVC  (in ml) is plotted against 
time for the entire 52 weeks of therapy with 
PFD versus Plac. Using a  ranked ANCOVA 
analysis, treatment with  PFD resulted in a 
significant between -group  difference in the 
primary end point, the  change from baseline 
to week 52 in the percentage of the predicted 
FVC (P<0.001). The treatment effect was evident by [CONTACT_5875] 13  and increased throughout 
the duration of the  trial. The mean decline  
from baseline in FVC was 235 ml in the PFD group and 428 ml in  the Plac group  (absolute 
difference, 193 ml; relative difference,  45.1%; 
P<0.001) . (Adapted from ref# 29)   
 
This rapid effect, if it occurs in SSc -ILD, should complement the slower onset of action associated 
with cytotoxic therapy alone . As can be seen from SLS I data (see Figures 2.1.2a -b), patients on Plac 
show progressive deterioration over the first year and significant improvement from CYC was not 
observed until at least [ADDRESS_876238], was observed with the use of MMF in SLS II (see Figure 2.1.2d ). In addition, 
given its different mechanism of action, the hope is that PFD might produce at least additive effects with respect to the ultimate improvement in lung function. Preliminary toxicity and tolerability testing has already been carried out in patients with SSc -ILD (20) and suggest that PFD is reasonably 
tolerated when given alone and in patients who are on concurrent therapy with MMF. Given these 
differences in the rapi[INVESTIGATOR_652605], we hypothesize that studies 
combining PFD and MMF should focus on outcome measures that address both the time to an 
observed improvement in lung function and the overall magnitude of the improveme nt.  
 
2.1.[ADDRESS_876239] been conducted ( PI[INVESTIGATOR_16335] -004, PI[INVESTIGATOR_16335] -006, and PI[INVESTIGATOR_16335] -016). A complete outcome summary 
detailing the findings from these studies is provided in the  Esbriet  Investigational Drug Brochure 
(11). The m ajor findings are presented here as a brief summary.  
[IP_ADDRESS] Primary Study Endpoints  in the treatment of IPF with PFD . 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   24 In the pooled Phase 3 analysis (PI[INVESTIGATOR_16335] -004/006/016) of the primary endpoint, there was a clear 
effect of treatment with PFD in reducing the decline in percent predicted FVC compared with 
placebo (p < 0.0001, ANCOVA ; Figure 2.1. 5a, adapted from ref #11 , Inves tigational brochure ).  
 
 
Figure 2.1. 5a Percent Predicted FVC: Cumulative Distribution of Change from baseline to Month 12 in 
Pooled Phase 3 Studies  (adapted from ref # 11, Investigational Brochure)  
 
There was a relative reduction of 43.8% in the proportion of patients with decline in percent 
predicted FVC > 10% or death from Baseline at Month 12 in the PFD group compared with the 
placebo group, as well as a 59.3% relative increase in the proportion with no decline in percent predicted FVC  (Figure 2.1. 5b).  
 
 
Figure 2.1. 5b Percent Predicted FVC : Proportion of patients with decline of > 10%  to Month 12 in 
Pooled Phase 3 Studies  
 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   25 [IP_ADDRESS]  Key Secondary  Endpoints  in the treatment of IPF with PFD . 
In the pooled Phase 3 analysis (PI[INVESTIGATOR_16335] -004/006/016) of key secondary endpoints, a beneficial 
effect of PFD  on exercise tolerance was seen, represented by a statistically significantly lower 
decline from Baseline to Month [ADDRESS_876240] (6MWT) d istance in the pi[INVESTIGATOR_652606] ( p = 0.0004)  (11). There was also a 38% relative 
reduction in the risk of disease progression or death at Month 12 in pi[INVESTIGATOR_7735] -treated patients 
compared with placebo -treated patients (hazard ratio [HR] 0.62; 95% CI, 0.51 - 0.75; p < 0.0001)  
(11). In the mortality analysis, a 48% relative reduction in the risk of death from any cause 
favoring PFD was seen (HR 0.52; 95% CI, 0.31 -0.87; p =0.0107, log -rank test)  (11). A smaller 
proportion  of PFD- treated patients died compared with placebo -treated patients (3.5% vs. 6.7%, 
respectively)  (11). 
 
2.1.6 The Feasibility of Combining PFD with MMF for the Treatment of SSc -ILD 
Directly relevant to this proposal, patients with SSc -ILD were randomized  1:1 in an initial safety and 
tolerability trial in patients with SSc-ILD (LOTUSS study , 20) to receive PFD when titrated from 
starting to final dose over a  2 week interval (one arm) vs a 4 week  interval (second arm). Titration 
started at a dose of 801 mg/day and increased up to a maintenance dose of 2403 mg/day . Patients 
received PFD for 16 weeks in total  and both treatment naïve patients and those already on other 
therapi[INVESTIGATOR_014], including treatment with MMF or CYC, were included in a stratified design. This design 
allowed an evaluation of whether the titration interval resulted in a difference in safety and tolerability and whether or not there were obvious differences when administered to treatment 
naïve patients or as an add -on therapy in combination with some form of immunosuppressive 
therapy. T his trial Assessments included treatment- emergent AEs (TEAEs) and exploratory disease 
outcomes. Sixty -three patients were randomized; 96.8% experienced a TEAE and more patients 
reported TEAEs during the titration vs  maintenance period  consistent with the known pattern of 
TEAEs described when PFD has been used for the treatment of IPF. The most commonly reported 
TEAEs were also consistent with those observed for PFD when used in the treatment of IPF (nausea, 
headache, fatigue) and the frequency and type of TEAEs were similar regardless of titration schedule (Table 2.1.6 a).  
Table 2.1.6a . Summary of TEAEs  in the LOTUSS Study . 
 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   26  
 
However, more patients discontinued treatment due to TEAEs in the 2 - vs 4-week titration group (5 
vs 1, respectively); all discontinuation events occurred >3 weeks after reaching the full dose of 
pi[INVESTIGATOR_7735]. MMF, taken by 63.5% of patients in addition to PFD, did not appear to affect 
tolerability  in the stratified analysis . Exploratory disease outcomes remained largely unchanged.  
The tolerability profile of PFD in this preliminary study of SSc -ILD was therefore considered to be 
similar to that in IPF. Tolerability was not affected by [CONTACT_652686] , although 
more subjects prematurely discontinued therapy in the [ADDRESS_876241] been observed in the treatment of IPF, will complement th e delayed anti -inflammatory and 
immunosuppressive effects of MMF, to produce a significantly more rapid and/or greater improvement 
in lung function over time than occurs in patients receiving control therapy with MMF (and Plac) alone.  
A secondary objective  is to demonstrate that combination therapy with PFD and MMF is well tolerated, 
in comparison to MMF alone, and not associated with limiting toxicity that impacts on the overall treatment effect.  
There are several impor tant concepts that collectively provide a strong rationale for the proposed study :   
First , SSc is a devastating disease in which pulmonary manifestations are the most frequent cause of 
morbidity and mortality  (9,38,54). Studies focused on the development of new treatments for SSc -ILD 
have the potential to make a significant impact on the lives of SSc patients.  
Second, SSc-ILD is a rare condition  with estimates of the prevalence in the [LOCATION_002] ranging 
between 40,000 to 165,000 overall case s (3), and falls within the Food and Drug A dministration's (FDA) 
designation of a "rare disease" for which there are limited FDA- approved therapi[INVESTIGATOR_014] . Studies that focus 
on novel clinical approaches to treatment are considered a high priority .  

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876242] imaging and translational biology, all represent 
unique strengths of the SLS Inve stigators that are  not likely to be reproduced elsewhere ( 10,26-27,50-
52).  
Fourth, while SLS I and II focused on  establishing the benefits of cytotoxic therapy ( utilizing CYC and/ or 
MMF) for SSc -ILD, the improvements in lung function remain modest and it is reasonable to speculate 
that a combin ation therapy, which addresses perceived limitations in the use of cytotoxic therapy, might 
enhance the treatment effect to a level that is universally appreciated as efficacious .  
Fifth, given that the predominant pathology in SSc -ILD is a fibrotic form of NSIP  (6), the addition of an 
anti-fibrotic drug like PFD with proven efficacy in the treatment of IPF appears logical ( 2,29,36,39,43).  
Sixth, as it can take up to 6 months of cytotoxic therapy before responses are apparent, during which 
time lung disease may progress  (51-52) , it is rational to add a drug like PFD that has a rapid onset of 
action that might ameliorate th e ongoing decline in lung that occurs for months after starting MMF. This 
is particularly relevant when the most active decline in lung function is known to occur early in the 
course of the disease  (46).  
Seventh , given that MMF and PFD act by [CONTACT_129427], it is reasonable to hypothesize that their 
combined use might produce additive or synergistic effects on lung function.  
Eighth, as demonstrated in the LOTUSS study  (20), it is expected  that PFD is safe  to administer to 
patients with  SSc-ILD and can be used in conjunction with MMF  with an acceptable tol erability and 
toxicity profile .  
As a result of all of these considerations, we have designed SLS III as a two-arm Phase II clinical trial in 
which all patients will receive background therapy with MMF as the best  tolerated cytotoxic therapy 
with documented clinical impact on the course of FVC -% over ti me (10,52). The inclusion and exclusion 
criteria, outcome measures, visit schedules and analysis approaches that have been developed and 
refined in the SLS I and SLS II studies will be carried forward, with only minor modification, and thereby [INVESTIGATOR_392288] a solid basis for the SLS III protocol. Treatment will last 18 months : the time associated with 
maximal response to cytoto xic therapy as defined in SLS I and II  (10,50) . In addition, patients will receive 
either PFD or matching Plac in a randomized double -blinded manner in order to objectively evaluate 
whether combination therapy produces a superior outcome when compared to c ytotoxic therapy alone. 
The primary outcome will focus  on the change from baseline in the mean forced vital capacity, 
measured as the percentage of the age- , height -, gender - and race -adjusted predicted value (FVC -%) 
over the course of the 18 -month double -blind treatment period.  FVC -% will be  measured at baseline 
(pre-treatment) and then quarterly after treatment begins during the entire double- blind treatment 
period (i.e., months 3, 6, 9, 12, 15 and 18).  A number of secondary outcomes are defined, following the logic and models developed in the SLS I and II studies. Given that the trajectories of the primary endpoint are expected to differ because of the mechanisms of action (and the time course of action) of the two treatment modalities, a longitudinal a nalysis approach incorporating all time points will be 
employed.  Specifically, the endpoint will be analyzed using a linear mixed model with participant -month 
in the study (3, 6, 9, 12, 15 and 18) as the unit of analysis and the change from baseline in FV C-% as the 
outcome, with terms for treatment group, baseline FVC -%month and the interaction of treatment group 
with month use d as fixed covariates.  Study participant will be treated as a random effect to account for 
the correlation of outcomes over time within a participant.  The model generates adjusted estimates of 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   28 change from baseline in the FVC -% for each treatment group and  month, and an F -test will be used to 
test the hypothesis that the mean change from baseline during the treatment period differs between 
the two treatment groups.  
 
2.3  POTENTIAL RISKS AND BENEFITS  
 
2.3.1 Known Potential Risks  
Two active drugs in oral capsule form will be administered to patients and include Mycophenolate Mofetil (MMF; Generic, Teva Pharmaceuticals, Inc.) and Pi[INVESTIGATOR_7735] (PFD; same as Esbriet® , 
Genentech, Inc.).  Th ey are both FDA approved medications for other related medical indications, 
but neither is currently approved by [CONTACT_652687] -ILD. MMF is approved 
for use as an immunosuppressant in solid organ transplantation ( cardiac, hepatic and renal) at doses 
up to 1.5 g twice daily and for the treatment of Lupus nephritis, an autoimmune manifestation of 
systemic lupus erythematosus, in the dose range of 1 to 3 g daily. PFD is currently approved for the 
treatment of IPF at a recommended dose of 801 mg (3 capsules  of 267 mg each ) 3 times daily. They 
will be administered in this study at doses that fall within the se FDA -defined  dosing ranges but as 
experimental therapy for SSc -ILD. 
This section will summarize their known risks , when applicable, from the FDA -approved package 
inserts. In addition, details are provid ed regarding observed adverse events when used in clinical 
investigations  that were closely related to those proposed by [CONTACT_3181] . Letters authorizing 
cross -filing to existing FDA data from a pharmaceutical manufacturer of these drugs is also provided 
in support of this protocol and the related IND filing.  An inactive placebo capsule (Plac; matching to 
PFD, Genentech, Inc.) will also be administered to study participants but will not be  considered 
further in this section.  
[IP_ADDRESS]   Mycophenolate Mofetil  
[IP_ADDRESS].1  Blac k Box Warnings:  
a) Embryofetal Toxicity .  Use during pregnancy is associated with increased risks of first 
trimester pregnancy loss and congenital malformations. Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning.  
b) Malignancies And Serious Infections . Immunosuppression may lead to increased 
susceptibilit y to infection and possible development of  lymphoma.  On ly physicians 
experienced in  immunosuppressive therap y and  management of renal, c ardiac or 
hepatic transplant  patients  should prescribe  MMF . Patients receiving the drug shou ld be 
managed in facilities equipped and  staffed with adequate  laboratory and supportive 
medical res ources. The   physician   r esponsible for maintenance therapy should have 
complete  information requisite for the follow -up of the patient . 
[IP_ADDRESS].2  Contraindications:  
Allergic reactions to MMF  have been observed; therefore, MMF  is contraindicated  in 
patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any  
component of the drug product.  
[IP_ADDRESS]. 3 Warnings  and Precautions : 
a) Embryofetal Toxicity.  MMF can cause fetal harm when administered to a pregnant  
female . Use of MMF during pregnancy is associated with an increased risk of first 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   29 trimester pregnancy loss and an increased risk of congenital malformations, especially 
external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney and nervous system.  
b) Pregnancy Exposure Prevention and Planning. Females of reproductive potential must 
be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be  counseled regarding pregnancy prevention and planning.  
c) Lymphoma and Malignancy.  Patients receiving immunosuppressive regimens involving 
combinations of drugs, including MMF , as part of an immunosuppressive regimen are at 
increased risk of developi[INVESTIGATOR_153201], particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As usual for patients with increased risk for skin cancer, exposure to s unlight and UV light should be limited by [CONTACT_652688] a sunscreen with a high protection factor. Lymphoproliferative disease or lymphoma developed in 0.4% to 1% of patients receiving MMF  (2 g or 3 g) 
with other immunosuppressive a gents in controlled clinical trials of renal, cardiac, and 
hepatic transplant patients. In pediatric patients, no other malignancies besides lymphoproliferative disorder (2/148 patients) have been observed.  
d) Serious Infections.  Patients receiving immunosuppressants, including MMF , are at 
increased risk of developi[INVESTIGATOR_652607], fungal, protozoal and new or reactivated viral infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. Because of the danger o f oversuppression of the immune 
system which can increase susceptibility to infection, combination immunosuppressant therapy should be used with caution.  
e) New or Reactivated Viral Infections.   Polyomavirus associated nephropathy (PVAN), JC 
virus associated progressive multifocal leukoencephalopathy (PML), cytomegalovirus (CMV) infections, reactivation of hepatitis B (HBV) or hepatitis C (HCV) have been reported in patients treated with immunosuppressants, including MMF . Reduction in 
immunosuppression should be considered for patients who develop evidence of new or reactivated viral infections. Physicians should also consider the risk that reduced immunosuppression represents to the functioning allograft.  
PVAN, especially due to BK virus infection, is associat ed with serious outcomes,  
including deteriorating renal function and renal graft loss. Patient monitoring may help detect  patients at risk for PVAN. 
PML, which is sometimes fatal, commonly presents with hemiparesis, apathy, confusion,  
cognitive deficiencies, and ataxia. Risk factors for PML include treatment with  
immunosuppressant therapi[INVESTIGATOR_652608]. In immunosuppressed patients, physicians  should consider PML in the differential 
diagnosis in patients reporting neurologic al symptoms and consultation with a 
neurologist should be considered as clinically  indicated. 
The risk of CMV viremia and CMV disease is highest among transplant recipi[INVESTIGATOR_652609] a graft from a CMV seroposit ive 
donor. Therapeutic approaches to limiting CMV disease exist and should be routinely  
provided. Patient monitoring may help detect patients at risk for CMV disease.   
Viral reactivation has been reported in patients infected with HBV or HCV. Monitoring  
infected patients for clinical and laboratory signs of active HBV or HCV infection is  
recommended.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   30 f) Neutropenia.   Severe neutropenia [absolute neutrophil count (ANC) <0.5 x 103/μL ] 
developed in up to 2.0% of renal, up to 2.8% of cardiac, and up to 3.6% of hepatic 
transplant patients receiving MMF  3 g daily (see ADVERSE REACTIONS). Patients 
receiving MMF  should be monitored for neutropenia. The development of neutropenia 
may be related to MMF  itself, concomitant medications, viral infections, or some 
combination of these causes. If neutropenia develops (ANC <1.3 x 103/μL), dosing with MMF  should be interrupted or the dose reduced, appropriate diagnostic tests 
performed, and the patient managed appropriately. Neutropenia has been observed most frequently in the period from 31 to 180 days posttransplant in patients treated for prevention of renal, cardiac, and hepatic rejection. Patients receiving MMF  should be 
instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.  
g) Pure Red Cell Aplasia (PRCA).   Cases of pure red cell aplasia (PRCA) have been reported 
in patients treated with MMF  in combination with other immunosuppressive agents. 
The mechanism for MMF  induced PRCA is unknown; the relative contribution of other 
immunosuppressants and their combinations in an immunosuppression regimen are also unknown. In some cases, PRCA was found to be reversible with dose reduction orcessation of MMF  therapy. In transplant patients, however, reduced 
immunosuppression may place the graft at risk.  
h) Gastrointestinal Disorders.   Gastrointestinal bleeding (requiring hospi[INVESTIGATOR_059]) has 
been observed in approximately 3% of  renal, in 1.7% of cardiac, and in 5.4% of hepatic 
transplant patients treated with MMF  3 g daily. In pediatric renal transplant patients, 
5/148 cases of gastrointestinal bleeding (requiring hospi[INVESTIGATOR_059]) were observed. Gastrointestinal perforations have rarely been observed. Most patients receiving MMF  
were also receiving other drugs known to be associated with these complications. Patients with active peptic ulcer disease were excluded from enrollment in studies with MMF . Because MMF  has been associated with an increased incidence of digestive 
system adverse events, including infrequent cases of gastrointestinal tract ulceration, hemorrhage, and perforation, MMF  should be administered with caution in patients 
with active serious digestive system disease.  
i) Concomitant Medications.  It is recommended that MMF  not be administered 
concomitantl y with azathioprine because both have the potential to cause bone marrow 
suppression and such concomitant administration has not been studied clinically. In view of the significant reduction in the AUC of mycophenolic acid ( MPA ) by 
[CONTACT_652689], caution should be used in the concomitant administration of MMF  with 
drugs that interfere with enterohepatic recirculation because of the potential to reduce the efficacy of MMF . 
j) Patients with HGPRT Deficiency.  MMF  is an inosine monophosphate dehydrogenase 
inhibi tor; therefore it should be avoided in patients with rare hereditary deficiency of 
hypoxanthine -guanine phosphoribosyl -transferase  such as Lesch- Nyhan and Kelley -
Seegmiller syndrome.  
k) Immunizations.  During treatment with MMF , the use of live attenuated v accines should 
be avoided and patients should be advised that vaccinations may be less effective.  
l) Drug Interactions.  Drug interaction studies with MMF  have been conducted with 
acyclovir, antacids, cholestyramine, cyclosporine, ganciclovir, oral contracept ives, 
sevelamer, trimethoprim/sulfamethoxazole, norfloxacin, and metronidazole. Drug interaction studies have not been conducted with other drugs that may be commonly 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   31 administered to renal, cardiac or hepatic transplant patients. MMF  has not been 
administe red concomitantly with azathioprine.  
• Acyclovir.  Coadministration of MMF  (1 g) and acyclovir (800 mg) to 12 healthy 
volunteers resulted in no significant change in MPA AUC and Cmax. However, the 
phenolic glucuronide metabolite of MPA (MPAG ) and acyclovir plasma AUCs were 
increased 10.6% and 21.9%, respectively. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are acyclovir concentrations, the potential exists for MMF  and acyclovir or its prodrug (eg, v alacyclovir) to compete 
for tubular secretion, further increasing the concentrations of both drugs.  
• Antacids With Magnesium and Aluminum Hydroxides.  Absorption of a single dose of MMF  (2 g) was decreased when administered to ten rheumatoid arthritis patie nts 
also taking Maalox® TC (10 mL qid). The Cmax and AUC(0 -24h) for MPA were 33% 
and 17% lower, respectively, than when MMF  was administered alone under fasting 
conditions. MMF  may be administered to patients who are also taking antacids 
containing magnesi um and aluminum hydroxides; however, it is recommended that 
MMF  and the antacid not be administered simultaneously.  
• Proton Pump Inhibitors (PPIs).  Coadministration of proton pump inhibitors ( PPIs; 
e.g., lansoprazole, pantoprazole) in single doses to healt hy volunteers and multiple 
doses to transplant patients receiving MMF  has been reported to reduce the 
exposure to MPA. An approximate reduction of 30 to 70% in the Cmax and 25% to 
35% in the AUC of MPA has been observed, possibly due to a decrease in MPA 
solubility at an increased gastric pH. The clinical impact of reduced MPA exposure on organ rejection has not been established in transplant patients receiving PPIs and MMF . Because clinical relevance has not been established, PPIs should be used with 
cauti on when coadministered to transplant patients being treated with MMF . 
• Cholestyramine.  Following single -dose administration of 1.5 g MMF  to 12 healthy 
volunteers pretreated with 4 g tid  of cholestyramine for 4 days, MPA AUC decreased 
approximately 40%. This decrease is consistent with interruption of enterohepatic recirculation which may be due to binding of recirculating MPAG with 
cholestyramine in the intestine. Some degree of enterohepatic recirculation is also 
anticipated following intravenous administration of MMF . Therefore, MMF  is not 
recommended to be given with cholestyramine or other agents that may interfere with enterohepatic recirculation.  
• Cyclosporine. Cyclosporine (Sandimmu ne®) pharmacokinetics (at doses of 275 to 
415 mg/day) were unaffected by [CONTACT_652690] 1.5 g bid of mycophenolate mofetil in 10 stable renal transplant patients. The mean (±SD) AUC(0 -12h) and Cmax of cyclosporine after 14 days of multiple do ses of MMF  were 
3290 (±822) ng ·h/mL and 753 (±161) ng/mL, respectively, compared to 3245 (±1088) 
ng·h/mL and 700 (±246) ng/mL, respectively, 1 week before administration of MMF . 
Cyclosporine A interferes with MPA enterohepatic recirculation. In renal trans plant 
patients, mean MPA exposure (AUC0 -12h) was approximately 30 -50% greater when 
mycophenolate mofetil is administered without cyclosporine compared with when mycophenolate mofetil is coadministered with cyclosporine. This interaction is due to cyclospor ine inhibition of multidrug- resistance -associated protein [ADDRESS_876243], thereby [CONTACT_652691]. This information should be taken into consideration  when MMF is used without cyclosporine; changes in MPA 
exposure should be expected when switching patients from cyclosporine A to one of 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   32 the immunosuppressants which do not interfere with MPA’s enterohepatic cycle 
(e.g., tacrolimus; belatacept).  
• Telmisartan.  Concommitant administration of telmisartan and MMF  resulted in an 
approximately 30% decrease in MPA concentrations. Telmisartan changes MPA’s elimination by [CONTACT_652692]- activated receptor gamma 
expression, which in turn results in  an enhanced UGT1A9 expression and activity.  
• Ganciclovir.  Following single -dose administration to 12 stable renal transplant 
patients, no pharmacokinetic interaction was observed between MMF  (1.5 g) and 
intravenous ganciclovir (5 mg/kg). Mean (±SD) ganciclovir AUC and Cmax (n=10) were 54.3 (±19.0) μg ·h/mL and 11.5 (±1.8) μg/mL, respectively, after 
coadministration of the two drugs, compared to 51.0 (±17.0) μg ·h/mL and 10.6 
(±2.0) μg/mL, respectively, after administration of intravenous ganciclovir alone. T he 
mean (±SD) AUC and Cmax of MPA (n=12) after coadministration were 80.9 (±21.6) μg·h/mL and 27.8 (±13.9) μg/mL, respectively, compared to values of 80.3 (±16.4) 
μg·h/mL and 30.9 (±11.2) μg/mL, respectively, after administration of 
mycophenolate mofetil alone. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are ganciclovir concentrations, the two drugs will compete for tubular secretion and thus further increases in concentrations of both drugs may occur. In patient s with renal impairment in which 
MMF and ganciclovir or its prodrug (eg, valganciclovir) are coadministered, patients should be monitored carefully.  
• Oral Contraceptives.  A study of coadministration of MMF  (1 g bid) and combined 
oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.20
 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 
0.10 mg) was conducted in 18 women with psoriasis over 3 consecutive menstrual cycles. Mean AUC(0 -24h) was similar for ethinylestradiol and 3 -keto desogestrel; 
however, mean levonorgestrel AUC(0 -24h) significantly decreased by [CONTACT_2902] 15%. 
There was large inter-patient variability (%CV in the range of 60% to 70%) in the data, especially for ethinylestradiol. Mean serum levels of LH , FSH and progesterone 
were not significantly affected. MMF  may not have any influence on the ovulation -
suppressing action of the studied oral contraceptives. It is recommended to coadminister MMF  with hormonal contraceptives (eg, birth control pi[INVESTIGATOR_4382], trans dermal 
patch, vaginal ring, injection, and implant) with caution and additional barrier contraceptive methods must be used.  
• Sevelamer.  Concomitant administration of sevelamer and MMF  in adult and 
pediatric patients decreased the mean MPA Cmax  and AUC0 -12h by 36% and 26% 
respectively. This data suggest that sevelamer and other calcium free phosphate binders should not be administered simultaneously with MMF . Alternatively, it is 
recommended that sevelamer and other calcium free phosphate binder s 
preferentially could be given [ADDRESS_876244] on 
the absorption of MPA.  
• Trimethoprim/sulfamethoxazole. Following single -dose administration of MMF  (1.5 
g) to 12 healthy male volunteers on day 8 of a 10 day course of trimet hoprim 160 
mg/sulfamethoxazole [ADDRESS_876245] on the bioavailability of MPA was observed. The mean (±SD) AUC and Cmax of MPA after concomitant administration were 75.2 (±19.8) μg ·h/mL and 34.0 (±6.6) μg/mL, respectively, 
compared to 79. 2 (±27.9) μg ·h/mL and 34.2 (±10.7) μg/mL, respectively, after 
administration of MMF  alone.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   33 • Norfloxacin and Metronidazole.  Following single -dose administration of MMF  (1 g) 
to 11 healthy volunteers on day 4 of a 5 day course of a combination of norfloxacin  
and metronidazole, the mean MPA AUC0 -48h was significantly reduced by 33% 
compared to the administration of MMF  alone (p<0.05). Therefore, MMF  is not 
recommended to be given with the combination of norfloxacin and metronidazole. 
There was no significant e ffect on mean MPA AUC0 -48h when MMF  was 
concomitantly administered with norfloxacin or metronidazole separately. The mean (±SD) MPA AUC0 -48h after coadministration of MMF  with norfloxacin or 
metronidazole separately was 48.3 (±24) μg·h/mL and 42.7 (±23) μg ·h/mL, 
respectively, compared with 56.2 (±24) μg·h/mL after administration of MMF  alone.  
• Ciprofloxacin and Amoxicillin plus Clavulanic Acid .  A total of [ADDRESS_876246]  14 days. Approximately 50% reductions in 
median trough MPA concentrations (predose)  from baseline ( MMF  alone) were 
observed in 3 days following commencement  of oral ciprofloxacin or amoxicillin plus 
clavulanic acid. These reductions in trough MPA concentrations tended to diminish within 14 days of antibiotic therapy and ceased within 3 days after discontinuation of antibiotics. The postulated mechanism for this interaction is an antibiotic -induced 
reduction in glucuronidase -possessing enteric organisms leading to a decrease in 
enterohepatic recirculation of MPA. The change in trough level may not accurately represent changes in overall MPA exposure; therefore,  clinical relevance of these 
observations is unclear.  
• Rifampin.  In a single heart -lung transplant patient, after correction for dose, a 67% 
decrease in MPA exposure (AUC0 -12h) has been observed with concomitant 
administration of MMF  and rifampin. Therefor e, MMF  is not recommended to be 
given with rifampin concomitantly unless the benefit outweighs the risk.  
• Other Interactions. The measured value for renal clearance of MPAG indicates removal occurs by [CONTACT_652693] . Consistent 
with this, coadministration of probenecid, a known inhibitor of tubular secretion, 
with MMF  in monkeys results in a [ADDRESS_876247] with MMF  by [CONTACT_652694]. Interference of MPAG hydrolysis may lead to less MPA available for 
absorption.  
[IP_ADDRESS].4  Adverse Events :  
The principal adverse events report ed during the administration of MMF  include  diarrhea, 
leukopenia, sepsis, vomiting, and there is evidence of a higher frequency of certain types of 
infections eg, opportunistic infection. Elderly patients (≥65 years), particularly those who are receiving MMF  as part of a combination immunosuppressive regimen, may be at increased 
risk of certain infections  (including CMV tissue invasive disease) and possibly gastrointestinal 
hemorrhage and pulmonary edema, compared to younger individuals . 
Adverse event profiles reported in the packaging insert for MMF are those described for solid organ transplant recipi[INVESTIGATOR_652610]. By [CONTACT_108], these patients had 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   34 recent major surgery, end -stage organ failure for one or more organ systems, variable 
degrees of recipi[INVESTIGATOR_652611], and w ere receiving combination 
immunosuppression with one or more concurrent medications. The relevance of these 
reports to the administration of MMF to patients with autoimmune disease such as S Sc, in 
the absence of organ system failure and concurrent immunosu ppressive therapy, is 
unknown.   
Information that is more relevant to the patient population and intended use described in this protocol comes from SLS  II, where patients with SSc- ILD with similar characteristics 
were randomized to receive either oral CYC f or one year followed by [CONTACT_652695] a second year 
(N=73 ) or a two year course of oral MMF (N=69) . Adverse event data comparing these two 
study groups is summarized as follows:  
a) Protocol defined and managed adverse events  (AEs) . According to the protocol, five 
specific types of adverse events were pre- defined as likely to be related to the 
administration of study drugs and to warrant protocol- defined management.  
• Anemia = Hgb <10 .0 g/dl  or <9 .0 g/dl  for those with Hgb <11 .0 g/dl  at enrollment  
• Leukopenia = WBC  <2.5x10
3/µl 
• Neutropenia = neutrophil count  <1.0x103/µl 
• Thrombocytopenia = Plat elet count < 100.0x103/µl 
• Hematuria = >25 Red blood cells (or 10 -15 range on more than one routine urine 
analysis ) in absence of a urinary tract infection or menses  
These protocol -defined AEs were tracked and recorded for all subjects until the time they 
either completed the study or withdrew or were withdrawn from active participation. The development of protocol -defined AEs from the SLS II study are summarized below  by 
[CONTACT_2939] . 
Table [IP_ADDRESS].4 a. Protocol -defined and managed adverse events  reported for SLS  II  
 
†p<0.05, Fisher’s exact test comparing the number of patients experiencing AE 
(some patients had more than one AE event).  
The following conclusions were drawn from this data:  
i.  Anemia and Leukopenia were the dominant causes of protocol -defined AEs  
during treatment with MMF, accounting for 23/29 reported events.  
ii.  Absolute neutropenia , while a common occurance in patients receiving CYC, 
occured  only rarely in those receiving MMF (4.3% of patients randomized to the 
MMF arm)  and at rates reported when MMF is used for other indications . 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   35  iii.  Thrombocytopenia , which occurs during the administration of CYC,  was not 
observed in the MMF arm.  
b) All adverse events by [CONTACT_652696].  All AEs, categorized by [CONTACT_652697], were tracked and recorded for all study subjects until the time they 
either completed the study or withdrew or were withdrawn from active participation. 
Recor ded AEs from the SLS II study are summarized below by [CONTACT_652698] (least to most frequent ). 
Table [IP_ADDRESS].4b . All adverse events summarized by [CONTACT_652699]  
N N (%  of AE ) N (%  of AE ) N N (%  of 
randomized ) N (%  of 
randomized ) 
Cancer  (including skin)  6 2 (33.3)  4 (66.7)  6 2 (2.7) 4 (5.8) 
Immune System 
Disorders  6 4 (66.7)  2 (33.3)  6 4 (5.5) 2 (2.9) 
Vision and Hearing  10 8 (80.0)  2 (20.0)  8 6 (8.2) 2 (2.9) 
Hepatobiliary Disorders  12 6 (50.0)  6 (50.0)  10 4 (5.5) 6 (8.7) 
Surgical & Medical 
Procedures  17 6 (35.3)  11 (64.7)  11 5 (6.8) 6 (8.7) 
Psychiatric Disorders  22 10 (45.5)  12 (54.5)  19 9 (12.3 ) 10 (14.5 ) 
Injury, Poisoning & 
Procedural 
Complications  25 15 (60.0)  10 (40.0)  18 10 (13.7 ) 8 (11.6 ) 
Nervous System 
Disorders  31 9 (29.0)  22 (71.0)  21 9 (12.3 ) 12 (17.4 ) 
Reproductive System & 
Breast Disorders  36 17 (47.2)  19 (52.8)  27 12 (16.4 ) 15 (21.7 ) 
Metabolism & Nutrition 
Disorders*  40 24 (60.0)  16 (40.0)  33 22 (30.1 ) 11 (15.9 ) 
Vascular Disorders  66 33 (50.0)  33 (50.0)  41 22 (30.1 ) 19 (27.5 ) 
Cardiac Disorders  67 32 (47.8)  35 (52.2)  39 21 (28.8 ) 18 (26.1 ) 
Renal & Urinary 
Disorders  93 44 (47.3)  49 (53.7)  53 27 (37.0 ) 26 (37.7 ) 
General Disorders  146 85 (58.2)  61 (41.8)  64 33 (45.2 ) 31 (45.0 ) 
Skin & Subcutaneous 
Tissue Disorders  174 92 (52.9)  82 (47.1)  78 43 (58.9 ) 35 (50.7 ) 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   36 Category  Number of Reported AE  Number of Pat ients with AE  
Total  CYC MMF  Total  CYC MMF  
N N (%  of AE ) N (%  of AE ) N N (%  of 
randomized ) N (%  of 
randomized ) 
Musculoskeletal & 
Connective Tissue 
Disorders  181 102 (56.4)  79 (43.6)  68 34 (46.6 ) 34 (49.3 ) 
Blood & Lymphatic 
System Disorders*  199 149 (74.9)  50 (25.1)  67 47 (64.4 ) 20 (29.0 ) 
Respi[INVESTIGATOR_696], Thoracic & 
Mediastinal Disorders  223 102 (45.7)  121 (54.3)  91 45 (61.6 ) 46 (66.7 ) 
Gastrointestinal 
Disorders  260 115 (44.2)   145 (55.8)  87 40 (54.8 ) 47 (68.1 ) 
Infections & Infestations  290 139 (47.9)  151 (52.1)  109 57 (78.1 ) 52 (75.4 ) 
Total  1904  994 (52.2)  910 (47.8)  139 71 68  
*p<0.05, Fisher’s exact test comparing the number of patients experiencing AEs.  
The following conclusions were drawn from this data:  
i.  The distribution of AEs is similar to that observed in the SLS I study with the  [ADDRESS_876248] to either the 
total # of AEs or the total # of patients with AEs , there was an unequal distribution 
between study arms with respect to two categories; blood and lymphatic disorders 
and metabolism and nutrition disorders. In each case, fewer events were observed in the patients treated with MMF as compared to those treated with CYC, supporting the overall conclusion from SLS II that treatment with oral MMF appe ars 
better tolerated than treatment with oral CYC .  
iii. When broken down further, it was determined that the difference between groups 
for blood and lympatic disorders was primarily driven by [CONTACT_652700] - 
reinforcing the findings from the recording of protocol- defined events noted above.  
iv. When broken down further, no statistically significant difference between groups was identified for individual categor ies within the subset  of metabolism and 
nutrition disorders . The only  notable  numerical imbalance (although not statistically 
significant) being for the category of weight loss, which occured more frequently in patients receiving CYC.  
c. Severe Adverse Events . All SAEs, categorized by [CONTACT_652696], were 
tracked and recorded for all study subjects . In addition, all SAE documentation was 
reviewed by [CONTACT_652701], one pulmonologist and one gener al internal medicine specialist, who 
determined the relatedness of the SAE according to the study protocol (related to study 
S c l e r o d e rm a  L u n g  S t u d y  I I I                                            [ C o n f i d e n t i a l ]  V e r s i o n  2 . 5  
P r o t o c o l  # U C L A -S L S 3  1 1 / 1 7 / 2 1  
F D A  I N D  # :  1 3 5 8 4 8   3 7  t r e a tm e n t ,  r e l a t e d  t o  u n d e r l y i n g  d i s e a s e ,  r e l a t e d  t o  o t h e r  c a u s e s  o r  r e l a t e d  t o  u n k n o w n  
c a u s e s ) .   
T a b l e  2 . 3 . 1 . 1 . 4 c - 1 .  S e r i o u s  a d v e r s e  e v e n t s  r e p o r t e d  f o r  S L S  I I .   
C a t e g o r y  #  o f  P a t i e n t s  #  o f  S A E s  MM F  C Y C  
C a n c e r  3  3  2  1  
R e n a l / B l a d d e r  2 2 1 1 
S y n c o p e /  S e i z u r e s  2 3 3 0 
H em a t o l o g i c  3 3 1 2 
M i s c e l l a n e o u s  6 6 5 1 
G a s t r o i n t e s t i n a l  6 7 2 5 
M u s c u l o s k e l e t a l /  S k i n  6 7 4 3 
R e s p i r a t o r y  I n f e c t i o n  9  9  2  7  
R e s p i r a t o r y  1 2  1 8  1 2  6  
C a r d i a c  1 6  2 0  1 0  1 0  
T O T A L  6 5  7 8  4 2  3 6  
• C a n c e r  c a s e s  i n c l u d e d  l ym p h om a  a n d  a d e n o c a r c i n om a  o f  t h e  l u n g  ( 2  c a s e s )  
• R e n a l / B l a d d e r  c a s e s  i n c l u d e d  o n e  r e n a l  c r i s i s  w i t h  s t r o k e  a n d  o n e  b l a d d e r  l e s i o n  w i t h  h em a t u r i a  
• H em a t o l o g i c  c a s e s  i n c l u d e d  a n em i a  ( 2  c a s e s )  a n d  a  b l o o d  c l o t  ( 1  c a s e )   
• M i s c e l l a n e o u s  c a s e s  i n c l u d e d  a n  a s s a u l t ,  s u l f a  a l l e r g y ,  w e i g h t  l o s s ,  a n d  e l e c t i v e  s u r g e r i e s   
• G a s t r o i n t e s t i n a l  c a s e s  i n c l u d e d  d y s p h a g i a / v om i t i n g ,  g a s t r o e n t e r i t i s ,  b i l e  d u c t  o b s t r u c t i o n ,  a n d  
s c l e r o d e rm a  b o w e l .   
• M u s c u l o s k e l e t a l / s k i n  c a s e s  i n c l u d e d  a r t h r i t i s ,  f r a c t u r e s ,  e l b o w  p a i n / u l c e r ,  a n d  i n f e c t e d  b u r s a  w i t h  
a b s c e s s   
• R e s p i r a t o r y  i n f e c t i o n s  i n c l u d e d  i n f l u e n z a ,  b r o n c h i t i s  a n d  p n e um o n i a  
• R e s p i r a t o r y  c a s e s  i n c l u d e d  p r o g r e s s i v e  d y s p n e a ,  r e s p i r a t o r y  f a i l u r e ,  s e v e r e  h y p o x em i a ,  p r o g r e s s i v e  
I L D ,  a n d  s h o r t n e s s  o f  b r e a t h  
• C a r d i a c  c a s e s  i n c l u d e d  h e a r t  f a i l u r e ,  p a l p i t a t i o n s ,  a r r h y t hm i a s ,  c h e s t  p a i n / p r e s s u r e ,  p e r i c a r d i t i s ,  
c a r d i a c  c a t h ,  i s c h em i c  h e a r t  d i s e a s e ,  a n d  n o n -i n f e c t i v e  n o d u l e  o n  m i t r a l  v a l v e  
 
T a b l e  2 . 3 . 1 . 1 . 4 c - 2 .  R e l a t e d n e s s  o f  S e r i o u s  A d v e r s e  Ev e n t s  r e p o r t e d  f o r  S L S  I I .   
 
T h e  f o l l o w i n g  c o n c l u s i o n s  w e r e  d r a w n  f r om  t h i s  d a t a :  
i.   S A E s  o c c u r r e d  s l i g h t l y  m o r e  f r e q u e n t l y  i n  t h e  MM F  g r o u p  t h a n  t h e  C Y C  g r o u p  
( n = 4 2  v s 3 6 ) ,  w h e r e a s  n um e r i c a l l y  m o r e  S A E s  i n  t h e  C Y C  g r o u p  ( n = 8 )  t h a n  i n  t h e  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   38 MMF group (n=3)  were deemed by [CONTACT_652702].  No statistically significant differences were noted 
between treatment arms.  
ii. Relatively equal numbers of serious adverse events were attributed to systemic 
sclerosis itself (16 in each group) or to other causes (MMF [n=11] vs CYC  [n=14 }.  
iii. While a numerically great er number of Respi[INVESTIGATOR_229858]’s were observed in the 
MMF Arm (12) than the CYC Arm (6), only 4 were determined by [CONTACT_652703] . 
 
[IP_ADDRESS]   Pi[INVESTIGATOR_7735] 
[IP_ADDRESS].1  Blac k Box Warnings:  
None   
[IP_ADDRESS].2  Contraindications:  
None  
[IP_ADDRESS].3  Warnings:  
a) Elevated  Liver Enzymes and drug- induced liver injury . Increases in Alanine 
Aminotransferase ( ALT),  Aspartate Aminotransferase ( AST) and bilirubin elevations  
have been reported in patients treated with PFD including cases of drug- induced liver 
injury . In postmarketing reporting, non -serious and serious cases of drug -induced liver 
injury, including severe liver injury with fatal outcome. Patients treated with PFD  2403 
mg/day in the three Phase [ADDRESS_876249] ≥3 
× ULN than placebo patients (3.7% vs. 0.8%, respectively). Elevations ≥10 × ULN in ALT 
or AST occurred in 0.3% of patients in the PFD 2403 mg/day group and in 0.2% of 
patients in the placebo group. Increases in ALT and AST ≥3 × ULN  were reversible with 
dose  modification or treatment discontinuation. Conduct liver function tests (ALT, AST, 
and bilirubin) prior to the initiation of therapy with PFD in all patients, then monthly for 
the first 6 months , every 3 months thereafter , and as clinically indicated . Mea sure liver 
function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.  
Dosage modifications or interruption may be necessary for liver enzyme elevations  
b) Photosensitivity Reaction or Rash.  Patients treated with PFD 2403 mg/day in the three 
Phase 3 studies had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). The majority of the photosensitivity reactions 
occurred during the initial [ADDRESS_876250] patients to avoid or minimize exposure to 
sunlight (including sunlamps), to use a sunblock (SPF 50 or higher), and to wear clothing 
that protects against sun exposure. Additionally, instruct patients to avoid concomitant medications known to cause photosensitivity. Dosage reduction or discontinuation may be necessary in some cases of photosensitivity reaction or rash.  
c) Gastrointestinal Disorders.   In the clinical studies, gastrointestinal events of nausea, 
diarrhea, dyspepsia, vomiting, gastro -esophageal reflux disease,  and abdominal pain 
were more frequently reported by [CONTACT_652704]. Dosage reduction or interruption for gastrointestinal events was required in 18.5% of patients in the 2403 mg/day group, as compared to 5.8% of 
patients in the placebo group; 2.2% of patients in the PFD 2403 mg/day group 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   39 discontinued treatment due to a gastrointestinal event, as compared to 1.0% in the 
placebo group. The most common (>2%) gastrointestinal events that led to dosage reductio n or interruption were nausea, diarrhea, vomiting, and dyspepsia. The incidence 
of gastrointestinal events was highest early in the course of treatment (with highest 
incidence occurring during the initial 3 months) and decreased over time. Dosage 
modificat ions may be necessary in some cases of gastrointestinal adverse reactions.  
2.3.1. 2.4 Adverse Events  reported during the treatment of IPF:   
Adverse reactions related to Liver Enzyme Elevations , Photosensitivity Reaction or Rash, and 
Gastrointestinal Disorders  represent the principal adverse reactions associated with the 
administration of PFD  and have already been described in the Warnings section above  and 
are detailed in the Investigational Broc hure ( 11). 
The safety of PFD has been evaluated in more than 1400 subjects with over  170 subjects 
exposed to PFD for more than 5 years in clinical trials.  PFD was studied in 3 randomized, 
double -blind, placebo -controlled trials (Studies 1, 2,  and 3) in which a total of 623 patients 
received 2403 mg/day of PFD  and 624 patients  received placebo. Subjects ages ranged from 
40 to 80 years (mean age of 67 years). Most  patients were male (74%) and Caucasian (95%). 
The mean duration of exposure to  PFD was 62 weeks (range: 2 to 118 weeks) in t hese 3 
trials. 
At the recommended dosage of 2403 mg/day, 14.6% of patients on PFD  compared to  9.6% 
on placebo permanently discontinued treatment because of an adverse event. The most 
common (>1%) adverse reactions leading to discontinuation were rash and n ausea. The 
most  common (>3%) adverse reactions leading to dosage reduction or interruption were 
rash,  nausea, diarrhea, and photosensitivity reaction.  
The most common adverse reactions with an incidence of ≥10% and more frequent in the 
PFD than placebo treatment group are listed in Table 2 .3.1. 2.4a (adapted from ref #12 ).  
Table 2.3.1. 2.4a. Adverse reactions occurring in ≥10% of PFD (ESBRIET )-treated patients 
and more commonly than pl acebo in s tudies 1, 2, and 3  (adapted from ref # 12). 
 
 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   40 Adverse reactions occurring in ≥5 to <10% of PFD -treated patients and more  commonly 
than placebo are photosensitivity reaction (9% vs. 1%), decreased appetite (8% vs. 3%), 
pruritus (8% vs. 5%), asthenia (6% vs. 4%), dysgeusia (6% vs. 2%), and non -cardiac  chest 
pain (5% vs. 4%).  
In addition to adverse reactions identified from clinical trials the following adverse 
reactions  have been identified during postapproval use of PFD . Because these reactions 
are reported voluntarily from a population of uncertain size, it is not always possible to 
reliably  estimate their frequency.  
a) Blood and Lymphatic System Disorders: Agranulocytosis  
b) Immune System Disorders: Angioedema  
c) Hepatobiliary Disorders: Bilirubin increased in combination with increases of ALT and AST  
2.3.1. 2.5 Adverse Events reported during the treatment of SSc -ILD:   
Directly relevant to this proposal, patients with SSc -ILD were treated in a multinational, 
open -label, randomized, parallel-group  safety and tolerability trial (LOTUSS study ; 11,2 0) 
and received PFD when titrated from starting to final dose over a 2 week interval (one arm) vs a 4 week interval (second arm). Titration started at a dose of 801 mg/day and increased up to a maintenance dose of 2403 mg/day . Patients received PFD for [ADDRESS_876251] AEs were mild or moderate and resolved without sequelae; severe AEs were reported in 19%, most 
commonly fatigue, diarrhea, and nausea and consistent with the experience in IPF. Similarly, all of the most commonly reported ( >10%) AEs have been seen in pi[INVESTIGATOR_652612]. 
The AE system organ class (SOC) with the greatest incidence was gastro intestinal disorders, 
with nausea, diarrhea, vomiting, GERD, dyspepsia, constipation, and stomach discomfort each occurring in > 10% of patients. GI events were mostly mild or moderate and none led to 
study treatment discontinuation.  
AEs of interest in this study (events known or suspected to be associated with PFD administration and occurring in organs or systems already affected in patients with scleroderma) were nausea (49.2%), vomiting (28.6%), and skin events: rash (20.6%), photosensitivity reaction (6 .3%), erythema (4.8%), and follicular rash (1.6%). Almost all of 
these events were mild or moderate and considered related to study treatment.  Three patients (4.8%) had SAEs (bronchitis, small intestinal obstruction, and pulmonary hypertension/interstitia l lung disease [P AH/ILD]); all but the P AH/ILD events resolved. No 
deaths occurred during this study. There were no clinically relevant abnormal findings in clinical laboratory tests including liver function tests (LFT), vital signs, body weight, or ECGs . 
 
2.3.1. [ADDRESS_876252] been instituted to minimize these risks and improve the risk:benefit  ratio for 
participants. First, while neither drug is approved for the treatment of SSc -ILD, they are 
approved for related conditions and will be used within the dosage range and with the accumulated knowledge of their effectiveness and potential toxicity gained from their prescribed uses. In addition, based on past experience with the administration of 
immunosuppressive therapi[INVESTIGATOR_652613] -ILD, the inclusion and exclusion criteria have 
been selected to enrich for subjects most-likely to benefit from therapy (see Inclusion Criteria) 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   41 and to avoid those subjects who are less -likely to benefit or more likely to experience 
treatment- related toxicity (see Exclusion Criteria). Concurrent medications that adversely 
interact with the study drugs or with the potential adverse effects of the study drugs will be 
excluded. Pregnancy status will be carefully evaluated, institution of appropriate precautions 
verified in participants of childbearing potential, and pregnancy status monitored throughout 
the study. In addition, frequent and routine laboratory monitoring will be carried out throughout the entire study protocol. The Clinical Investigator is responsible for reviewing and 
acting on toxicity data in accordance with a protocol- defined action plan. The Clin ical 
Investigator will be guided in the management of study drugs by [CONTACT_652705]. In view of a recent FDA warning concerning the occurrence of progressive multifocal leukoence phalopat hy in subjects receiving 
MMF (always in conjunction with other immunosuppressive therapy), subjects in SLS II will be monitored closely for evidence of any neurologic symptoms or findings suggestive of the early development of progressive multifocal leukoencephalopathy, such as apathy, confusion, 
cognitive deficiencies, ataxia or hemiparesis.  
 
2.3.[ADDRESS_876253] to the known progression of disease that occurs without treatment ( 10,50-52) , sug gesting that it has a disease modifying effect and supporting its 
ongoing clinical evaluation as a potential treatment for SSc -ILD. PFD is currently approved for the 
treatment of IPF  and as presented in Section 2.[ADDRESS_876254] been observed in the 
treatment of IPF, will complement the delayed anti -inflammatory and immunosuppressive effects of 
MMF, to produce a significantly more rapid and/or greater improvement in  lung function over time than 
occurs in patients receiving control therapy with MMFand Plac.  
The Primary Objective is therefore to assess the impact of combined PFD and MMF, as compared to 
treatment with MMF alone (i.e combined with Plac), on the overall course of lung function over an 18 -
month course of therapy.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876255].  
 
4 STUDY DESIGN AND ENDPOINTS  
 
4.1  DESCRIPTION OF THE S TUDY DESIGN  
 
The SLS  III study is designed as a  Phase II multi -center, double -blind, parallel group, randomized and 
placebo -controlled clinical trial addressing the treatment of patients with active and symptomatic SSc -
ILD. Enrollment will occur at 15 to 20 participating academic clinical centers withi n the [LOCATION_002]. 
150 patients who are either treatment- naïve or only recently started on treatment (<6 mo of prior 
treatment with a potentially disease -modifying therapy) will be randomized in a 1:1 assignment to 
receive either oral MMF and Plac  (acting as a control arm) or a combination of oral MMF and oral PFD 
(acting as an experimental arm), with both regimens administered for [ADDRESS_876256] imaging measures of lung inflammatory and fibrotic changes, dyspnea, assessments of skin inflammation and thickening, and patient reported measures of 
symptoms and quality of life.  Tolerability and t oxicity of the two treatments will also be assessed. 
 
4.2.1  Primary Endpoint  
The primary endpoint  is the change from baseline, measured at 3 -month intervals, in the mean 
forced vital capacity (represented as the percentage of the age -, height -, gender - and race -adjusted 
predicted value,  i.e. FVC -%) over the course of the 18 -month double -blind treatment period.   
 
4.2.2  Secondary Endpoints  
4.2.2. 1 The change from baseline to 18 months, measured at 3 -month intervals, in single -breath 
diffusing capacity for carbon monoxide (DLCO), calculated as a percent of the age -, height -, 
gender -, race - and hemoglobin -adjusted predicted value (DLCOHb -%).  
[IP_ADDRESS]  The change from baseline to 18 months, measured at 3 -month intervals, in  the Modified 
Rodnan Skin Score (mRSS).  
[IP_ADDRESS]  The change from baseline to 18 months, measured at 3 -month intervals, in dyspnea, as 
measured by [CONTACT_652706] (BDI and TDI , respectively. )  
[IP_ADDRESS]  The change from baseline to 18 months, measured at 3 -month  or 6-month  intervals, in 
Patient Reported Outcomes (PROs), which provide subjective measures of dyspnea and quality 
of life based on patient responses to standardized patient questionnaires  which include:  
a) St. George Respi[INVESTIGATOR_6015] ( SGRQ ); 3 month intervals  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   43 b) Health assessment questionnaire modified for scleroderma ( SHAQ ); 6 month interval s 
c) Patient -reported outcomes measurement information system 29 -item health profile  
(PROMIS -29 version 2.0) ; 6 month intervals  
[IP_ADDRESS]  The change from baseline to [ADDRESS_876257] measures of SSc -ILD which 
specifically include : 
a) Quantitative lung fibrosis  score in the whole lung (QLF -WL).  
b) Quantitative lung fibrosis  score in the lobe of maximal involvement (QLF -LM).  
c) Quantitative interstitial lung disease  score in the whole lung (QILD -WL).  
d) Quantitative interstitial lung disease  score in the l obe of maximal involvement (QILD -
LM).  
e) Total lung capacity at maximum inspi[INVESTIGATOR_1516] (HRCT -TLC)  
[IP_ADDRESS]  Differences in the frequency distribution of individual patient responses when grouped into 
defined intervals of improvement or worsening (defined by [CONTACT_652707] 18 months) for the following outcome measures:  
a) Forced vital capacity (represented as the percentage of the age -, height -, gender - and 
race -adjusted predicted value,  i.e. FVC -%) 
b) Single -breath diffusing capacity f or carbon monoxide (DLCO), calculated as a percent of 
the age, height, gender -, race - and hemoglobin -adjusted predicted value (DLCOHb -%).  
c) Modified Rodnan Skin Score (mRSS).  
d) Transitional Mahler Modified Dyspnea Index (TDI)  
[IP_ADDRESS] The time (in months) req uired for each treatment arm to achieve  a 3.0% or greater 
improvement from baseline in the FVC -% over the 18 -month treatment period . 
[IP_ADDRESS]  A threshold analysis based on the percentage of subjects in each treatment arm achieving 
greater than a 5% improvement from baseline in FVC -% over the 18 -month treatment period . 
[IP_ADDRESS]  Tolerability and toxicity of combined MMF  and Plac v s MMF  and PFD over the course of 18 
months.  
 
4.2.3  Other Important Endpoints  
[IP_ADDRESS]  Physician an d Patient Global Assessments  
a) Physician global assessment of patient’s “overall health” in the past week on a Likert 
scale; 6 month intervals  
b) Physician transition questions comparing patient’s  i) overall health and ii) lung 
involvement  to that at the baseline visit; 6 month intervals  
c) Patient global assessment of “overall health” in the past week on a Likert scale; 6 
month intervals  
d) Patient  transition questions comparing their  i) overall health and ii) lung involvement  to 
that at the ba seline visit ; 6 month intervals  
[IP_ADDRESS]  UCLA Scleroderma Clinical Trial Consortium GIT 2.0 ( UCLA SCTC GIT 2.0); 6 month intervals  
[IP_ADDRESS]  Leicester Cough Questionnaire  (LCQ); 6 month intervals  
 
  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   44 4.2.4 Exploratory Endpoints  
Exploratory endpoints will include the following:  
[IP_ADDRESS] Identification of baseline features that predict treatment responsiveness, disease 
progression and the course of lung and skin disease over time.  
[IP_ADDRESS] Identification of biomarkers that predict disease features, treatment responsiveness, 
disease progression and the course of lung and skin disease over time.  
[IP_ADDRESS] Composite outcome measures that distinguish early and late treatment responses 
[IP_ADDRESS]  Performance of CRISS index at [ADDRESS_876258] meet all of the following 
inclusion criteria. Notes are included , as needed,  to provide additional explanation and/or background 
rationale for s elected  criteria (see bullet points) . Patients will provide cons ent prior to the screening  and 
screening is included as part of the consent process. N ote that the screening occurs in stages in order to 
limit unnecessary testing : 
Screening criteria that must be met prior to moving forward to HRCT imaging 
5.1.1  Age >18 yrs 
5.1.2   Scleroderma as determined by [CONTACT_941] 2013 ACR/EULAR classification criteria.  
5.1.3   Grade ≥2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index  
(Becomes short of breath with moderate or average tasks such as walking up a gradual hill, 
climbing less than three flights of stairs, or carrying a light load on the level.  
5.1.4   FVC-% of  ≤85% at screening.  
• NOTE: Inter -test variability for FVC -% can range up to 10% and therefore some 
participants with an FVC-% between 80 -85% at screening might exceed an FVC-% of 85% 
when testing is repeated at the baseline. 
• NOTE: The acceptable reproducibility of t he FVC -% at baseline will be governed by 
[CONTACT_266335] #[ADDRESS_876259] non -Raynaud manifestation of SSc within the prior 84 months.  
• This criteria is based on the natural history SSc -ILD which is known to be more 
progress ive early after the onset of scleroderma and become less active over time.  
 
Screening HRCT imaging    
5.1.6   Presence of any ground glass opacification (any GGO) on thoracic HRCT  
• This criteria defines a population with active and measurable parenchymal lung 
involvement . 
 
Final s creening criteria fulfilled at  Baseline Visit, but prior to randomization  
5.1.7    Repeat FVC -% at the baseline visit within 10% of the FVC -% value measured at screening. If 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   45 these criteria are not met, a repeat FVC -% may be obtained within [ADDRESS_876260] 
may qualify for randomization if the repeat FVC -% agrees within 10% of the FVC -% obtained 
at screening . 
 
5.2  PARTICIPANT EXCLUSIO N CRITERIA  
An individual who meets any of the following criteria will be excluded from participation in this study .  
The majority of exclusion criteria are assessed at screening, unless explicitly stated.  Notes are included , 
as needed,  to provide additional explanation and/or background rationale for s elected  criteria  (see 
bullet points) .  
5.2.1  Disease features supporting the primary diagnosis of another connective tissue disease such 
as rheumatoid arthritis, systemic lupus erythematosus or mixed connective  tissue disease  
(Features consistent with a secondary Sjogren syndrome or scleroderma -associated 
myopathy will be allowed).  
5.2.2    FVC-% <45% at either screening or baseline.  
• to avoid severe, probably irreparable disease  associated with higher morbidity  
5.2.3    FEV1/FVC ratio <0. 65 at either screening or baseline.  
• to avoid concurrent and clinically -significant obstructive lung disease which  can increase 
the risk  for infection, need for corticosteroid therapy, and interferes with use of 
spi[INVESTIGATOR_652614]  
5.2.4    DLCOHb -% of <30%  at screening or < 25% at baseline . 
a)   All participants with a DLCOHb-% between 30 to 40% must have pulmonary artery 
pressures documented by [CONTACT_652675], right heart catheterization or 
magnetic resonance imaging in order to be considered for inclusion.  
• the risk for concurrent scleroderma-related pulmonary vascular d isease is increased in 
patients with higher FVC/DLCO ratios, warranting additional testing before including 
such subjects in the study.  
• In order to account for normal test -to-test variability, subjects with an acceptable 
DLCOHb -% of between 30%  to 40%  at screening, with no evidence of clinically significant 
pulmonary hypertension, will remain eligible at their baseline measurement as long as  
the DLCOHb -% is >25% predicted.  
5.2.[ADDRESS_876261] of care clinical assessment performe d outside of 
the study protocol.  
• to avoid concurrent scleroderma -related pulmonary vascular disease that could alter 
primary and secondary outcome measures in a manner independent of the effect of the investigational drugs . 
• The presence of mild pulmonary hypertension, identified as either an estimated right ventricular  systolic pressure of </=40 mmHg on echocardiogram or mean  systolic 
pulmonary artery pressure of </=30 mmhg on right heart catheterization is acceptable for inclusion in the study if there are no signs of right heart dysfunction and treatment 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   46 includes no mo re than one oral PAH medication.  
5.2.6    Evidence of uncontrolled congestive heart failure, unstable ischemic heart disease, history 
of complicated pulmonary embolism  impacting on heart or lung function , or unstable 
cardiac arrhythmia requiring chronic anticoagulation.  
• to avoid undiagnosed scleroderma cardiomyopathy and unstable patients whose concurrent disease might  impact on the measured study outcomes . 
5.2.[ADDRESS_876262] not attributable to SSc   
• e.g., lung mass, cavitary lesion, airspace consolidation, mediastinal adenopathy, etc.  
5.2.8    Hematologic abnormality at screening including:  
a)  Leukopenia (white blood cells [WBC] <4.0x10
3/µl)  
b)  Thrombocytopenia (platelet count < 120.0x103/µl) 
c)  Clinically significant anemia [Hemoglobin (Hgb) <10.0 g/dl]   
Participants with an identified and correctable etiology may be eligible  if repeat t esting 
within the maximal 90 -day screening period meets all criteria.  
• to avoid persistent  bone marrow abnormalities or bleeding that would complicate 
detection and treatment of a primary side effect of MMF therapy . 
5.2.[ADDRESS_876263] (LFTs) or total bilirubin that are >2.0 x upper normal limit.  
5.2.10 S erum creatinine >2.0mg/dl  
5.2.11  History of recurrent aspi[INVESTIGATOR_1516], uncontrolled heartburn, or gastroesophageal reflux disease with a reflux scale score of >1.00 as determined by a UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Scale (UCLA SCTC  GIT), Version 2.0.  
Participants with uncontrolled heartburn or GERD that is amenable to medical management 
may be eligible if repeat testing within the maximal 90 -day screening period meets this 
criteria. 
• both medications can exhibit significant GI toxic ity and it would be inappropriate to 
include patients already exhibiting clinically significant and uncontrolled GI symptoms . 
5.2.12  Known achalasia, esophageal stricture or esophageal dysfunction sufficient to limit the 
ability to swallow medication.  
• this trial re quires that patients take a large number of capsules at frequent intervals 
throughout the day and these conditions represent significant obstacles to compliance.  
5.2.13  Pregnancy (documented by [CONTACT_652676]) and/or breast feeding  
5.2.14  If of child bearing potential (a female participant < 55 years of age who has not been postmenopausal for ≥ 5 years or who has not had a bilataeral salpi[INVESTIGATOR_1656], hysterectomy 
and/or oophorectomy), failure to employ two reliable means of contraception wh ich may 
include   surgical sterilization, barrier methods, spermicidals, intrauterine devices, and/or hormonal contraception, unless the participant chooses abstinence (to avoid heterosexual intercourse completely) .  If a subject chooses abstinence, then a  second reliable means of 
contraception is not needed . 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   47 5.2.15  Prior use of potential disease modifying antirheumatic drugs (DMARDs) according to the 
following exposure rules:  
a)  Use of oral cyclophosphamide (CYC), MMF, azathioprine or other oral or short  half- life 
DMARDs (as detailed in Section 7.5.1a) for more than  [ADDRESS_876264] year, as 
determined at the time of the initial screening visit. 
b)  Treatment with more than three intravenous doses of CYC, more than one course of 
Rituximab or other intravenous or injectable DMARDs (as detailed in Section 7.5.1b) in the past year.  
c) ) More distant h/o treatment with a DMARD is allowed as long as the patient has a new 
diagnosis/new epi[INVESTIGATOR_652593] -ILD since stoppi[INVESTIGATOR_652615] 15a or 15b. 
• these criteria have been adopted as the cut -off for enrolling treatment naïve 
patients as we are particularly focused on the contribution of early treatment on the 
study outcome s. 
5.2.[ADDRESS_876265]  (as detailed in Section 7.5.1a&b )  
in the [ADDRESS_876266] o f the patient .
  
• the study focuses on  treatment- naïve patients (as defined above) and a wash -out period 
from pre-study drugs with potential DMARD activity will help to clarify  the contribution 
of early exposure to PFD on the treatment outcome.  
• subjects who meet all other criteria, but have been on limited therapy  with MMF  and 
decide to participate,  will be assessed by [CONTACT_652708]’s best clinical interest to stop MMF and complet e a 30-day 
washout  period or to continue on pre -study drug therapy until the time of 
randomization . 
5.2.17  Active infection (lung, ulcers or elsewhere) whose management would be compromised by [CONTACT_256204].  
5.2.18  Other serious concomitant medical illness (e.g., acti ve malignancy within the past 5 years 
other than surgically -removed local skin cancer such as a basal cell carcinoma), chronic 
debilitating illness (other than SSc), unreliability or drug abuse that might compromise the patient’s participation in the trial. 
5.2.19  Current use, or use within the 30 days prior to their baseline visit , of prednisone (or 
equivalent) in doses >10 mg/day.  
• to avoid increased drug toxicity  due to combined immunosuppression . 
• subjects who meet all other criteria, but have been on hi gher doses of prednisone, will 
be allowed to decrease their prednisone (or equivalent) dose and proceed to the baseline visit at the completion of the [ADDRESS_876267] 6 months.   
• to avoid the increased risk of pulmonary complications and variation in lung function that 
would be independent from the primary study objectives.  
5.2.21  Use of contraindicated medications, including medications with putative disease -modifying 
properties that do not meet the exposure limits described in Exclusion Criteria #15 and #16 , 
moderate or strong inhibitors of cytochrome P450 (CYP) isozyme 1A2 (CYP1A2) (note 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   48 ciprofloxacin allowed up to a dose of 500 mg twice daily), and moderate inducers of CYP1A2 
(such as tobacco smoke or phenytoin). See Section 7.[ADDRESS_876268].  
 A study eligibility form will be completed at the end of screening  and baseline (i.e., prior to 
randomization)  to assure that all criteria have been met before a subject is eligible for randomization.  
 
5.3  DISCONTINUING DRUG TREATMENT OR COMPLETE  WITHDRAWAL  FROM THE 
STUDY  
Patients participating in this study may discontinue active drug treatment  but continue with follow -up. 
They may also completely withdraw from  the study (i.e. drop out; end their participation entirely).  
 
5.3.1   Reasons for Discontinuing Drug Treatment or Withdraw ing from Study  
Patients participating in this study may discontinue active drug treatment or completely withdraw from the study (or their participation terminated ) for the following anticipated reasons.  
[IP_ADDRESS]  Ongoing participation in this research study is voluntary and patients may discontinue active drug treatment or completely withdraw from the study  at any time without an identified 
cause or the ne ed for explanation .  
[IP_ADDRESS]  Patients may also discontinue  or be removed from active drug treatment due to adverse 
event s (AEs), laboratory abnormality, or other medical condition or situation such that 
continued use of one or both  of the study  drugs is not considered to be in the ir best 
interest. 
[IP_ADDRESS]  Patients who become p regnan t and/or start breast feeding ; which are  absolute 
contraindication s to continued therapy ,  will be required to stop active drug therapy . 
5.3.1. 4 Patients who meet the pre- defined criteria for a “Treatment Failure” (see Section 5.3.2) will 
be withdrawn from the active drug treatment  . 
 
5.3.2  Definition and Handling of Treatment Failures  
Subjects who, after >3 months of study, demonstrate a n absolute  fall in FVC -% of ≥ 15 % from their 
baseline determination will be classified as “treatment failures” (e. g., an initial FVC -% of 75% would 
need to drop to ≤60% to be classified as a treatment failure). A treatment failure will also be 
defined , after >3 mont hs of study,  when the FVC -% falls below a lower limit of <35%, regardless of 
the absolute change from baseline (e.g., an initial FVC -% between 45% and 49% that declines to 
≤35%). To meet these definitions, subjects must have two FVC-% measurements greater than 15 
days apart, both showing an absolute  decrement of  ≥15 % from baseline and/or a FVC -% of ≤ 35%. 
Subjects with treatment failures will be withdrawn from  active drug treatment ( both PFD/Plac and 
MMF ). The clinical management of treatment failures will be at the discretion of the patient and 
their treating physician. The study blind will not be broken unless the treating physician is convinced 
that unblinding is required in order to appropriately treat the patient  and their request is reviewed 
and agree d to by [CONTACT_19305]. Subjects who fail treatment will be encouraged to return 
for key outcome determination s at 12 and 18 month s, at which time any  medication prescribed by 
[CONTACT_652709] 12 and 18- month visit s. 
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   49 5.3.3  Handling of Premature Participant Withdrawals  
Should a participant prematurely  discontinue  all active drug treatment for any reason , he/she will 
be asked to return for key outcome determination s at 12 and 18 months . Their clinical management 
during the intervals between these visits will be at the discretion of the patient and their treating 
physician.  At the 12 and 18 month visits , any medication prescribed by [CONTACT_652710] 12 and 18-month visit s. The participant will also be asked to participate in an exit visit, either by 
[CONTACT_48052], to document t he reason for withdrawal and the status of the participant at the 
time of the withdrawal. Should the participant die, the cause of death will be determined and 
recorded if possible. This additional data will be utilized in the statistical analysis of the primary and secondary study outcomes as defined by [CONTACT_652711] .  
If only PFD/Plac is prematurely discontinued, and the participant continues to take MMF according to the protocol, then they will continue their participation in all study visits according to the normal 
study protoc ol. 
If MMF is prematurely  discontinued, the participant must stop the PFD/Plac study medication as 
well and will be asked to return for key outcome determination s at 12 and 18 months . Their clinical 
management during the intervals between these visits will be at the discretion of the patient and 
their treating physician.  At the 12 and 18 month visits , any medication prescribed by [CONTACT_652712] 12 and 18- month visit s. 
Participants who completely withdraw from the study (drop out; end their participation entirely) will 
be asked to participate in an exit visit, either by [CONTACT_48052], to docum ent the reason for 
withdrawal and the status of the participant at the time of the withdrawal.  Should the participant 
die, the cause of death will be determined and recorded if possible.  
 
5.4  PREMATURE TERMINATIO N OR SUSPENSION OF S TUDY  
The investigators  and/or sponsor reserve the right to terminate the study at any time. If this becomes 
necessary, appropriate procedures for continuing long -term follow -up and assuring the adequate 
treatment and safety of the participating subjects will be arranged after r eview and approval by [CONTACT_91332] s, Institutional Review Boards and the FDA.  
The DSMB will also provide external oversight concerning the safety and scientific integrity of the study 
for the duration of the clinical trial.  The DSMB will review the p rogress of the study toward meeting 
enrollment goals, adverse and serious adverse event profiles, and study outcome measures at regular 
intervals to occur at least twice annually.  The DSMB may recommend at any time that the study should 
be terminated due to drug toxicity , patient safety, poor compliance  and/or futility considerations. In 
such cases, their recommendations will be reviewed and discussed with the Executive Committee, which will make a final determination.    
 
  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   50 6 STUDY AGENT  
 
6.1  STUDY AGENT (S) AND CONTROL DESCRIPTION  
 
6.1.1  Source and Acquisition of Study Drugs  
The Investigational Drug Section, Department of Pharmaceutical Services, University of [LOCATION_004] 
Los Angeles (UCLA) Ronald Reagan Medical Center will serve as the Pharmacy Core, providing 
centralized  drug procurement, accountability and distribution for all study drugs (MMF , PFD ) and 
the Plac. 
[IP_ADDRESS]  Mycophenolate Mofetil (MMF)  will be purchased from a generic vendor, Teva 
Pharmaceuticals, Inc., or other generic ve ndor authorized to market by [CONTACT_652713], MMF will be acquired from an alternative manufacturer 
approved by [CONTACT_652714] e quivalent 250 mg capsules. Participating study 
sites and impacted patients will be advised of any change in appearance of the capsules, 
bottles and labeling without other required change to the Protocol.  
[IP_ADDRESS]  Pi[INVESTIGATOR_7735] (PFD)  will be shipped directly by [CONTACT_3455], Genentech, Inc., to the 
UCLA Pharmacy Core . 
[IP_ADDRESS]  Placebo (Plac),  formulated to match PFD and manufactured by [CONTACT_8229], Inc.,  will be 
shipped directly to the UCLA Pharmacy Core . 
 
6.1.[ADDRESS_876269] be transferred at 
the time of prescription into new generic bottles and fresh labels attached by [CONTACT_159439]. In addition to patient specific labeling information, the information from the study label will be replicated except that the contents will indicate capsules that contain either “267 mg of PFD or matching Plac”.  
[IP_ADDRESS]  Mycophenolate Mofetil (MMF)   
Formulat ion and strength:  Size [ADDRESS_876270] opa que gelatin capsules containing 250 mg 
Appearance:   Opaque capsules, Blue and Orange   
 (Teva example,  coloring  will vary by [CONTACT_4657])  
Packaging:   Supplied in Bottles of  either  100 capsules (NDC 0093- 7334- 01) or 500 
capsu les (NDC 0093 -7334-0 5) with barcodes and labels   
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   51  (Teva example, labeling will vary by [CONTACT_4657])
 
 
 
[IP_ADDRESS]  Pi[INVESTIGATOR_7735] (PFD)   
Formulation and strength:  Size [ADDRESS_876271] opaque gelatin capsules containing 267 mg  
Appearance:   Opaque, White 
Packaging:   Labeled for investigational use only, marked as Pi[INVESTIGATOR_652616] 270 capsues with labeling as follows:  
 
6.1.2. 3 Placebo (Plac)   
Formulation and strength:  Size [ADDRESS_876272] opa que gelatin capsules containing 267 mg  
Appearance:  Opaque, White 
Packaging:   Labeled for investigational use only, marked as Plac on bottle  
Supplied in Bottles of 270 capsues with labeling as follows:  

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876273] Storage & Stability  
Prefilled and sealed bottles will be shipped from the manufacturers with labeled expi[INVESTIGATOR_1659]; 
beyond which they will not be used in the study. MMF  capsules will be stored  at room temperature; 
defined as betwee n 68°F  (20°C ) to 77°F ( 25°C) . PFD and Plac  capsules will also be stored  at room 
temperature ; defined in this case as betwee n 68°F  (20°C ) to 86°F ( 30°C) . Brief excursions in 
temperature allotted for shippi[INVESTIGATOR_51497].  
 
6.1.4  Route, Administration, Titration Schedule and Target Dose  
[IP_ADDRESS]  Drug:   MMF : [ADDRESS_876274] gelatin capsules  
 Route:  Oral, taken without food and at least one hour prior to taking a PPI.   
   T itration Schedule and Target Dose (as tolerated) :  
Dose  # of Capsules  Schedule  Dose Duration  
500 mg  2 Twice daily  4 weeks  
1000 mg  4 Twice daily  4 weeks  
1250 mg  5 Twice daily  4 weeks  
1500 mg  6 Twice daily  Duration of study  
Randomized patients who were on pre -study treatment with MMF, and for whom it was 
determined that they should continue on treatment without a 30 -day washout period, will 
be evaluated by [CONTACT_652715]:  
a)  if their pre -study dose  matches one of the levels indicated above  and they are tolerating 
the dos e, they may be started at the same dose level . This dose level should be 
administered  for the initial 4 weeks of the study and then titrated  as indicated by [CONTACT_652716].  
b)  if their pre -study dose does not match one of the levels indicated above, they may start 
at the level that is closest to but does not exceed their pre-study dose . They will 
continue on that dose for the initial [ADDRESS_876275] drug titrated  as 
indicated by [CONTACT_652717].  
c)  at the discretion of the responsible study physician, the study patient may be started at 
a dose that is lower than their pre -study dosing if it is determined to be in the  best 

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876276] drug titrated  as indicated by [CONTACT_652717].  
 
[IP_ADDRESS]  Drug:   PFD: [ADDRESS_876277] gelatin capsules  
 Route:  Oral, taken with food   
   T itration Schedule and Target Dose (as tolerated) :  
Dose  # of Capsules  Schedule  Dose Duration  
267 mg  1 Three times daily  2 weeks  
534 mg  2 Three times daily  2 weeks  
801 mg  3 Three times daily  Duration of study  
 
[IP_ADDRESS]  Drug:   Plac: [ADDRESS_876278] gelatin capsules  
 Route:  Oral, taken with meals   
  T itration Schedule and Target Dose (as tolerated) :  
Dose  # of Capsules  Schedule  Dose Duration  
267 mg  1 Three times daily  2 weeks  
534 mg  2 Three times daily  2 weeks  
801 mg  3 Three times daily  Duration of study  
 
6.1.5 Pre-specified Dose Adjustment & Modifications  
The toxicity profiles for MMF and PFD are well established as outlined in Section 2.3  and drug 
discontinuation and/or dose modification should be managed in a manner consistent with the 
following criteria in order to provide a nearly uniform response to pre -defined toxicity at all centers.  
However, i n clinical situations that fall outside of these parameters and if warranted based on good 
clinical practice, a site investigator may independently modify drug dosing as needed to assure 
patient safety. If such a change is required, the reasons for the deviation are to be documented and the Executive Committee notified within 3 days.  Medications that are contraindicated while on 
treatment with the study drugs are detailed separately in Section 7.5.  
In the event that one study drug is permanently discontinued due to tolerability, adverse event or other medical consideration, then continued use of the remaining study drug will be  according to 
the following  pre-specified management:  
• If only PFD/Plac is permanently discontinued, th e participant may continue to take  MMF  
according to the protocol  and continue their participation in all study visits according to the 
normal protocol -defined  schedule of events .   
• If MMF is prematurely discontinued, the participant must stop the PFD/Plac study medication as well and will be asked to return for key outcome determinations at 12 and 18 months  as detailed in Section 5.3.3 (  Handling of Premature Participant Withdrawals ). 
[IP_ADDRESS]  Pre-specified dose adjustments for  MMF .  
The following abnormalities and laboratory test  monitoring result s require study drug 
adjustment , either temporary (until normalization) or permanent, as indicated by [CONTACT_652718], its severity and/or course of resolution upon discontinuation of therapy.  
a) Allergic reaction associated with the  administration  of MMF . 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   54 Dose Management : Study drug will be stopped and subject withdrawn from study.  
b) Evidence of clinically significant Bone Marrow Suppression including any one or more of 
the following  
- WBC < 2.5x103/µl 
- Absolute neutrophil count  <1.0x103/µl 
- Platelet count <10 0.0x103/µl 
- Hemoglobin < 10.0 gm/dl or a drop in hemoglobin to < 9.0 gm/dl if the baseline hemoglobin was < 11.0 gm/dl  
Dose Management : Management as follows:  
• Hold study drug until there is a stabilization of the hematologic abnormality at a value above the toxicity threshold levels indicated above. In addition, if other 
causes of noted reduction s are identified  (e.g., gastrointestinal bleeding), they 
should be treated and stabilized before restarting on study drug.  
• Once threshold level s are exceeded  (an indication of recovery), MMF will be 
reintroduced at a daily dose of  1000 mg (500 mg twice daily doses) and inceased 
by 500 mg (one 250 mg capsule for each of the twice daily dose s) every two 
weeks.  At the discretion of the clinical site investigator, after taking into account whether the study drug was likely or probably related to the adverse event, the  final maintenance dose may be either the last regular dose of MMF 
taken by [CONTACT_652719] -dose less (500 mg/day less).  
• In the event of repeat toxicity, the same cycle should be repeated except with 
the intention of achieving a maintenance dose equal to 1000 mg/day less for MMF.   
c) Documentation of gastrointestinal ulcer, bleeding or abdominal emergency .  
Dose Management:  Management as follows:  
• Hold study drug until there is a clinically stable resolution of the problem . In 
addition, if other causes of noted conditions  are identified  (e.g., polyps, 
diverticulitis, untreated peptic ulcer disease ), they should be treated and 
stabilized before restarting on study drug.  
• Once a stable  recovery  occurs, as judged by [CONTACT_652720] r, MMF 
will be reintroduced at a daily dose of 1000 mg (500 mg twice daily doses) and inceased by 500 mg (one 250 mg capsule for each of the twice daily doses) every two weeks.  At the discretion of the clinical site investigator, after taking into account  whether the study drug was likely or probably related to the 
adverse event, the final maintenance dose may be either the last regular dose of 
MMF taken by [CONTACT_652719] -dose less (500 mg/day less).  
• In the event of repeat toxicity, the same cycle should be repeated except with 
the intention of achieving a maintenance dose equal to 1000 mg/day less for MMF.  
d) Pregnancy or initiation of breastfeeding. 
Dose Management : Study drug will be permanently disconti nued and subject withdrawn 
from study.  
e) Serum creatinine > 2.0 mg/dl or estimated GFR to < 40 ml/min/1.73 m2 (corrected) in 
the absence of other etiology . 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   55 Dose Management : Hold study drug until there is a clinically stable resolution of the 
problem. In addition, if  other causes of noted condition s are identified (e.g., 
medications, dehydration, etc. ), they should be treated and stabilized before restarting 
on study drug.  If there is no improvement, the study drug will be stopped and subject 
withdrawn fro m study.  
f) Ongoing infection whose management would be significantly compromised by 
[CONTACT_652721]- associated immunosuppression  or any hospi[INVESTIGATOR_059], surgery or 
infection requiring antibiotic therapy where the immununosuppressive effects of MMF are determined by [CONTACT_652722] e the patient’s 
response to therapy.  
Dose Management : Hold  study drug until the potential interaction with the medical 
condition in question has resolved. Once the patient is stable, the study drug can be restarted without dose modification.  
g) Development of a p roven malignancy other than basal cell cancer of the skin or cervical 
carcinoma in situ rem oved entirely by [CONTACT_652723] . 
Dose Management : Study drug will be permanently discontinued  and subject withdrawn 
from study.  
h) Any adverse event felt by [CONTACT_652724] a clinical significan ce sufficient to warrant holding or 
discontinuing drug.  
Dose Management:  Management as follows:  
• Hold study drug until there is a clinically stable resolution of the problem. In addition, if other causes of noted conditions  are identified , they should be 
treated and stabilized before restarting on study drug.  
• Once a stable recovery occurs, as judged by [CONTACT_652725] , MMF 
will be reintroduced at a daily dose of 1000 mg (500 mg twice daily doses) and inceased by 500 mg (one 250 mg capsule for each of the twice daily doses) every two weeks.  At the dis cretion of the clinical site investigator, after taking 
into account whether the study drug was likely or probably related to the adverse event, the final maintenance dose may be either the last regular dose of 
MMF taken by [CONTACT_652719] -dose less (500 mg/day less).  
• In the event of repeat toxicity, the same cycle should be repeated except with the intention of achieving a maintenance dose equal to 1000 mg/day less for MMF.  
• Alternatively, for less severe or dangerous adverse events (e.g., dyspepsia) not responding to concomitant medications: the study drugs may be  discontinued at 
the discretion of the clinical site investigator until the adverse event disappears. 
At that point the subject can be restarted at one-half of the original dose. The subject can return to the full dose of MMF after 2 weeks or 500 mg less ( one 
capsule less for each of the twice daily doses) as clinically indicated . All such 
discretionary  plans for adjusting study drug dosing should  be approved within 3 
days of initiation by [CONTACT_19305].  
i) Unresolved toxicity or inability to tolerate therapy with MMF for >60 days.   
Dose Management:  Study drug will be permanently discontinued and subject withdrawn 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   56 from  the treatment phase of the  study.  
 
6.1.5. 2 Pre-specified dose adjustments for PFD/Plac.   
The following abnormalities and laboratory test monitoring results require study drug 
adjustment, either temporary (until normalization) or permanent, as indicated by [CONTACT_652718], its severity and/or course of resolution upon discontinuation of therapy.  
a) For liver enzyme elevations in a patient who exhibits  >2 but  <3x the upper limit  of 
normal (ULN) for ALT and/or AST without clinical symptoms or hyperbilirubinemia after starting PFD/Plac therapy.  
Dose Management : Management as follows:  
• Any confounding medica tions that might increase liver function tests should be 
discontinued and any other potential causes identified and treated.  
• Liver function tests should be performed at 7 -14 day intervals to monitor.  
• Continue the current dose of study drug and then c hoose one of the following 
two managments based on the follow -up liver function test results:  
i. If liver function tests worsen to >3X ULN, then follow recommendations as noted in b), c) or d) below.  
ii. If liver function tests are stable or show improvement (or continued 
improvement) on repeat testing in 7 -14 days, then the study drug 
should be continued at the current dose .  
b) For liver enzyme elevations  in a patient who exhibits >3 but ≤5 × the ULN  for ALT and/or 
AST without clinical symptoms or hyperbilirubinemia after starting PFD/Plac  therapy .  
Dose Management : Management as follows:  
• Any confounding medications that might increase liver function tests should be 
discontinued and any other potential  causes  identified and treated.  
• Liver function tests should be performed at 7 -14 day intervals to monitor as 
needed based on resulting laboratory and clinical findings.  
• Choose one of the following two managments based on the results of repeat 
liver function testing:  
iii. If liver function tes ts worsen (but still do not exceed [ADDRESS_876279]) on repeat 
testing in [ADDRESS_876280] 
decreased to < 2X normal.  PFD/Plac should then be re -started at one 
capsule three times daily, re -titrated using the original study titration 
protocol (see Section [IP_ADDRESS]) and increased up to the full dosage as 
tolerated.  
iv. If liver function tests are stable or show improvement (or continued improvement) on repe at testing in 7 -14 days, then the study drug may 
be handled using one of two options at the discretion of the clinical site investigator:  
- continue at the current dosage without interruption and continue to monitor  at 7-14 day intervals. 
- reduce the PFD/Plac  dose by 1 capsule for each of the three times 
daily doses  and continue to monitor  at 7-14 day intervals .  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   57 c) For liver enzyme elevations in a patient who exhibits >3 but ≤5 × ULN  for ALT and/or AST 
that is accompanied by [CONTACT_652726] /Plac  
therapy.  
Dose Management:  Study drug will be permanently discontinued  and subject withdrawn 
from study.  
d) For liver enzyme elevations in a patient who exhibits >5 × ULN  for ALT and/or AST after 
starting PFD /Plac  therapy.  
Dose Management:  Study drug will be permanently discontinued  and subject withdrawn 
from study.  
e) For gastrointestinal symptoms that are of sufficient clinical importance to warrant drug 
dose adjustment  (typi[INVESTIGATOR_652617], diarrhea, vomiting, and dyspepsia) , the 
patient should take the following steps , if not already in place and clinically indicated,  
prior to considering dose management:  
• Take the study medication with food.  
• Spread the dose throughout the meal rather than taking all capsules at once.  
• Add appropriate pharmacologic therapy to control acid and dys motility .  
Dose Management: . 
• Reduce PFD /Plac  dose by 1 capsu le for each of the three times daily doses and if 
symptoms improve/resolve, can increase back to the original dosing after 2 weeks as tolerated. If the higher dose is still not tolerated, then 1 capsule less for each of the three times daily doses can be continued.  
• Reduce PFD /Plac  dose by 1 capsu le for ea ch of the three times daily doses  and if 
symptoms do not improve, t he study drug should be held  until the potential 
interaction with the medical condition in question has resolved. Once the patient is stable, the study drug can be re -started and titrated a ccording to the 
original schedule as tolerated.  
f) For photosensitivity skin reactions  or rash that do not respond to UVA/UVB sunscreen, 
sun avoidance, and /or the  use of over the counter topi[INVESTIGATOR_533862], and are 
of sufficient clinical importance to warrant drug dose adjustment.  
Management: . 
• Reduce PFD /Plac  dose by 1 capsu le for each of the three times daily doses and if 
symptoms improve/resolve, can increase back to the original dosing after 2 weeks as to lerated. If the higher dose is still not tolerated, then 1 capsule less 
for each of the three times daily doses can be continued.   
• Reduce PFD/Plac dose by 1 capsu le for each of the three times daily doses and if 
symptoms do not improve, t he study drug should be held until the potential 
interaction with the medical condition in question has resolved. Once the patient is stable, the study drug can be re -started and titrated according to the 
original schedule as tolerated.  
g) An infection whose management  requires the  use for Ciprofloxacin at a dose of 750 mg 
twice daily (or other fluoroquinolone at high dose)  for 2 weeks or less  will require a dose 
adjustment for PFD/Plac.  
• During the course of antibiotic treatment, the daily dose of PFD /Plac  should be 
reduced by 1 capsule three times a day during the period of concommitent use 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   58 (patients on 3 capsules should reduce to 2, while patients on 2 capsules should 
reduce to 1) . 
h) Any adverse event felt by [CONTACT_652727]/Plac and of a clinical significance sufficient to warrant adjusting or 
discontinuing drug.  
Dose Management:  Management as follows:  
• Reduce PFD/Plac dose by 1 capsue for each of the three times daily doses and if 
symptoms im prove/resolve, can increase back to the original dosing after 2 
weeks as tolerated. If the higher dose is still not tolerated, then 1 capsule less for each of the three times daily doses can be continued as the maximally tolerated treatment dose.  
• Alternatively, at the discretion of the site investigator, the study drugs may be 
held  at the discretion of the clinical investigator until the adverse event 
disappears. PFD/Plac should then be re -started and using the standard titration 
protocol increased  to the full dosage as tolerated.  
i) Unresolved toxicity or inability to tolerate therapy with PFD /Plac  for >60 days.  
Dose Management:  Study drug will be permanently discontinued  and subject withdrawn 
from the treatment phase of the study.  
 
6.1.[ADDRESS_876281]  timing, amount and administration of the study drugs. The following 
procedures will be used to promote patient compliance and allow drug compliance monitor ing. 
[IP_ADDRESS]  Patient aides to promote compliance:  
a) Wallet -size Study Drug Identification Cards  will be prepared at each study visit that  describe 
the current dose and schedule of each drug to be taken during the coming study interval 
until the next scheduled visit.  
b) Study Drug Administration Calendars  with daily check- boxes will be generated  for patient s 
at each study visit  to map out and record each dose of each study drug when taken.  
c) “One-Week Drug Dispensers ” will be provided to the patients and they will be taught how to 
fill them at each visit, and at home on a weekly basis, so that medications are easily and reliably dispensed  without having to count out capsules  and remember each dose . Two 
dispensers will be provided: a) a twice daily dispenser for MMF  and b) a three -times daily 
dispenser for PFD/Plac.  
d)  An SLS III Study Bag will be provided to subjects  and they will be instructed to put all study 
drugs and records into this bag (study drug bottles, pi[INVESTIGATOR_274106], study folder with drug 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   59 calendars, etc.) and carry it with them to/from every clinic visit . 
[IP_ADDRESS]  Study approaches  promot ing the monitoring of drug compliance :  
a) Individual drug inventory records will be kept for each patient, recording number of bottles 
and capsules dispense and the number returned at the next visit.  
b) Mandatory pi[INVESTIGATOR_4382]/capsule counts of unused medication will be required at each visit and reconciled with the patients drug usage calendar.  
 
6.[ADDRESS_876282] number , visit number , date  medication dispensed, number of bottles and bottle ID, number of 
capsules dispensed at each visit and the number counted as remaining at the subsequent visit. All 
used bottles will be returned and stored on site until an inventory control is carried out by [CONTACT_8760].  
 
6.2.4  Monitoring & Compliance Oversight by [CONTACT_652728] d rugs. Errors and 
discrepencies between the different reporting sources will be reconciled as part of the individual site monitoring process carried out by [CONTACT_15791]. Compliance will be calculated for each visit and for each 
subject from the information supplied in this manner.  
 
7 STUDY PROCEDURES AND  SCHEDULE  
 
7.1  STUDY PROCEDURES/EVA LUATIONS  
In the event of an emergency  that disrupts patient or institutional access and usual study care, such as 
an unexpected disaster or pandemic , refer to Protocol Section 17.0  (EMERGENCY DISASTER/ PANDEMIC 
MANAGEMENT PLAN ) for allowable adjustments to the study procedures and schedule that may be 
invoked as dictated by [CONTACT_652729].  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   60  
7.1.1  Study Specific Procedures  
[IP_ADDRESS] Spi[INVESTIGATOR_038] . Spi[INVESTIGATOR_652618] 
(National Board of Respi[INVESTIGATOR_1511]) or experienced staff that meet American Thoracic 
Society (ATS) recommendations ( 15). All spi[INVESTIGATOR_652619] ( ATS)/European 
Respi[INVESTIGATOR_3764] ( ERS) Task Force ( 34,41 ). Forced e xpi[INVESTIGATOR_652620] “acceptable” and that two of these maneuvers meet end -of-test and repeatability criteria 
for FVC and Forced Expi[INVESTIGATOR_469352] ( FEV1 ). Printouts of all data and 
curves will be sent to the Pulmonary Function C ore at UCLA for central quality control 
monitoring with individual optimization and re -training for study specific requirements at 
each site if required to assure standardized and reproducible measurements . Spi[INVESTIGATOR_66754] w ill be expressed both as measured values and as a percentage of gender- specific 
predicted values using the regression equations of Ha nkinson ( 17) for spi[INVESTIGATOR_038]. For 
spi[INVESTIGATOR_038], the race -specific regression equations of Hankinson ( 17) w ill be used for African-
Americans and Mexican -Americans  and normal referenced values multiplied by 0.88 for 
Asians (17a) . Spi[INVESTIGATOR_652621] (screening), just prior to 
initiation of study medication (baseline) and every 3 months for the  entire 18 months of the 
study.    
In the event that a participant has already completed  spi[INVESTIGATOR_652622] 30 days of 
Screening Visit #1 and the testing  meets all eligib ility criteria, it may be used in lieu  of 
repeating  the spi[INVESTIGATOR_652623] #[ADDRESS_876283] pass a 
Quality Assurance review by [CONTACT_652730].   
[IP_ADDRESS] Single -breath diffusing capacity for carbon monoxide (DLCO)  and DLCO adjusted for 
hemoglobin (DLCOHb) . DLCO measurements will be performed in accordance with 
publishe d ATS/ERS guidelines using equipment and testing techniques that meet ATS/ERS 
requiremen ts (33).  At least 2 acceptable tests that meet repeatability criteria ( 33) will be 
performed and the mean DLCO value (uncorrected for Hgb) from acceptable measurements  
reported. Other reported values will include the inspi[INVESTIGATOR_652624], which must be 
within 10% of the expi[INVESTIGATOR_652625], and the alveolar volume. DLCO will then be 
corrected for hemoglobin that will be measured at the corresponding study visit  as part of 
the blood monitoring and reported as DLCOHb. DLCO and DLCOHb will be expressed both as 
measured values and as a percentage of gender -specific predicted values ( DLCO -% and 
DLCOHb -%) using the regression equations of Neas ( 37). The race -specific equations of Neas 
et al. ( 53) will also be used for calculation of the predicted values of DLC O for African -
Americans.  DLCO measurements  will be performed at entry (screening), just prior to 
initiation of study medication (baseline) an d every 3 months for the entire 18 months of the 
study.    
In the event that a participant has already completed DLCO testing within 30 days of the 
Screening Visit #1 and the testing meet s all eligibility criteria, it may be used in li eu of 
repeating  the DLCO measurements at Screening Visit #[ADDRESS_876284] been performed at the same facility that will be used during the 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876285] pass a Quality 
Assu rance review by [CONTACT_652730].   
[IP_ADDRESS] Thoracic HRCT with Quantitative Image Analysis . Thoracic HRCT will be performed using a 
standardized volume acquisition protocol developed by [CONTACT_652731] [ADDRESS_876286] scanners with 16 to  64 
channel scanners will be used at each site to minimize breath -hold times  (4-6 seconds ).  The 
subject will be imaged prone and at suspended end -inspi[INVESTIGATOR_1516] ( HRCT -TLC). Technologists 
will be trained to coach maximal inspi[INVESTIGATOR_99807] -hold from the subject and will instruct 
them to “Take your biggest breath in until you feel your lungs are completely full, in the 
same way you do in the lung function laboratory, and then signal when you feel co mpletely 
full and hold your breath.” Subjects will be instructed how to signal  when their lungs are 
completely full and the technologists will again remind them  to hold their breath for the 
entire scan. Digitalized imaging data collected during the scan is transferred from the clinical site to the UCLA  HRCT QIA Core using HIPAA compliant electronic transfer protocols  and 
stored on a dedicated server with built -in encryption security and automated backup in 
place.  
Within the UCLA HRCT QIA Core, s cans are reconstructed and entered into a quantitative 
image workstation to produce quantitative scores. The imaging analysis process consists of three steps: (1) semi -automated lung segmentation which requires  approv al by a 
radiologist; (2) execution of an automat ed classification model that  classifies  pi[INVESTIGATOR_652626], ground glass, honeycomb and normal lung patterns within the segmen ted whole 
lung region; and (3)  division of the entire lung into anatomical lobes . HRCT scores for 
quantitative lung fibrosis (QL F), quantitative ground glass opacifications (QGG)  and 
quantitative honeycomb changes (QHC ) are determined separately from the percentage of 
overall pi[INVESTIGATOR_652627] (QLF), hazy parenchymal opacity through which normal lung markings were visible in the absence of reticular opacity or architectural distortion ( QGG) or 
clustered air- filled cysts with dense walls ( QHC), respectively. The q uantitative ILD (QILD) 
score represent s the sum of all abnormally classified scores  (QLF+QGG+QHC). Scores a re 
then  summated for the whole lung (WL ; e.g. QLF- WL) which  includ es all pi[INVESTIGATOR_652628], and for the lobe  of maximal involvement ( LM; e.g. QLF- LM). These approaches have 
been well standardized and reported for the evaluation of SSc -ILD, with documented 
changes in response to immunosuppression with both cyclophosphamide and MMF  (27-
28,52 ). Total lung capacity will also be determined from the image analysis protocol and is 
known to be highly correlated with plethysmograph ic measures of total intrathoracic gas 
volume measured by [CONTACT_15209][INVESTIGATOR_652629]. Defined CT outcome measures will therefore 
include at a minimum:  
a) Quantitative lung fibrosis score in the whole lung (QLF -WL).  
b) Quantitative lung fibrosis  score in the lobe of maximal involvement (QLF -LM).  
c) Quantitative ground glass opacificati on score in the whole lung (Q GG-WL).  
d) Quantitative ground glass opacification score in the lobe of maximal involvement 
(QGG- LM).  
e) Quantitative honeycomb change  score in the whole lung (Q HC-WL).  
f) Quantitative honeycomb change score in the lobe of maximal inv olvement (Q HC-
LM).  
g) Quantitative interstitial lung disease  score in the whole lung (Q ILD-WL).  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   62 h) Quantitative interstitial lung disease score in the lobe of maximal involvement 
(QILD -LM).  
i) Total lung capacity at maximum inspi[INVESTIGATOR_1516] (HRCT -TLC)  
The UCLA HRCT QIA core will screen the thoracic HRCT performed during screening for 
specific abnormalities that may lead to exclusion from the trial including, but are not 
limited: pulmonary nodules/masses, bronchiectasis, evidence of active infection, lobar or segmental collapse, and/or mediastinal/hilar mass(es) or nodes.  Scans with abnormal 
findings will be reported to the site investigators and reconstructed images obtained at the local site will be available for review by [CONTACT_652732].  
A radiation physicist from the UCLA HRCT QIA Core will initially assess the equipment and 
perform standardization protocols using phantom image results obtained at each site prior to the initiation of clinical testing. Site equipment will be programmed with the study -
specific protocols to assure safe ty and reproducibility. The estimated radiation dose that 
subjects will receive as a result of the proposed CT scans is ~120 millirem, or 2.4% of the 5,[ADDRESS_876287] that was performed outside of the study, but within the required time window prior to 
randomization ( < 60 days), it may be considered as a potential substitute for the official 
screening HRCT. To be eligible for such use, the d igitalized imaging data collected during the 
scan must be  transferred from the clinical site to the UCLA HRCT QI A Core using HIPAA 
compliant electronic transfer protocols as already noted. A review will be carried out to  
determine whether it was performed in a manner consistent with the key requirements for a full study scan performed at TLC, whether the image quality is adequate for assess ing 
required inclusion and exclusion criteria, and whether digital image analysis can be adequately performed to yield required study outcome data as already described . If the 
scan is determined to be adequate by [CONTACT_652733]. If it is determined that the scan is not  adequate by [CONTACT_91980], the patient may decide 
whether to proceed with  a full protoco l-defined HRCT in order to continue with the study 
screening.  
[IP_ADDRESS] Mahler Baseline and Transitional Dyspnea Index . The paper version of Mahler’s Baseline 
Dyspneic Index (BDI) will be administered to  subjects by a trained interviewer at the time of 
the baseline visit and the Translational Dyspneic Index (TDI)  will be administered to subjects 
by a trained interviewer every [ADDRESS_876288] all evaluations for a given  patient.  The TDI has 
proven to be a sensitive measure of treatment response in both SLS I and II studies  (25,51).  
[IP_ADDRESS] Skin thickness and function scores . Skin thickness score will be quantified using the 
modified Rodnan measurement method  (mRSS) , with a scale that ranges from 0 (no skin 
involvement) to a maximum of 51. Clinical assessment of skin thickness will be made in each 
of 17 body areas with 0 -3 score (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe 
thickness). Documented coefficient of variation is 12% for intra- observer reliability and 25% 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   63 for inter- obse rver variability ( 7-8).  Skin thickness scores have been found to significantly 
improve when therapy with cyclophosphamide was compared to placebo in SLS I ( 50-51 ) 
and similar improvements in response to MMF were confirmed in SLS II which likely 
contribute  to the overall treatment effect (52) . The capacity for PFD to enhance the effects 
of therapy with MMF on skin disease in patients with SSc is currently unknown and will be specifically evaluated as a component of this study using the mRSS assessment.  The mRSS 
will be performed at baseline and at 3 month intervals throughout the study  and should be 
carried out by [CONTACT_31722]  (if at all possible).  
[IP_ADDRESS]  Composite end point.  Combined Response index in Systemic Sclerosis (CRISS). CRISS, a 
combined outcome index to assess treatment r esponses in SSc, was developed through an 
iterative process combining expert consensus conferences and data -driven approaches, and 
was recently validated as a therapeutic outcome measure ( 21). This composite index is a 2 -
step process where step 1 assesses clinically meaningful decline in cardio -pulmonary -renal 
involvement and step 2 assesses changes in mRSS, FVC -%, patient global assessment, 
physician global assessment, and HAQ DI (from the SHAQ) as a combined outcome meas ure. 
It will be assessed at 6 -, 12, and 18 month period.  
7.1.1. 7 Physician and Patient Global Assessment . The Physician G lobal Assessment employs a 0-10 
likert scale to assess the patient’s  “overall health ” in the past  1 week. The single- item 
question is anchored from 0 (excellent health) to 10 (extremely poor). In addition, the physician  will assess change s in the patient’s overall health and lung involvement by 
[CONTACT_652734]: Compared to the  baseline visit, how  would you rate your patient’s i) 
overall health  and ii) overall lung involvement: much better, a little better, no change, a little 
worse, much worse . Using a similar approach the Patient Global Assessment employs a [ADDRESS_876289] 1 week. The single-item 
question is anchored from 0 (excellent health) to 10 (extremely poor). In addition, the patient will assess c hange s in the patient’s overall health and lung involvement by [CONTACT_652735] : Compared to your baseline visit, how would you rate your i) overall health and ii) 
overall lung involvement: much better, a little better, no change, a little worse, much worse . 
Global Assessments  will be administered at baseline (no transition component ) and every 6 
months thereafter.
 
[IP_ADDRESS] Patient Reported Outcomes (PROs)  in the form of patient responses to standardized 
patient questionnaires . A spectrum of validated questionnaires will be used to assessed 
patient related outcomes that include disease specific, overall health, and their perspectives 
on symptoms, performance and quality of life  (Complete questionnaire can be found in 
Appendix A): 
a) St. George’s Respi[INVESTIGATOR_208465] (SGRQ): SGRQ, a respi[INVESTIGATOR_3765] -specific 
HRQOL instrument that was originally developed for use in chronic obstructive pulmonary disease, has more recently been used in interstitial lung disease.  It will be self- administered at baseline and every 3 months there after. This instrument, although 
not specifically designe d for SSc, has recently been validated in SSc -ILD ( 5). It has been 
shown to be correlated inversely with FVC and directly with HRCT and exercise performance and to perform better in relation to exercise capacity and lung imaging than other non -respi[INVESTIGATOR_696] -specific questionnaires for the evaluation of HRQoL in SSc -
ILD. 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   64 b) Health assessment questionnaire modified for scleroderma (SHAQ): The SHAQ will be 
administered at baseline and every 6 months thereafter. The SHAQ was shown to be 
favorably responsive to CYC t herapy in S LS I ( 26). 
c) Patient -reported outcomes measurement information system 29 -item health profile 
(PROMIS -29). The National Institutes of Health Patient -Reported Outcomes 
Measurement Information System (PROMIS) roadmap initiative utilized a cooperative  
group approach to develop and standardize item banks to measure patient -reported 
outcomes relevant across medical conditions. The resulting PROMIS- [ADDRESS_876290] on Social Roles, and has been valid ated  to 
measure health status outcomes in patients with SSc while requiring limited time t o 
repeat (average <2 min ) (18 ). It will be administered at baseline and every 6 months 
thereafter.  
d) UCLA Scleroderma Clinical Trial Consortium GIT 2.0. The UCLA SCTC GIT is a validated 36-
item, self -reported measure assessing bowel involvement, symptoms and related 
emotional well-being, and social functioning administered at baseline, 6 months, 12 
months, 18 months  (23-24).  A modified version, including only q uestions #1 -8, will be 
used at screening to determine study eligibility  as related to t he extent of GI symptoms . 
e) Leicester Cough Questionnaire  (LCQ) : This self-administered 19 -item questionnaire for 
the quantitative assessment of symptoms of cough frequency and severity will be completed at baseline and every 6 months  (30). This will be supplemented with a 
ranking of cough severity, frequency, and sputum production using a simple likert scale (42,53).  
[IP_ADDRESS] Blood collection for the Biological Specimen Repository . Blood samples will be serially 
collected from each study patient prior to  (baseline) , during (at 12 months) and at the 
completion of therapy  (18 months) . These samples will be immediately processed on site 
into s erum, plasma , buffy coat and whole blood RNA samples (PAXgene RNA collection ) 
according to a standard protocol, labeled and temporarily stored at the site at < -70°C prior 
to batch shippi[INVESTIGATOR_86286] a central repository for long- term storage. The Bio -specimen Repository 
will reside at the University of [LOCATION_004], Los Angeles, where a mas ter inventory will be kept 
of all samples. The Executive Committee will oversee all requests (both internal and external to the study) to access these samples for ancillary biological studies  directed toward the 
understanding of scleroderma, SSc -ILD, and t he treatment protocol . 
[IP_ADDRESS]  Study drug reconciliation.  A drug inventory is kept for every patient and contains the date, 
lot number, bottle number, type (MMF vs PFD/Plac) and number of capsules  released to the 
patient. Patients are also provided with a medication calendar to complete and bring back at 
each visit and are required to return with all bottles of study drug that are in their possession regardless of whether they are opened, in use or empty. Bottle and pi[INVESTIGATOR_652630].  
[IP_ADDRESS]  Assessment of adverse events.   As detailed in Section [ADDRESS_876291] of Care Study Procedures  
[IP_ADDRESS] Complete medical history and physical examination. A complete medical history and 
physical exam covering details related to the patient’s history of scleroderma, their entire medical history with a review of systems, and their current physical findings  will be 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   65 performed during the initial screening visit  and at 12 months . This will include a review o f 
pertinent medical records provided by [CONTACT_5363]/or their referring physicians.  
[IP_ADDRESS] Focused Interval history and examination. A review of current symptoms, medications, 
physical findings and any changes noted by [CONTACT_76409] a physician since a prior visit  will 
be performed at baseline, monthly for the first 6 months and then every 3 months.  
[IP_ADDRESS] Vital signs.  Vital signs will include: pulse, blood pressure, respi[INVESTIGATOR_697],  temperature (oC), 
weight (kg), and SpO2 by [CONTACT_652736], baseline  , 
monthly for the first 6 months and then every 3 months .  Height (cm) will only be done at 
screening.   
[IP_ADDRESS] Toxicity Monitoring with Blood Tests . A comprehensive set of laboratory results performed 
on a current blood sample to evaluate any toxicity or adverse events associated with 
Scleroderma or its treatment with the study drugs. Blood tests will include: comprehensive metabolic panel (to include serum electrolytes, BUN, Cr, glucose, albumin, ALT, AST, alkaline phosphatase, bilirubin, total protein) and a complete blood count with differential (to 
include WBC, Hgb, hematocrit, platelet count, and cellular differential count including 
absolute neutrophil count).  Monitoring will occur at initial screening,  monthly for the first 6 
months and then every 3 months .   
In the event that a participant has had all required laboratory tests completed within 30 
days of the Screening Visit #1, the results may substitute for the official screening laboratory 
tests.   
[IP_ADDRESS] Pregnancy Testing . An initial serum pregnancy test at screening and subsequent monitoring 
with urine pregnancy testing to be performed on all femal e participants of child- bearing 
potential  at baseline, monthly for the first [ADDRESS_876292] UDY SCHEDULE  
The complete schedule for study visits is detailed below and summarized in the subsequent Study Flow Diagram ( Figure 7. 3a) and Table o f Study Visits (see below Schedule of Events, Table 7. 3a).  
In the event of an emergency that disrupts patient or institutional access and usual study care, such as an unexpected disaster or pandemic, refer to Protocol Section 17.0  (EMERGENCY DISASTER/ PANDEMIC  
MANAGEMENT PLAN) for allowable adjustments to the study procedures and schedule that may be invoked as dictated by [CONTACT_652729].  
7.2.1  Screening Visits (Study Day - 90 through 0; Screening Visit #1&2)  
In order to be eligible for randomization , patients must proceed through a series of screening steps. 
At Screening Visit #1, a  preliminary evaluation is performed and if eligibility criteria are met  the 
patient will proceed to the screening HRCT scan  (Screening Visit #2) to assess for the presence of 
any ground glass opacity and to exclude concurren t findings of concern that may require additional 
evaluation or exclude the patient from further participation .  If all inclusion and exclusion criteria are 
met, the patient will proceed to the baseline evaluation where a final check of pulmonary function 
and pregnancy testing is required to meet randomization criteria: 
[IP_ADDRESS] Screening Visit #1. (preferably within 60 d, but no earlier than 90 d prior to randomization)  
a. Patient p rovide s written informed consent and research HIPAA authorization prior to 
any evaluation or testing . 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876293] 3 
months and any prior use of medications detailed in Section 7.5.1 ( Prohibited 
Medications & Treatments with Potential Disease Modifying Effects ).  
f. Pulmonary function testing for spi[INVESTIGATOR_652631] 30 days  of the screening visit and 
approved in advance by [CONTACT_652737] A. 
g. A limited subset of t he UCLA SCTC GIT questionnaire  (including only Questions #1 -8) is 
completed by [CONTACT_2299]  
h. The patient has blood drawn for monitoring blood tests and serum pregnancy test (if 
applicable).  
[IP_ADDRESS] Screening Visit #2.  (may not be completed until results from screening visit #[ADDRESS_876294] be completed within 6 0 days of randomization)  
a) Thoracic HRCT with visual review for the presence of entry and exclusion criteria and 
with Quantitative Image Analysis  
7.2.2  Enrollment/Baseline Visit (Study Day 0; Visit #1)  
Subjects w ho meet all defined inclusion and exclusion criteria  (up to this point) will be asked to 
return for the baseline visit. This will preferably occur within [ADDRESS_876295]  at the baseline visit.  
a) A focused i nterval history and examination will be performed.  
b) Vital signs obtained.  
c) Review of concomitant medications  
d) Pulmonary function testing for spi[INVESTIGATOR_652632].  
e) Urine pregnancy test performed  (if indicated)  
f) Patie nt Reported Outcomes (PROs) in the form of patient responses to standardized patient 
questionnaires  (SGRQ; SHAQ; PROMIS -29; UCLA SCTC GIT;  LCQ).  
g) Complete the Mahler Baseline Dyspnea Index . 
h) An assessment of skin thickness and function scores  (mRSS)  
i) Patient  and P hysician Global Assessment s (no transition questions)  
j) Blood collection for the Biological Specimen Repository  
If the repeat FVC -% fails to be within 10% of the value obtained at screening or is not > 45% and ≤ 
85%, the subject  will be offered one opportunity to repeat testing within [ADDRESS_876296] meets the repeat FVC -% inclusio n criteria, and assuming that pregnancy testing is 
negative if required, the site coordinator will complete the online eligibility case report form  and 
login to the electronic web -based randomization application to randomize the participant .  
Once randomization has occurred , the UCLA Pharmacy Core or the designated site Pharmacy, will 
confirm the drug and bottle assignment. In conjunction with a prescription signed by [CONTACT_652738]                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   67 investigator, study drugs will be dispensed according to established pro tocol. Randomization will 
occur via the Data Coordinating Center and result in a notification of study assignment group to the 
UCLA Pharmacy Core and the Site  Pharmacy . Study drug (PFD/Plac) will be released  in a double -
blinded manner and neither the study investigators or staff, or the patient,  will know the treatment 
assignment.   
7.2.3  Follow -up Visits (Months 0.5 -18, Study Visits #2 -21) 
There are a number of potential side effects of the study drugs that may be detected only through 
regular follow -up and blood testing monitoring . Given the nature of the study drugs, good clinical 
practice will require study visits for the purpose of monitoring every month for the first [ADDRESS_876297] will be maintained with the subjects through regularly scheduled phone contacts to assure that drug titration and dosing, changes in health and 
adverse events are adequately tracked and recorded.  
[IP_ADDRESS] Regular Follow -up Visits (Months 1 through 18; Visits 3, 5 -9, 12, 15, 18, 21).  
Regular follow -up visits include a combination of toxicity monitoring and outcome 
assessments. Not all assessments a re performed at each visit. Therefore, after each task  
listed below, a list of visit numbers (and corresponding month on study drug) is included to 
indicate when the task will be performed.  Each visit must be completed within a specified 
time window with respect to the protocol defined follow -up date : Visit #3 = +7d; Visits  #5-9 
and 12 = +10 d; Visit #15, 18, 21 = + 14d.  
a) A focused i nterval history and examination will be performed.  
[Visit # 3  (month 1), 5 -9 (months 2 -6), 12 (month 9), 18 (month 15), 21 (month 18)]  
b) Vital signs obtained.  
[Visit # 3 (month 1), 5 -9 (months 2 -6), 12 (month 9), 15 (month 12), 18 (month 15), 21 
(month 18)]  
c) Assessment of adverse events  
[Visit # 3 (month 1), 5 -9 (months 2 -6), 12 (month 9), 15 (month 12), 18 (month 15), 21 
(month 18)]  
d) Review of concomitant medications  
e) Study drug reconciliation  
[Visit # 3 (month 1), 5 -9 (months 2 -6), 12 (month 9), 15 (month 12), 18 (month 15), 21 
(month 18)]  
f) Study drug dispensing [Visit # 3 (month 1), 5 -9 (months 2 -6), 12 (month 9), 15 (month 12), 18 (month 15), 21 
(month 18)]  
g) Toxicity monitoring with blood tests.  
[Visit # 3 (month 1), 5 -9 (months 2 -6), 12 (month 9), 15 (month 12), 18 (month 15), 21 
(month 18)]  
h) Urine pregnancy test  performed (if indicated)  
[Visit # 3 (month 1), 5 -9 (months 2 -6), 12 (month 9), 15 (month 12), 18 (month 15), 21 
(month 18)]  
i) Pulmonary function testing for spi[INVESTIGATOR_652632].  
[Visit # 6 (month 3 ), 9 (months 6), 12 (month 9 ), 15 (month 12), 18 (month 15), 21 
(month 18)]  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   68 j) Patient Reported Outcomes (PROs) in the form of patient responses to standardized 
patient questionnaires   
• SGRQ   
[Visit #6 (month 3), 9 (month 6), 12 (month 9), 15 (month 12), 18 (month 15), 21 
(month 18)]  
• SHAQ; PROMIS -29; UCLA SCTC GIT; CRISS; LCQ  
[Visit #9 (month 6), 15 (month 12), 21 (month 18)]  
k) Complete the Mahler Transitional Dyspnea Index . 
[Visit #6 (month 3), 9 (months 6), 12 (month 9), 15 (month 12), 18 (month 15), 21 (month 18)]  
l) An assessment of skin thickness and function scores  (mRSS)  
[Visit #6 (month 3), 9 (months 6), 12 (month 9), 15 (month 12), 18 (month 15), 21 (month 18)]  
m) Physician and Patient Global Assessment s. 
[Visit #9 (month  6), 15 (month 12), 21 (month 18)]  
[IP_ADDRESS] Additional Assessments at the 12 -Month & 18 Month Visit ( Visit # 15 and 21). 
a) In addition to testing completed at the Regular Follow -up Visits described above, the 
following will take place  at the 12 Month Visit: 
• Blood collection for the Biological Specimen Repository  
• The patient undergoes a complete medical history and physical examination . 
b) In addition to testing completed at the Regular Follow -up Visits described above, the 
following will take place  at the 18 Month Visit: 
• Blood collection for the Biological Specimen Repository  
Thoracic HRCT with  Quantitative Image Analysis   
[IP_ADDRESS] Phone Follow -up Visits .  
Month 0.5  (Visit #2); Month 1.5  (Visit #4);  Months 7 -8 (Visit # 10-11); Months 10 -11 (Visit 
#13-14); Months 13 -14 (Visit #16- 17); Months 16 -17 (Visits 19- 20) 
(Visit windows +7d for Visits 2 & 4; + 10d for all others)  
a) Focused interval history  
b) Assessment of adverse events  
c) Review of Concomit ant medications  
d) Study drug reconciliation (focused review of current dose and changes since last visit, 
missed doses, remaining supply)    
7.2.4  Final Phone Follow -up Visit / Early Termination Final Phone Visit  
Month 19 ( Visit #22) or within 30 days of completely withdrawing from study   
(Visit window +10d)  
a) Focused interval history  
b) Assessment of adverse events  
c) Review of medications and alternative treatments (if premature termination visit)   
d) Reasons for leaving study (if premature termination visit)  
7.2.5 Follow -up for Participants who Prematurely Discontinue  Study Drug Treatment or who 
Completel y Withdraw from the Study  
Should a participant prematurely discontinue all study drugs he/she will be asked to return for the 
key outcome determination s at 12 and 18 months , as detailed above. In addition , at that time, any 
medication prescribed by [CONTACT_652739] . 
S c l e r o d e rm a  L u n g  S t u d y  I I I                                            [ C o n f i d e n t i a l ]  V e r s i o n  2 . 5  
P r o t o c o l  # U C L A -S L S 3  1 1 / 1 7 / 2 1  
F D A  I N D  # :  1 3 5 8 4 8   6 9  T h e  p a r t i c i p a n t  w i l l  a l s o  b e  a s k e d  t o  p a r t i c i p a t e  i n  a n  e x i t  v i s i t  a s  d e t a i l e d  i n  7 . 2 . 4  a b o v e .  S h o u l d  t h e  
p a r t i c i p a n t  d i e ,  t h e  c a u s e  o f  d e a t h  w i l l  b e  d e t e rm i n e d  a n d  r e c o r d e d  i f  p o s s i b l e .  
I n  t h e  e v e n t  t h a t  o n e  s t u d y  d r u g  i s  p e rm a n e n t l y  d i s c o n t i n u e d  d u e  t o  t o l e r a b i l i t y ,  a d v e r s e  e v e n t  o r  
o t h e r  m e d i c a l  c o n s i d e r a t i o n ,  t h e n  c o n t i n u e d  u s e  o f  t h e  r em a i n i n g  s t u d y  d r u g  w i l l  b e  a c c o r d i n g  t o  
t h e  f o l l o w i n g  p r e -s p e c i f i e d  m a n a g em e n t :   
• I f  o n l y  P F D / P l a c  i s  p e rm a n e n t l y  d i s c o n t i n u e d ,  t h e  p a r t i c i p a n t  m a y  c o n t i n u e  t o  t a k e  MM F  
a c c o r d i n g  t o  t h e  p r o t o c o l  a n d  c o n t i n u e  t h e i r  p a r t i c i p a t i o n  i n  a l l  s t u d y  v i s i t s  a c c o r d i n g  t o  t h e  
n o rm a l  p r o t o c o l -d e f i n e d  s c h e d u l e  o f  e v e n t s .    
• I f  MM F  i s  p r em a t u r e l y  d i s c o n t i n u e d ,  t h e  p a r t i c i p a n t  m u s t  s t o p  t h e  P F D / P l a c  s t u d y  
m e d i c a t i o n  a s  w e l l  a n d  w i l l  b e  a s k e d  t o  r e t u r n  f o r  k e y  o u t c om e  d e t e rm i n a t i o n s  a t  1 2  a n d  1 8  
m o n t h s  a s  d e t a i l e d  i n  S e c t i o n  5 . 3 . 3  (  H a n d l i n g  o f  P r em a t u r e  P a r t i c i p a n t  W i t h d r a w a l s )  
7 . 2 . 6  U n s c h e d u l e d  V i s i t s  f o r  A d d i t i o n a l  S a f e t y  M o n i t o r i n g  
A s  d e t a i l e d  i n  P r o t o c o l  S e c t i o n  8  o n  S a f e t y ,  p a t i e n t s  w h o  e x p e r i e n c e  d e f i n e d  a d v e r s e  e v e n t s  t h a t  
r e q u i r e  a d d i t i o n a l  s a f e t y  m o n i t o r i n g  w i l l  b e  a s k e d  t o  r e t u r n  a t  d e f i n e d  i n t e r v a l s  f o r  a d d i t i o n a l  
f o l l o w -u p  a n d  b l o o d  t e s t  m o n i t o r i n g  ( i f  i n d i c a t e d ) .  I t  i s  e s t i m a t e d  t h a t  r o u t i n e  l a b o r a t o r y  s a f e t y  
m o n i t o r i n g  m a y  b e  r e q u i r e d  e v e r y  1 -2  w e e k s  u n t i l  t h e  s i d e  e f f e c t  i s  r e s o l v e d  o r  u n t i l  a  p r o p e r  d o s e  
o f  m e d i c a t i o n  i s  i d e n t i f i e d .  
7 . 2 . 7  L o n g -t e rm  F o l l o w -u p  
O n  a  v o l u n t a r y  b a s i s ,  a s  a  c om p o n e n t  o f  t h e  c o n s e n t  p r o c e s s ,  p a r t i c i p a n t s  w i l l  b e  a s k e d  w h e t h e r  
t h e y  a r e  w i l l i n g  ( o r  n o t )  t o  b e  c o n t a c t e d  o n  a n  a n n u a l  b a s i s  f o r  u p  t o  5  y e a r s  a f t e r  c om p l e t i n g  t h e  
s t u d y  p r o t o c o l  a t  w h i c h  t im e  t h e y  w o u l d  b e  a s k e d  t o  p r o v i d e  a n  u p d a t e  r e g a r d i n g  t h e i r  h e a l t h  
s t a t u s ,  s ym p t om s  r e l a t e d  t o  t h e i r  s c l e r o d e rm a  a n d  t o  d e s c r i b e  a n y  o t h e r  t r e a tm e n t s  t h a t  t h e y  m i g h t  
h a v e  r e c e i v e d  f o r  t h i s  c o n d i t i o n .   
 
7 . 3    S UMM A R Y  O F  S T U D Y  S C H E D U L E  A N D  A S S E S SM E N T S  
F i g u r e  7 . 3 a  S t u d y  S c h e d u l e  F l o w  D i a g r am  
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   70 Table 7.3a: Table of Study Visits  & Assessments   
SCREENING AND  INITIAL 6 MONTHS  
Type of Visit:  Screen  Baseline  
Phone  Regular  
Phone  Regular  Regular  Regular  Regular  Regular  
Visit #:  S1-2 1 2 3 4 5 6 7 8 9 
Study Month:   0 0.5 1 1.5 2 3 4 5 6 
           Assessments            
Medical  history  X X X X X X X X X X 
Physical  exam  X X  X  X X X X X 
Vital signs ** X X  X  X X X X X 
Concomitant Medication  
  X X X X X X X X X X 
Medication  Reconciliation   X X X X X X X X X X 
Adverse events    X X X X X X X X 
Lung  function  testing  X X     X   X 
Blood  Test Monitoring  X   X  X X X X X 
Questionnaires  UCLA 
SCTC GIT  X     X   X 
HRCT scan of chest  X          
Pregnancy  test*  X X  X  X X X X X 
Blood  for Bio-Repository   X         
* For women  who  are able to become pregnant ; require a blood test at screening then urine testing . 
** Only need height at screening.  
 
MONTHS 7 – 19 & EXTRA VISITS  
Type of Visit:  Phone  Regular  
Phone  One 
Year  Phone  Regular  
Phone  18 
Month  Final 
Phone  Extra  
Visit #:  10-11 12 13-14 15 16-17 18 19-20 21 22  
Study Month:  7, 8 9 10, 11  12 13, 14  15 16, 17  18 19 Yrs 2 -5 
           Assessments            
Medical  history  X X X X X X X X X X 
Physical  exam   X  X  X  X   
Vital signs **  X  X  X  X   
Concurrent  Medication  X X X X X X X X X X 
Medication Reconciliation  X X X X X X X X  X 
Adverse events  X X X X X X X X X X 
Lung  function  testing   X  X  X  X   
Blood  test monitoring   X  X  X  X   
Questionnaires   X  X  X  X   
HRCT scan of chest         X   
Pregnancy  test*   X  X  X  X   
Blood  for BioRepository     X    X   
* For women  who  are able to become pregnant ; require a blood test at screening then urine testing . 
** Only need height at screening.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   71  
 
7.4  C ONCOMITANT MEDICATIO NS & TREATMENTS DURI NG THE STUDY  
All concomitant prescription , over -the-counter and non -prescription  medications taken during study 
participation will be recorded on the case report forms (CRFs)  and checked for compatibility with the 
study drugs  as defined in Section 7. 5.  
  
7.5  PROHIBITED MEDICATIO NS AND  TREATMENTS  DURING THE STUDY  
 
7.5.1  Prohibited Medications & Treatments with DMARD Activity  
Medications from the following list, and their biosimilars,  are prohibited and may not be taken prior 
to screening in amounts (or for time intervals) that  exceed allowable  limits as detailed in Exclusion 
Criteria #15 and #16. They may not be taken  while participating in the active drug treatment phase 
of this study  (except for MMF and PFD when specifically admi nistered as study drugs according to  
the study protocol) . 
Prior use of these medications must be consistent with Exclusion Criteria #15  
a) Oral or short half-life  drugs with potential DMARD activity  
• Anakinra  
• Apremilast  
• Azathioprine  
• Baricitinib   
• Cyclophosphamide oral  
• Cyclosporine   • Dasatinib   
• Imatinib  
• Leflunomide  
• Methotrexate  
• Mycophenolate mofetil  
• Nilotinib  • Nintedanib  
• Pi[INVESTIGATOR_7735]  
• Pomalidomide  
• Rilonacept  
• Tacrolimus  
• Tofacitinib  
  
b) Intravenous or injectable  drugs with potential DMARD activity  
• Abatacept  
• Adalimumab  
• Alemtuzumab  
• Belimumab  
• Canakinumab  
• Certolizumab   • Cyclophosphamide IV  
• Etanercept  
• Guselkumab 
• Golimumab  
• Infliximab  
• Ixekizumab   • Rituximab  
• Sarilumab  
• Secukinumab  
• Tocilizumab  
• Ustekinumab  
 
7.5.2  Prohibited Medications & Treatments that may Increase Immune Suppression Risk  
a) Prednisone >10mg/day (or equivalent corticosteroid).  
NOTE: a brief pulse of prednisone to <30 mg /day  that lasts no more that 7 days before 
returning to a dose of < 10 mg is permissible if indicated for a temporary intercurrent 
medical condition.  
a) Live vaccines administered within 30 days of, or after randomization  including:                                                            
• Bacillus of Calemett and Guerin (BCG) Vaccine  
• Measles Virus  
• Mumps  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   72 • Polio Virus  
• Rotovirus     
• Rubella       
• Small pox  
• Typhoid  
• Varicella Virus                             
• Yellow Fever                   
• Live influenza vaccine                                              
 
7.5.3  Prohibited Medications that may Interfere with Study Drug Absorption/Metabolism  
a) Antacids  containing Magnesium and Aluminum Hydroxides  should  not be taken together (at 
the same time) with MMF  due to their impact on the absorption of MMF . 
NOTE: Antacids may be used, but should not be taken within 2 hrs of MMF . 
b) Proton Pump Inhibitors  (PPIs)  should not  be taken together (at the same time) with MMF  
due to their impact on the absorption of MMF.  
NOTE:  PPIs may be used, but should not be taken within 2 hrs of MMF.  
c) Sevelamer  and other calcium free phosphate binders  should not  be taken together ( at the 
same time ) with MMF  due to their impact on the absorption of MMF.  
NOTE:  Calcium free phosphate may be used, but should not be taken within 2 hrs of 
MMF . 
b) Cholestyramine  should not  be taken due to interference with enterohepatic recirculation of 
MMF  
c) Cyclosprine  should not  be taken due to interference with enterohepatic recirculation of 
MMF  
d) Norfloxacin and Metronidazole  should not  be taken together as a combination therapy 
while on therapy with MMF due to interference with serum levels of MMF  
e) Ciprofloxacin and /or Amoxicillin plus Clavulanic Acid  may temporarily interfere with the 
enterohepatic recirculation of MMF producing temporary reductions in serum MMF levels.  
NOTE:  Temporary use for 2 weeks or less is of unclear significance but sustained use of 
these antibiotics is not recommended.  
f) Ciprofloxacin and other Fluoroquinolones  which are moderate inhibitors of CYP1A2 may 
interfere with the metabolism of PFD, significantly increas ing drug exposure . 
NOTE:  Use of Ciprofloxacin at a maximal dose of 500 mg twice daily for up to two weeks 
is allowed.  
NOTE:  If temporary use for Ciprofloxacin at a dose of 750 mg twice daily (or other 
fluoroquinolone at high dose) is required for 2 weeks or less , the daily dose of PFD 
should be reduced by 1 capsule three times a day during the period of concommitent 
use (patients on 3 capsules should reduce to 2, while patients on 2 capsules should reduce to 1)  
g) Rifampin  may temporarily interfere with serum levels of MMF.  
NOTE:  Temporary use for 2 weeks or less is of unclear significance but sustained use of 
these antibiotics is not recommended.  
h) Fluvoxamine , enoxacin or other strong CYP1A2 inhibitors should not  be taken  due to their 
impact on the metabolism of PFD, which can significantly increase drug exposure  
i) Smoking , which is a strong in ducer  of CYP1A2, is not allowed during the study  
 
7.5.4 Restrictions on Medications with Other Adverse Interactions  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   73 a) Hormonal contraceptives may not be effective during administration of MMF due to 
interactions with drug metabolism and a second type of contraception must be used to participate in study  if one of the following hormonal contraceptive is used : 
• Levongogrestrel  
• Norethindrone  
• Mestranol  
• Norgestrel  
• Ethinyl estradiol  
• Etonogrestrel  
b) Use of tanning beds or medical phototherapy that includes UV light exposure are 
contraindicated during the use of PFD due to their impact on photosensitivity reactions.  
 
7.6  PROPHYLACTIC MEDICAT IONS, TREATMENTS, AN D PROCEDURES  
Prophylactic use of topi[INVESTIGATOR_652633]: PFD is associated with photosensitivity . In addition to 
advising patients to wear protective clothing, hats, and avoid extended sun (or tanning light) exposur e, 
they will be advised to use  over the counter sunblock as a prophylactic therapy if sun exposure is 
anticipated . 
Prophylactic consumption of PFD with food: Patients are advised to take PFD with food to help decrease gastrointestinal side effects.  
 
8 ASSE SSMENT OF SAFETY  
 
8.1  SPECIFICATION OF SAF ETY PARAMETERS  
Safety parameters will include  frequency of events and/or incidence of study subjects experiencing 
events, by [CONTACT_652740] : 
a) Study -defined Treatment failures  
b) Study -defined Treatment emergent AEs of Special Interest  
c) All treatment emergent AEs, total and by [CONTACT_652741]  
d) All treatment related AEs , total and by [CONTACT_652741]  
e) All treatment emergent SAEs , total and by [CONTACT_652741]  
f) All treatment related SAEs , total and by [CONTACT_652741]  
g) All treatment emergent deaths  
h) All treatment -emergent AEs and SAEs that result in discontinuation of treatment  
i) Time to treatment failure, treatme nt emergent AEs and SAEs that result in discontinuation of 
treatment, and death  
 
8.1.1  Definition of Adverse Events (AEs)  
Adverse event means any untoward medical occurrence, such as  an abnormal laboratory finding, 
physical sign, symptom, or diagnosis of a disease state , that is temporally associated with the use of 
an interventional  treatment or procedure in a human subject regardless of whether or not it is 
considered interventi on-related [consistent with 21 CFR 312.32 (a)].  
[IP_ADDRESS]  Treatment -emergent AEs  (TEAEs) : 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   74 TEAEs are those that start or worsen after the start of study treatment and up to 7 days (for AEs) 
and 30 days (for serious AEs) after the last dose of study treatment.  This AE definition would 
include the following:  
• Any pre -existing condition th at increases in severity or changes in nature during or as a 
consequence of the study treatment administration  
• Complications resulting from protocol- mandated procedures  
• AEs occurring as a result of product withdrawal, abuse or overdose  
• A change in a laboratory variable if considered by [CONTACT_652742] (or should have caused) the investigator to reduce or discontinue the use of 
the product or init iate a non -protocol therapy or procedure  
8.1.1. [ADDRESS_876298] :   
AEs of Special Interest represent a specific subset of all AEs and are defined by [CONTACT_652743]: 1) their likely association with the investigational 
drug(s) , and 2) the presence of pre -specified study drug management guidelines that are to be 
followed when the AE occurs.   
 
8.1.2  Definition of Serious Adverse Events (SAEs)  
An AE or suspected adverse reaction is considered "serious" if, in the view of either the investigator 
or sponsor, it results in any of t he following outcomes:  
• Death,  
• A life-threatening AE 
• Inpatient hospi[INVESTIGATOR_10909]   
• A persistent or significant incapacity or substantial disruption of the ability t o conduct 
normal life functions   
• A congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_6721], based upon appropriate medical judgment, they may jeopardize 
the patient or subject an d may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of  drug dependency or drug 
abuse.  [Consistent with 21 CFR 312.32 (a)]  
 
8.1.3  Definition of Unanticipated Problems (UP – unexpected AEs &  Problems)  
An AE or suspected adverse reaction  is considered "un anticipated " if it is not listed or characterized  
in the Package Insert or in the current Investigator Brochure or is not listed at the specificity or 
severity that has been observed; or, if an investigator brochure is not required or available, is not 
consistent with the risk information described in the general investigational plan or elsewhere in the 
current application, as amended. For example, under this definition, hepatic necrosis would be unexpected (by [CONTACT_14213]) if the investigator brochure referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_14214]) if the investigator brochure listed only cerebral vascular accidents. "Unexpected," as used in this definition, also refers to AE s or suspected adverse reactions 
that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   75 from the pharmacological properties of the drug, but are not specifically mentioned as occurring 
with the particular drug under investigation.  [Consistent with 21 CFR 312.32 (a)]  
 
8.2  CLASSIFICATION OF AN  ADVERSE EVENT  
 
8.2.1  Severity of Event  
The intensity of all AEs will be graded using a five -point grading scale in which the following 
descriptions of severity will apply. Note that for some AEs, Grades 4 and/or 5 may not be applicable. In those case s only 3 different grades (Grade 1 -3) are to be considered : 
 
[IP_ADDRESS]  Grade 1:  “Mild”;  asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
[IP_ADDRESS]  Grade 2:  “Moderate”; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental ADL*.  
[IP_ADDRESS]  Grade 3:  “Severe”; medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self care ADL**.  
[IP_ADDRESS]  Grade 4:   “Life -threatening consequences”; urgent intervention indicated.  
[IP_ADDRESS] Grade 5:  “Death related to AE”.  
*Instrumental ADL refer to preparing meals,  shoppi[INVESTIGATOR_3112], using the  telephone, 
managing money, etc.  
**Self care ADL refer to bathing, dressing and  undressing, feeding self, using the toilet, taking  
medications, and not bedridden.  
 
8.2.2  Relationship to Study Drug  
For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s causality based on temporal relationship and his/her clinical judgment. A binary asse ssment 
(related/not related)  will be made and take into consideration the natural history of the underlying 
disease, concurrent illness, concomitant therapy, study -related procedures, accidents, and other 
external factors. While the relationship to the stu dy drug (related/not related) is part of the 
documentation process, it is not a factor in determining what is or is not reported in the study.  All 
AEs are recorded regardless of relatedness.  
8.2.[ADDRESS_876299] contributed to 
the event.  
8.2.2 .2 Not Related  There is not a reasonable possibility that the administration of the study agent caused the event, there is no temporal relationship 
between the study agent and event onset, or an alternate etiology 
has been established  or appears to provide a plausible explanation 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   76 (e.g. the participant’s clinical condition, underlying disease or 
concomitant trea tments) . 
 
8.2.[ADDRESS_876300]  in 
addition to their inclusion in the overall frequency and incidence of AEs.   
• Leukopenia, defined as WBC <2.5 x103/µl of blood  
• Neutropenia, defined as an absolute neutrophil count  < 1.0x103/µl of blood   
• Clinically significant anemia, defined as blood  hemoglobin < 10.0 gm/dl or a drop in  
hemoglobin to < 9.0 gm/dl if the baseline hemoglobin was < 11.0 gm/dl  
• Liver enzyme elevations  that exceed 3 × the upper limit of normal (ULN) ALT and/or AST . 
• New onset or worsening of existing g astrointestinal s ymptoms that do not respond to 
medical manage ment and are of sufficient clinical importance to warrant drug dose 
adjustment  (including nausea, diarrhea, vomiting, and dyspepsia) . 
• Documentation of gastrointestinal ulcer, gastrointestinal bleeding or abdominal emergency  
• Infection requiring hospi[INVESTIGATOR_059], intravenous antibiotics, or judged as requiring the withdrawal of immune suppression for effective treatment.  
• New or reactivated viral infections  including PVAN, JC virus associated PML, CMV infections, 
reactivation of HBV or HCV . 
• Photosen sitivity skin reactions  that do not respond to sunscreen, avoidance, and as -needed 
use of over the counter topi[INVESTIGATOR_142739], and are of sufficient clinical importance to warrant drug dose adjustment.  
• Development of a p roven malignancy other than basal cell cancer of the skin or cervical 
carcinoma in situ rem oved entirely by [CONTACT_9256] . 
• Angioedema  
 
8.[ADDRESS_876301] evaluation time points that includes 
open -ended questions such as :  
• “How have you felt since your last clinical visit?” 
• “Have you had any new or changed health problems since you were last here?”  
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate CRF. Information to be collected includes event description, ti me of onset, clinician’s 
assessment of severity, relationship to study product (assessed only by [CONTACT_12213] a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876302] be documen ted appropriately regardless of relationship. All AEs will be followed to 
adequate resolution.  
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the stud y participant’s condition deteriorates at any 
time during the study  (in frequency, severity or character) , it will be recorded as an AE  and a descriptor 
will be used as a modifier term to convey that it relates to a pre -existing condition that has changed (e.g. 
“more frequent headaches”). UPs will be recorded in the data collection system throughout the study.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
The Principal Investigator [INVESTIGATOR_652634], are collected and reported to the FDA,  appropriate IRB(s), and to Genentech, Inc. in 
accordance with CFR 312.32 (IND Safety Reports).  
 
8.3.1  Adverse Event Reporting  
All AEs will be mapped to  system organ classes (SOC) using preferred MedDRA SOC terms , graded 
for severity and relationship to study drugs as detailed above, and recorded with start dates 
occurring any time after informed consent is obtained until at least 7 days (for non -serious AEs ) or 
30 days ( for SAEs) after the last day of study participation. At each study visit, the investigator will 
inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information unt il resolution or stabilization. A record of all AEs, by [CONTACT_652744].  
 
8.3.2  Serious Adverse Event Reporting  
All SAEs will be mapped to system organ classes (SOC) using preferred MedDRA SOC terms, graded for severity and relationship to study drugs as detailed above, and recorded with start dates  
occurring any time after informed consent is obtained until [ADDRESS_876303] be reported within 24 hours of receipt. The designated study medical monitor or 
designee may be contact[CONTACT_652745].  
Hospi[INVESTIGATOR_652635] , which are not related to an AE,  do not require reporting:  
• Hospi[INVESTIGATOR_167726] . 
Deaths  occur ring in patients who have withdraw n from the active treatment phase of the study will 
not be considered SAEs if the death occurs more than [ADDRESS_876304] dose of study treatment.  
When recording a death, the event or condition that caused or contributed to the fatal outcome  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   78 should be reported as the single medical concept. If the cause of death is unknown and cannot be 
ascertained at the time of reporting, the report  will be identified as an  “Unexplained Death”.  
Investigators must report all SAEs to their governing IRB/IEC, as required by [CONTACT_311872].  
A record of all S AEs, by [CONTACT_652746].  
 
8.3.3  Unexpected Adverse Event /Problem (UP)  Reporting  
All adverse events that meet the definition of an UP  should be reported to the local governing IRB 
within specific timelines as described below:  The UP report will include the following information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project  
number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that hav e been 
taken orare proposed in response to the UP.  
[IP_ADDRESS]  Reporting to the IRB required w ithin 10 working days:  
• Any internal or external adverse event ( UP) which meets all of the following criteria:  
a) Unexpected  (in occurance, severity or in frequency of occurance  that was not previously 
known and/or described in the approved informed consent document or other protocol related documents ), 
b) and Related or possibly related to the research participation,  
c) and places subjects or others at greater risk of harm t han was previously known or 
recognized  (i.e. a serious adverse event, a new or increased risk to subjects/others)  
[IP_ADDRESS]  Reporting within 3 working days:  
• An SAE, including subject death, that meet all of the following criteria:  
a) Occurred in an interventional study (i.e., involving a drug, biologic, device procedure and/or behavioral interventions),  
b) Unexpected,  
c) and judged to be r elated or possibly related to research participation  
 
8.3.4  Reporting of Pregnancy  
a) Pregnancies should be reported from the time th e patient signs the informed consent 
until [ADDRESS_876305] be immediately 
discontinued if a patient becomes pregnant. Although pregnancy is not considered an SAE, a report should be completed and expeditiously submitted to the DCC and to 
Genentech, Inc. Follow -up to obtain the outcome of the pregnancy should also 
occur.Abortion, whether accidental, therapeutic, or spontaneous, should always be classified as serious,  and expeditiously reported as an SAE. Similarly, any congenital 
anomaly/birth defect in a child born to a female subject exposed to the study drug should be reported as an SAE.   
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876306] who participated in 
the study, will report  such event  as an SAE  to Genentech . 
 
8.4  STUDY HALTING RULES  
The investigators and/or sponsor reserve the right to terminate the study at any time. If this becomes necessary, appropriate procedures for continuing long -term follow -up and assuring the adequate 
treatment and safety of the participating subjects will be arranged after review and approval by [CONTACT_4530], Institutional Review Boards and the FDA.  
The appointed DSMB will also provide external oversight concerning the safety and scientific integrity of 
the study for the duration of the clinical trial.  The DSMB will review the progress of the study toward meeting enrollment goals, adverse and serious adverse event profiles, and study outcome measures at regular intervals to occur at least twice annually.  The DSMB  may recommend at any time that the study 
should be terminated due to drug toxicity , patient sa fety, poor compliance  and/or futility 
considerations.  In such cases, their recommendations will be reviewed and discussed with the Executive 
Committee, which will make a final determination.   
 
8.[ADDRESS_876307] 
(DSMB , See Section 15.1.5 ) composed of individuals with the appropriate expertise  in SSc -ILD, the study 
drugs and/or clinical trials research  including experts in  Rheumatology, Pulmonary Medicine,  Internal 
Medicine and/or Bioethics, and Biostatistics. The DSMB Chair will be appointed by [CONTACT_652747] a salaried  appointment with any of 
the pa rticipating institutions. The DSMB Chair will then recommend  the remainder of the Committee 
Members for consideration by [CONTACT_652748].  
The DSMB will review the protocol and recommend modific ations with respect to monitoring, safety and 
outcome assessments that will be addressed by [CONTACT_652749] .  Once the 
trial is initiated, the DSMB will review cumulative trial results to evaluate the treatment for benefic ial 
and adverse effects, including the review of all AEs, SAEs and UP .  The board will also monitor the 
performance of individual clinics and study performance indicators (drug monitoring and compliance, visit compliance, recruitment, etc.). The DSMB will meet every 6 months by [CONTACT_369390]/or web videoconferencing for the duration of the trial and will interact directly with the Data Coordinating Center for access to study data and interim reports , and with the Executive Committee regarding any 
recommendations for procedural changes, study modifications or management of perceived safety or data integrity issues .  
 
8.5.1  Morbidity and Mortality Committee  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   80 A separate Morbidity and Mortality Review Committee (MMRC) will be appointed by [CONTACT_652750].  The composition of the MMRC will include at least one member 
specializing in pulmonary medicine and one in rheumatology. The purpose of this co mmittee will be 
to review all reported SAEs (as detailed in Sections 8.1 to 8.3) and provide an independent and blinded determination as to:  
a) The proximate cause of the SAE.  
b) Relationship of the SAE to the study drug as detailed in Section 8.2.2.  
c) The expectedness of the SAE as defined in Section 8.1.3.  
Individual SAE case reports will be reviewed as they occur by [CONTACT_652751], in consultation with the reporting site inve stigator, that the determination of the proximate cause, relationship to the study drug and 
determination of expectedness are consistent with the documentation and reporting guidelines.  
Independent reviews by [CONTACT_652752], in batches, at a time when the records 
for a group of 12 -20 SAEs are ready for review  or at the conclusion of the study if less than 12 SAEs 
are recorded.  Each member of the MMRC will independently review cases and provide a 
determination. No further review will be required when all reviewers agree as to the relationship of the SAE to the study drug and the expectedness. Cases in which reviewers disagree on these determinations will be discussed at a MMRC teleconference and a final determination reported as either a consensus opi[INVESTIGATOR_1649] (when all three reviewers agree after discussion) or a majority opi[INVESTIGATOR_1649] 
(indicating the majority opi[INVESTIGATOR_652636]). The MMRC findings will represent the final study determination with respect to reporting SAE outcom es. 
 
9 CL INICAL MONI TORING 
Throughout the course of the study, data will be monitored for accuracy and completeness and study procedures will be monitored for adherence to the protocol and Good Clinical Practices (GCP). In addition to frequent contacts through e -mail and telephone, on-site monitoring visits will be 
coordinated by [CONTACT_652753] (SABER) unit at the University of Michigan.  SABER (the Data Coordinating Center for this study) will be responsible for operational aspects an d monitoring of the trial, including at least annual monitoring visits and/or 
remote source data verification.   
The clinical monitor will ensure that:  
• Data collected and entered into the database are verifiable against source documents for the participants.  The clinical monitor will need access to subject medical records and other study -
related records needed to verify the entries on the electronic case report forms.   
• Appropriate consent is obtained for each participant prior to study procedures.  
• The rights and well -being of participants are being protected.  
• The study is conducted in accordance with the currently approved protocol (including study treatment being used in accordance with the protocol), with any other study agreements, with GCP and with applicable regulatory requirements.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   81 • Study medication is properly dispensed and accounted for.  The study monitor will also perform 
drug accountability checks and review the clinical site’s regulatory document binder to assure completeness of documen tation in all respects of clinical study conduct.   
• Details of clinical site monitoring are documented in a Clinical Monitoring Plan (CMP). The CMP 
describes in detail who will conduct the monitoring, at what frequency monitoring will be done, at 
what level of detail monitoring will be performed, and the distribution of monitoring reports.  
  
10 STATISTICAL CONSIDER ATIONS   
 
10.1 STATISTICAL AND ANALYTICAL PLANS  
A statistical analysis plan (SAP) will be written for the study that contains detailed descriptions of the analyses to be performed.  The SAP will be finalized prior to unblinding of the data.  
 
10.[ADDRESS_876308] been 
observed in the treatmen t of Idiopathic Pulmonary Fibrosis (IPF), will complement the delayed anti-
inflammatory and immunosuppressive effects of MMF, to produce a significantly more rapid and/or greater improvement in lung function over time than occurs in patients receiving cont rol therapy with 
MMF (and Plac) alone.  Statistically, the following null and alternative hypotheses will test the superiority of the combination of PFD+MMF versus MMF+Plac in improving the change from baseline in mean forced vital capacity (as a percentage of the age -, height -, gender - and race -adjusted predicted 
value, indicated as FEV -%) over the course of the 18 -month double -blind treatment period (primary 
endpoint):  
  H
0:  Δ PFD+MMF  = Δ MMF+Plac 
HA:  Δ PFD+MMF  ≠ Δ MMF+Plac  
where Δ reflects the adjusted mea n change from baseline trajectory over the 18 -month treatment 
period.     
 
10.3 ANALYSIS DATASETS  
Several analysis sets will be used in analyses:  
• The main population for efficacy will be the modified intention -to-treat population ( m-ITT), defined 
as all participants randomized, receiving at least one dose of study medication, and having at least 
one post -baseline efficacy assessment. Subjects will be analyzed by [CONTACT_220261].  
• A second analysis set will be used to assess the robustness of the primary and key secondary conclusions in the subset of participants in the m-ITT analysis set who complied with the protocol 
sufficiently to ensure that these data would be likely to represent the effect of treatment according to the underlying scientific model.   The Per Protocol (PP) analysis set will consist of all subjects in the 
m-ITT population who do not have a major protocol violation, inclusive of violation of entry criteria.  
• The Safety Population is defined as all participants who are randomized and rec eive at least one 
dose of the study medication.  The Safety Population will be used for all safety analyses.  Subjects will be analyzed by [CONTACT_220261].  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876309] deviation, range (e.g., minimum and maximum).  Qualitative variables will be summarized using counts and percentages.  Summaries will be provided by [CONTACT_6654].  Unless otherwise specified, statistical analyses will be performed using SAS Version 9 or higher.  Where appropriate, statistical tests will be conducted at the 0.05 significance level using two -tailed tests 
and p -values will be reported.  
 
10.4.2 Analysis of the Primary Efficacy Endpoint  
The primary endpoint is change from baseline in the mean forced vital capacity, measured as the percentage of the age- , height -, gender - and race -adjusted predicted value (FVC -%) over the course 
of the 18 -month treatment period, as reported quarterly (i.e., months 3 , 6, 9, 12, 15 and 18). Given 
that the trajectories of the primary endpoint are expected to differ because of the mechanisms of action of the two treatment modalities, a longitudinal approach incorporating all time points will be employed.  Specifically, the endpoint will be analyzed using a linear mixed model with participant -
month in the study (3, 6, 9, 12, 15, 18) as the unit of analysis and the change from baseline in FVC -% 
as the outcome, with terms for baseline FVC -%, treatment group, month , the inter action of month 
(x) treatment group , and prior MMF therapy (stratification factor: naïve, >0 to < 3 months, and >3 
months to 6 months) , as fixed covariates.  Study participant will be treated as a random effect to 
account for the correlation of outcomes ove r time within a participant.  The model generates 
adjusted estimates of change from baseline in the FVC -% for each treatment group and month, and 
an F-test will be used to test the hypothesis that the mean change from baseline during the 
treatment period differs between the two treatment groups.  The model- based adjusted mean 
change from baseline in FVC -% will be presented graphically by [CONTACT_652754], 
with 95% confidence intervals (CIs) provided at each month.  
The primary analysis of the primary efficacy endpoint will use the m-ITT analysis set.  Appropriate 
non-linear parametric or non -parametric tests may be applied if the assumptions of the model are 
not satisfied.  Details will be presented in the SAP.  
To assess the robustness of treatment effects, a secondary analysis of the primary efficacy endpoint will be performed using the PP analysis set.  In addition, two separate a priori analyses will be 
conducted using the model described above with the m-ITT analysis set:  one with baseline CT 
fibrosis scores as a covariate, and one with baseline mRSS as a covariate.  
Sensitivity analyses will be performed to assess how subjects who withdrew may affect conclusions of the analysis.  In particular, our primary analytic approach assumes a missing -at-random 
mechanism ( 45) and one sensitivity analysis will employ a nonignorable model.  With nonignorable 
missingness, the stochastic process that generates missingness is explicitly modeled.  We will jointly model the longitudinal measures with the missing data mechanism using a p attern mixture model 
(31).  Depending on the extent and pattern of missingness, other simpler sensitivity analyses may be 
used:  for example, change from baseline to the end of treatment for subjects completing the study 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   83 (completers) may be analyzed using an analysis of variance model.  The model will include the same 
covariates that are included in the primary mixed effects analysis.   
In addition to the assessment of the overall trajectory of pulmonary response which integrates the timing of the onset of response and the overall magnitude of effect at [ADDRESS_876310] at the end of the treatment period.  
In addition, frequency distributions of changes from baseline to 18 months in FVC -% will be 
presented by [CONTACT_652755] (i.e., not model -based) estimates of treatment 
effects for the m- ITT analysis set, for those who completed 18 months of treatment and those who 
prematurely discontinued treatment.  Additional analyses may be performed to asses s more 
granular changes in treatment adherence (e.g., premature discontinuation of study treatment prior to 3, 6, 9, 12, 15 and 18 months) depending upon the observed extent and timing of 
discontinuation.   
 
10.4.3 Analysis of the Secondary Endpoints  and E xploratory Outcomes  
[IP_ADDRESS]  Analyses of Secondary Endpoints.   
There are three categories of secondary outcomes:  
1. Continuous outcomes such as change from baseline in mRSS, QLF -max and QILD -lung 
from HRCT, hemoglobin -adjusted DLCOHb -%, PROs, and compliance with pi[INVESTIGATOR_652637];  
2. Dichotomous outcomes such as the proportion of subjects who report improvement on the TDI at 18 months during the treatment period.   
3. Time (in months) required for each treatment arm to achieve a 3.0% or greater 
improvement from baseline in the FVC -% over the 18 -month treatment period . 
Continuous secondary outcomes will be compared between treatment groups using the same 
methods as described for the primary analysis of the primary endpoint.  For dichotom ous 
secondary outcomes, logistic or Poisson regression will be used with treatment group, site , and 
prior MMF therapy (stratification factor: naïve, >0 to < 3 months and >3 months to 6 months) 
included as covariates.   For these dichotomous models, odds rati os (for logistic models) or 
relative risks (for Poisson models), with corresponding 95% CIs, will be presented; p -values for 
the test of treatment differences will also be presented.  For time to event outcomes, Kaplan -
Meier methods will be used to graphic ally present treatment differences; median time to event 
with 95% CIs and stratified (by [CONTACT_652756]) log -rank test p -values will be presented.  The 
m-ITT analysis set will be used in the analyses of secondary endpoints.  
In addition, the graphical de scriptive approach described above to summarize the frequency 
distributions of changes from baseline to 18 months will be provided for key secondary endpoints (to be detailed in the SAP).  
[IP_ADDRESS]  Analyses of Exploratory Outcomes .   
Comparable methods as described above for primary and secondary outcomes will be used for the exploratory aims described in Section 4.2.3.  For example, identification of baseline features that predicted treatment responsiveness, disease progression and course of lung and skin 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876311] deviation, median, interquartile range, 
minimum and maximum will be used to summarize changes from baseline to each study visit in 
laboratory tests and vital signs.  Percent change from baseline will be added for laboratory values as 
outlined in the SAP.  The primary organ system associated with each adverse event will be coded by  
[CONTACT_7195].  Kaplan- Meier methods will be used to summarize graphically the time to 
treatment failure, treatment emergent AEs and SAEs that result in discontinuation of treatment, and death.  
 
10.4.5 Adherence & Retention Analyses  
Participant disposition will be summarized descriptively.  The number and percentage of participants 
randomized, completed, and withdrawing, along with reasons for withdrawal, will be tabulated 
overall, and by [CONTACT_1570].  The number of participants in each analysis population will be reported.  Other disposition and study conduct information, including major protocol violations will be summarized.  Duration of the study follow -up will be summarized overall and by [CONTACT_6490].  
Compliance with study medication will be assessed and summarized, including the proportion of 
participants who adhered to study treatment at each study visit, the median duration of adherence to study treatment and the proportion of participants who permanently discontinued study medication b y reason for treatment permanent discontinuation, overall and by [CONTACT_1570].    
 
10.4.[ADDRESS_876312] to demographic and baseline variables (e.g.,  age, race, FVC -%, mRSS).  No statistical tests will be used 
to compare the treatment groups.   
 
10.4.7 Planned Interim Analyses  
[IP_ADDRESS]  Safety Review  
Safety outcomes will be presented at each DSMB meeting.  These include number of and 
proportion of subjects with SAEs (including segregation of those involving deaths), treatment -
emergent AEs, AEs of Special Interest, discontinuation of study medication du e to AEs, and 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876313] been approved for other 
indications, their safety profile has been well characterized.  Thus, no specific rules for halting study enrollment or study interventions for safety are specified; however, the DSMB may 
request formal inferential testing to assess the risk -benefit profile of these study medications in 
this study population.  
[IP_ADDRESS]  Efficacy Review 
No interim analysis is planned.  
 
10.4.8 Additional Sub- Group Analyses  
No other sub -group analyses (other than those described above for the primary and secondary 
efficacy endpoints) are planned.   
 
10.4.9 Multiple Comparison/Multiplicity Analyses  
No adjustments for multiplicity are planned since there is one primary analysis of the primary 
endpoint at the end of the study.  Secondary analyses of the primary endpoint and analyses of the secondary endpoints serve to a ssess the robustness of the results and consistency of treatment 
effect on clinical outcomes important in this disease.  
 
10.4.10 Tabulation of Individual Response Data  
SAEs, deaths, and AEs resulting in discontinuation of study medication will be tabulated  for 
participants who experience these events.  
 
10.4.11 Exploratory Analyses  
Additional analyses may be performed to explore both safety and efficacy measures collected in this study.  The precise methods and analyses will be determined after the database is locked and the blind is broken.  Thus all such analyses will be interpreted cautiously and not used for formal inference, although inferential statistics may be used as part of the data summary.    
 
10.5 SAMPLE SIZE  
 
10.5.1 Introduction & Background to Sample Size Determination  
An initial sample size target of 150 participants (up to 190 consented and screened subjects to achieve 75 randomized per treatment group) was identified based on recent clinical trial experience and logistical considerations including the number of clinical centers with appropriate leadership and infrastructure to be considered as state of the art for treating SSc -ILD.  Statistical analysis, using 
a clinical trials simulation approach, was then employed to estimate the power to de tect various 
treatment effects on the primary endpoint with a two -sided Type I error of 5% and an 18 -month 
attrition estimate of 24%.   
Data from the SLS I and II clinical trials ( 44,50-52) were used to estimate the baseline characteristics 
of the proposed  study population and their response ov er time to treatment with MMF , including 
the impact of prior treatment with MMF  (occurring prior to study randomization) , on the predicted 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   86 course of lung function changes over time . Note that SLS III will employ essentially the same patient 
recruiting centers and investigators as those that participated in the prior studies ( with some new 
additions ) and that the enrollment criteria have been  relatively  conserved over time to assure 
reproducibility. Furthermore, both the control arm and experimental arm of the proposed study will 
be treated with a course of cytotoxic therapy that is essentially identical to that re ported from the 
SLS I  and II studies.  For the impact of PFD, safety and tolerability data from the LOTUSS trial (20) 
and outcome data from studies in which PFD was used to treat IPF ( 12-13) were considered 
informative . 
 
10.5. 2 Assumptions  
Based on th ese available data, the following assumptions were used to generate clinical outcome 
scenarios for the potential response of FVC -% over time for both the control arm (MMF+Plac) and 
the experimental arm (MMF+PFD) of SLS III:  
1)  Data from SLS I and II were used as the best available data to estimate the standard 
deviation of the FVC -% values at different times in the study and the mean change in FVC -% 
at 3, 6, 9, 12, 15 and 18 months were assumed to follow a multivariate normal distribution, with equivalent variances in the two treatment groups.  
2) In the same manner, data from the II stud y was used to inform th e estimated impact of prior 
therapy with MMF, occurring prior to randomization, on the  expected mean change in FVC -
% and the variance  of the FVC -% values at different times after randomization.  
3)  We measured the correlation structure over time for repeated measurement of the FVC -% 
in individual subjects participating in the SLS I study and applied that to the prediction of outcomes for SLS III. As one might assume, correlation between measurements taken at 
closer intervals is greater than measurements taken farther apart and from SLS I data the 
correlations among outcomes 3 months apart was 0.866, 6 months apart was 0.834, and 9 months apart was 0.802.   
4) Treatment with cytotoxic therapy (MMF or CYC) is associated with an initial period of deteriorating lung function during the first [ADDRESS_876314] inflammation and tissue destruction.  This initial loss of lung function can average from - 0.25 % to -2.5%.  
5)  After an  initial  3-6 month  period that is associated with a relative decline of lung function,  
continued treatment with cytotoxic therapy is associated with a relative improvement in 
lung function over time that ranges from approximately +2.0 to + 3.0% at 12 months and 
from approximately +3.0 to +5.0% at 18 months.  
6)  These time- dependent treatment response features , with an initial decline and delayed 
improvement, have a direct  impact o n the predicted course of the FVC -% over time in 
subjects who  present to the study after several months of prior MMF therapy. The 
percentage of patients on cytotoxic therapy prior to randomization, and the length of prior 
treatment,  need  to be accounted  for in predicting the overall course and magnitude of  the 
change in FVC -% over time.  
7) In contrast to the delayed effects of MMF, use of PFD for the treatment of IPF is associated with a rapid onset that slows the decline in lung function and is seen as  early as 3 months.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   87 8)  In addition, given that the mechanisms of action for MMF and PFD are fundamentally 
different, it is reasonable to speculate that combination therapy (MMF+PFD) will have an overall impact on lung function at [ADDRESS_876315] of combining PFD and MMF in the experimental arm with that of MMF plus Plac  in the control arm on pulmonary function during the 
18-month double -blind period.  The primary endpoint is change from baseline in the mean forced 
vital capacity, measured as the percentage of the age -, height -, gender - and race -adjusted predicted 
value ( FVC-%) over the course of the 18 -month double -blind treatment period.  FVC is measured at 
baseline (pre -treatment) and then quarterly after treatment begins during the treatment period 
(i.e., months 3, 6, 9, 12, 15 and 18).  Participants are required to ha ve FVC -% ≤ 85% at screening.   
 
10.5.4 Clinical Trial Scenarios and Simulations to Estimate Study Power  in Treatment Naïve 
Patients  
Two outcome scenarios were considered based on the two potential mechanisms of action by [CONTACT_652757]. Both scenarios assume that the average response pattern to MMF alone (the control arm ) would approximate the 
average response pattern to cytotoxic therapy observed from SLS II. In that study, the overall 
improvement from baseline in the FVC -% was approximately 3.0% at the 12 month time point and 
4.25% at 18 months. Two different response scenarios were then proposed to represent the range of possible responses in patients treated with combined MMF+PFD (the experimental arm).  
• In Scenario [ADDRESS_876316] of PFD to the later improvement in lung function. The collective result is a 2.5% greater response to treatment at 12 months in the exper imental 
versus control arms and this difference between the groups remains the same for the duration of the 18 -month study.  
• In Scenario [ADDRESS_876317] on the overall improvement in FVC -% 
that continues throughout the entire treatment period.  The collective result is a 3.125% greater response to treatment at 12 months in the experimental versus control arms which continues to slowly increase to a final 3.25% difference between the two groups at 18 months.  
Figure 10.5.4.  Hypothesized Response Trajectories over the 18 -Month Double- Blind Treatment 
Period by [CONTACT_652758], all participants naïve to therapy.   
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876318] a response based on each Scenario was then calculat ed by [CONTACT_208296] 1,000 
clinical trials simulations for each scenario in SAS 9. 4, using a linear mixed model with participant -
month in the study (3, 6, 9, 12, 15 and 18) as  the unit of analysis and the change from baseline in 
FVC-% as the outcome, with terms for treatment group, baseline FVC- %, month and the interaction 
of treatment group with month as a fixed covariate and participant as a random effect to account 
for the correlation of outcomes over time within a participant.  (This is a simplification of the model used for the primary analysis of the primary endpoint described above .)  We used a compound 
symmetry variance -covariance structure.  The average power is calculated as the number of 
simulations where the F -test used to test the hypothesis that the mean change from baseline during 
the double -blind treatment period differs between the two treatment groups is rejected (p <0.05) 
divided by [CONTACT_652759].  9 5% CIs for power are calculated based on the exact binomial 
proportion.  
Table [ADDRESS_876319] differences in the response pattern from baseline to 18 months for 
the primary outcome (change in FVC -%) when comparing the course of change in lung function over 
time for the MMF+PFD arm and the MMF+Plac arm according to the two proposed outcome scenarios. Results assume a 5% two -sided type I error and are provided for three different sample 
sizes (N = 75 /arm; 70/arm and 65/arm)  
Assumptions:  
-  Drop -out rates, variances and data inter- correlations presented below are derived from SLS I and 
II data and assumed to be identical for the two defined scenarios  
-  A 5% two -sided type I error is assumed  
-  The difference in the outcome measure between treatment arms (relative difference in the 
change from baseline in absolute FVC % -predicted) for each scenario was estimated based on the 
hypothetical response to PFD proposed for each scenario as detailed i n Figure 10.5.4 . 
Scenario 1 Difference 
between treatment 
arms (FVC -%) Scenario 2 Difference 
between treatment 
arms (FVC -%) Dropout 
(Cumulative %)  SD Estimate  
 Assumed Correlations 
(AR1):  
Mo   3:     0.5 
Mo   6:     1.375 Mo   9:     2.25 
Mo 12:     2.5  Mo   3:     0.75 
Mo   6:     1.75 Mo   9:     3.0 
Mo 12:     3.125  Mo   3:  6.5%  
Mo   6:   13%  
Mo   9:   17%  
Mo 12:   20%  Mo   3:   4.1 
Mo   6:   5.1 Mo   9:   6.2 
Mo 12:   6.9  3-mo intervals:    0.866  
6-mo intervals:    0.834  
9-mo intervals:    0.802  
12-mo intervals:  0.790  

Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   89 Mo 15:     2.5  
Mo 18:     2.5  Mo 15:     3.25  
Mo 18:     3.25  Mo 15:   23%  
Mo 18:   24%  Mo 15:   6.2  
Mo 18:   6.2  15-mo intervals:  0.780  
Power Calculations  Scenario 1 : 
Evaluation of Statistical Power by [CONTACT_19462], adjusting for drop outs over time, based on 1000 
clinical trial outcome simulations:  
N per arm at 
baseline  N per arm 
at 18 mo  Estimated 
Statistical Power  95% Lower Bound of 
Statistical Power  95% Upper Bound of 
Statistical Power  
75 57 82.3%  79.8%  84.6%  
70 53 78.6%  75.9%  81.1%  
65 49 76.3%  73.5%  78.9%  
Power Calculations  Scenario 2 : 
Evaluation of Statistical Power by [CONTACT_19462], adjusting for drop outs over time, based on 1000 clinical trial outcome simulations:  
N per arm at 
baseline  N per arm 
at 18 mo  Estimated 
Statistical Power  95% Lower Bound of 
Statistical Power  95% Upper Bound of 
Statistical Power  
75 57 95.6%  94.1%  96.8%  
70 53 92.6%  90.8%  94.2%  
65 49 91.8%  89.9%  93.4%  
Note that with the given m -ITT design, the linear mixed effects model will actually include data from 
all subjects who have at least a baseline and one follow -up measure of FVC -%. In this setting, even 
with an overall 24% attrition by [CONTACT_5638] 18 months, it is estimated that 83% of the maximal possible study outcome data points (assuming no attrition) would be included in the analysis.   
According to Scenario 1, which is strictly based on the documented capacity for PFD to slow the rate of decline of lung function in patients with IPF who are not receiving any other treatment, a sample size of 75 patients per treatment arm is required to obtain a minimum power of 80% (i.e .,  80% is 
within the 95% CI for this prediction).  If PFD has novel effects when combined with MMF so that it both reduces the rate of lung decline and works in concert with MMF to improve overall lung 
function (i.e. , Scenario 2), then the predicted outcome will be much more reliably detected and a 
smaller sample size would be sufficient.   
 
10.5.[ADDRESS_876320]  been on prior 
treatment with MMF (or DMARD with similar activity) for a period of 3, 6 or 9 months. Additional 
assumptions associated with these modified Scenarios  include:  
1) The mean change in FVC -% over a given 3-month interval and the corresponding impact on the 
standard deviation of the FVC -% measurement will always reflect the total time  that a patient 
has been on therapy , including therapy  that was  administer ed before randomization  and 
therapy that was administered following randomization .  
S c l e r o d e rm a  L u n g  S t u d y  I I I                                            [ C o n f i d e n t i a l ]  V e r s i o n  2 . 5  
P r o t o c o l  # U C L A -S L S 3  1 1 / 1 7 / 2 1  
F D A  I N D  # :  1 3 5 8 4 8   9 0  2 )  T h e  t r e a tm e n t  e f f e c t  i s  m e a s u r e d  a s  t h e  c h a n g e  f r om  b a s e l i n e ,  i n  w h i c h  b a s e l i n e  i s  d e t e rm i n e d  
a t  t h e  t im e  o f  r a n d om i z a t i o n  ( b a s e l i n e  v i s i t ) .  T h e  b a s e l i n e  F V C -%  m e a s u r e m e n t  t h e r e f o r e  
e s t a b l i s h e s  t h e  z e r o  r e f e r e n c e  v a l u e  f o r  e v a l u a t i n g  c h a n g e  o v e r  t im e  i n  r e s p o n s e  t o  t h e  t im e  
t h a t  a  p a t i e n t  i s  o n  t h e  p r o t o c o l .   I n  t h i s  s e t t i n g ,  p a t i e n t s  w h o  h a v e  b e e n  o n  3  m o n t h s  o r  m o r e  
o f  MM F  w i l l  n o t  b e  e x p e c t e d  t o  e x p e r i e n c e  t h e  i n i t i a l  d e c l i n e  i n  l u n g  f u n c t i o n  t h a t  o c c u r s  w h e n  
e n r o l l i n g  t r e a tm e n t  n a ï v e  p a t i e n t s .  
3 )  A s  o n e  o f  t h e  h y p o t h e s i z e d  b e n e f i t s  o f  s t a r t i n g  P F D  a n d  MM F  a t  t h e  s am e  t im e  i n  t r e a tm e n t  
n a ï v e  p a t i e n t s  i s  t h e  p r e v e n t i o n  o f  a n  e a r l y  d e c l i n e  i n  l u n g  f u n c t i o n ,  t h e r e  i s  a  r e l a t i v e  
t r e a tm e n t  p e n a l t y  i n  t h e  p r e d i c t e d  P F D +MM F  a rm  w h e n  p a t i e n t s  h a v e  b e e n  o n  p r i o r  t h e r a p y  
w i t h  MM F .  T h i s  r e s u l t s  i n  l e s s  a n d  l e s s  s e p a r a t i o n  b e t w e e n  t h e  c o u r s e  o f  t h e  t w o  t r e a tm e n t  
a rm s  a s  t h e  l e n g t h  o f  t im e  o n  p r i o r  MM F  i n c r e a s e s .  T h i s  im p a c t  m u s t  b e  a c c o u n t e d  f o r  w h e n  
m o d e l i n g  t r e a tm e n t  o u t c om e s  a n d  p r e d i c t i n g  s t u d y  p o w e r .  
 
F i g u r e  1 0 . 5 . 5.   H y p o t h e s i z e d  R e s p o n s e  T r a j e c t o r i e s  o v e r  t h e  1 8 -M o n t h  D o u b l e -B l i n d  T r e a tm e n t  
P e r i o d  b y  T r e a tm e n t  G r o u p  f o r  S c e n a r i o  2  b a s e d  o n  l e n g t h  o f  t im e  o n  MM F  t h e r a p y  p r i o r  t o  
r a n d om i z a t i o n .  
 
T h e  p o w e r  t o  d e t e c t  a  r e s p o n s e  a c c o r d i n g  t o  S c e n a r i o  2 ,  w h e n  t a k i n g  i n t o  a c c o u n t  t h e  l e n g t h  o f  
p r i o r  t r e a tm e n t  w i t h  MM F  ( n a ï v e ,  3  m o ,  6  m o  a n d  9  m o  s t r a t a )  a n d  t h e  p e r c e n t a g e  o f  s u b j e c t s  
w i t h i n  e a c h  o f  t h e s e  s t r a t a ,  w a s  t h e n  c a l c u l a t e d  b y  c a r r y i n g  o u t  1 , 0 0 0  c l i n i c a l  t r i a l s  s im u l a t i o n s  f o r  
e a c h  s i t u a t i o n  i n  S A S  9 . 4  a s  a l r e a d y  d e s c r i b e d .  W e  v a r i e d  t h e  p r o p o r t i o n  o f  p a t i e n t s  f r om  1 0 0 %  
n a ï v e  d o w n  t o  5 0 %  n a ï v e ,  w i t h  t h e  d i s t r i b u t i o n  a c r o s s  t h e  p r i o r  t r e a tm e n t  w i t h  MM F  s t r a t a  v a r i e d  a s  
d e s c r i b e d  b e l o w .  E s t im a t e s  o f  t h e  d i f f e r e n c e s  b e t w e e n  t r e a tm e n t  a rm s  a n d  t h e  s t a n d a r d  d e v i a t i o n  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876321] differences in the response pattern from baseline to 18 months for 
the primary outcome (change in FVC -%) when comparing the course of change in lung function over 
time for the MMF+PFD arm and the MMF+Plac arm according to Scenario 2 with different mixtures 
of treatment naïve  patients and those who were on prior MMF therapy for 3, 6 or 9 months as 
indicated . Results assume a 5% two -sided type I error and are provided for three different sample 
sizes (N = 75/arm; 70/arm and 65/arm)  
 a. Scenario 2:  N = 75 per arm  
% per stratum  
(length of prior MMF)  Estimated statistical power based on 
1000 clinical trial outcome simulations  
Naive  3 mo  6 mo  9 mo  Power  95% Lower 
Bound  95% Upper 
Bound  
1.00  0.00    95.6%  94.1%  96.8%  
0.80  0.20    93.8%  92.1%  95.2%  
0.75  0.25    92.2%  90.4%  93.8%  
0.70  0.30    90.8%  88.8%  92.5%  
0.60  0.40    90.5%  88.5%  92.2%  
0.50  0.50    86.1%  83.8%  88.2%  
0.80  0.10  0.10   91.4%  89.5%  93.1%  
0.70  0.20  0.10   89.5%  87.4%  91.3%  
0.70  0.10  0.20   90.2%  88.2%  92.0%  
0.60  0.30  0.10   89.0%  86.9%  90.9%  
0.60  0.20  0.20   88.2%  86.0%  90.1%  
0.60  0.10  0.30   85.2%  82.8%  87.3%  
0.50  0.40  0.10   84.7%  82.3%  86.9%  
0.50  0.30  0.20   82.7%  80.2%  85.0%  
0.50  0.20  0.30   82.7%  80.2%  85.0%  
0.50  0.10  0.40   79.7%  77.1%  82.2%  
0.70  0.10  0.10  0.10  86.4%  84.1%  88.5%  
0.60  0.20  0.10  0.10  86.2%  83.9%  88.3%  
0.60  0.10  0.20  0.10  83.7%  81.3%  85.9%  
0.50  0.30  0.10  0.10  79.9%  77.3%  82.3%  
0.50  0.20  0.20  0.10  79.3%  76.7%  81.8%  
 b. Scenario 2: N = 70 per arm  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   92 % per stratum  
(length of prior MMF)  Estimated statistical power based on 
1000 clinical trial outcome simulations  
Naive  3 mo  6 mo  9 mo  Power  95% Lower 
Bound  95% Upper 
Bound  
1.00  0.00    91.8%  89.9%  93.4%  
0.80  0.20    91.3%  89.4%  93.0%  
0.70  0.30    88.1%  85.9%  90.0%  
0.60  0.40    86.0%  83.7%  88.1%  
0.50  0.50    84.6%  82.2%  86.8%  
0.80  0.10  0.10   89.4%  87.3%  91.2%  
0.70  0.20  0.10   88.7%  86.6%  90.6%  
0.70  0.10  0.20   85.6%  83.3%  87.7%  
0.60  0.30  0.10   85.7%  83.4%  87.8%  
0.60  0.20  0.20   82.9%  80.4%  85.2%  
0.60  0.10  0.30   81.5%  79.0%  83.9%  
0.50  0.40  0.10   83.0%  80.5%  85.3%  
0.50  0.30  0.20   81.5%  79.0%  83.9%  
0.50  0.20  0.30   79.9%  77.3%  82.3%  
0.50  0.10  0.40   79.9%  77.3%  82.3%  
 
c. Scenario 2: N = 65 per arm  
% per stratum  
(length of prior MMF)  Estimated statistical power based on 
1000 clinical trial outcome simulations  
Naive  3 mo  6 mo  9 mo  Power  95% Lower 
Bound  95% Upper 
Bound  
1.00  0.00    91.8%  89.9%  93.4%  
0.80  0.20    88.2%  86.0%  90.1%  
0.70  0.30    85.5%  83.2%  87.6%  
0.60  0.40    81.4%  78.9%  83.8%  
0.50  0.50    79.7%  77.1%  82.2%  
0.80  0.10  0.10   87.1%  84.9%  89.1%  
0.70  0.20  0.10   85.5%  83.2%  87.6%  
0.70  0.10  0.20   83.2%  80.7%  85.5%  
0.60  0.30  0.10   78.4%  75.7%  80.9%  
0.60  0.20  0.20   77.5%  74.8%  80.0%  
 According to these  predictions for  Clinical Trial Scenario 2 , representing  the primary outcome to be 
investigated, the study is adequately powered (80% power or greater) to detect a difference 
between the two treatment arms when the sample size is [ADDRESS_876322] 50% treatment naïve patients . If the remaining 50% of enrolled patients are limited to no more 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876323] 50% of patients who are treatment 
naïve and up to 50% of patients who rece ntly started on therapy within 6 months of entering the 
study  (as detailed in Table 10.5.5 above) . With this mixture of patients, the power remains  adequate 
even if only 70 patients are enrolled in each arm (total randomizatio n 140 patients), providing 
optimal flexibility for the enrollment phase of the study.  
 
When a similar statistical approach is applied to Clinical Trial Scenario 1, in which  only a small 
additive effect of PFD is modeled in addition the the underlying treatment response to MMF, the 
power to detect a difference between the two treatment arms is  adequate (80% power or greater)  
when the sample size is [ADDRESS_876324] 75% treatment naïve 
patients.  When the percentage of treatment naïve patients is reduced to 50%, the predicted power 
is at best 75% (assumes % per stratum of 50% naïve, 40% 3 mo, 10% 6 mo).  
 
10.6 MEASURES TO MINIMIZE  BIAS  
 
10.6.1 Enrollment/Randomization/Masking Procedures  
This study will use randomization and masking as two of the cardinal principles of clinical trials to minimize bias.  
Randomization.  Participants will be randomized after all screening assessments have been 
completed and the investigator has verified that eligibility criteria have been met.  At the time of 
randomization, participants will be assigned a unique randomization number; no participant may begin treatment prior to randomization.  Eligible participants will be randomized to PFD+MMF or MMF+Plac in a 1:1 manner, stratified by [CONTACT_68566]  (pooled into 4 groups) a nd prior MMF exposure 
(naïve, >0 to <3 months, and >3 months to <6 months).   Randomization to the different strata will be 
capped if necessary to maintain at least 50% of randomized subjects within the treatment naïve 
strata (no prior therapy with MMF or DMARD) in order to maintain adequate power (as detailed in  
Section 10.5). The DCC will prepare the randomization schedule, using computer -generated block 
randomization with the block size(s) known only by [CONTACT_15791].  A secure web -based application will be 
built that will be used by [CONTACT_652760] (e.g., participant ID,  
stratification factor ) and to obtain the randomization number.  The information can be printed and 
sent and/or emailed directly to the site pharmacists.  Participants who withdraw from the study prior to completion of the treatment period will not be replaced.   
Blinding.   This is a double -blind study.  The study staff (except for select staff at the Data 
Coordinating Center and Research Pharmacists) and the participant are blinded to the treatment assignment.   
 
10.6.2 Evaluation of Success of Blinding  
Not applicable.  
 
10.6.3 Breaking the Study Blind/Participant Code  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   94 Blinding is critical to the integrity of this clinical study. All participants will receive MMF in an open -
label manner and blinding pertains only to their assignment to either PFD or matching placebo. 
There are two  identified  situations in which unblinding to identify the investigational drug will be 
considered.  
[IP_ADDRESS]  Unblinding associated with protocol -defined Treatment Failure.  
As detailed in Section 5.3.2 , subjects w ho meet criteria for a protocol-defined  treatment failure 
will be withdrawn from both PFD/Plac and MFF (i.e., the active drug treatment phase o f the 
trial) and their clinical management trans fered  to an identified treating physician at the 
discretion of the patient. The study blind will not be broken unless the treating physician is convinced that unblinding is required in order to appropriately treat the patient and their 
request is reviewed and agreed to as compelling by [CONTACT_19305].  
[IP_ADDRESS]  Unblinding associated with emergent medical necessity.  
In addition,  in the event of a medical emergency in which knowledge of the investigatio nal 
product is deemed critical to the participant's management, the blind for that participant may 
be broken.  Before breaking the blind of an individual participant’s treatment, the investigator 
should have determined that the information is necessary, i.e., that it will alter the participant’s immediate management. Unless time is of the essence  due to the emergency nature of the 
participant's medical condition, any request for unblinding must be reviewed and agreed to as 
compelling by [CONTACT_652761]. However, the investigator holds sole responsibility for 
the decision to unblind in case of emergency.  
In many cases, particularly when the emergency is not investigational product -related, the 
problem may be properly managed by [CONTACT_652762]. Should unblinding of a study participant be necessary because of an emergency, the site personnel will login to the password -protected electronic database 
application (developed and m aintained by [CONTACT_15791]) that will provide the treatment assignment.
  
Audit procedures will ensure that the name [CONTACT_652807].  As an additional safety measure, the personnel at the clinical sites  
will be provided with telephone numbers to contact [CONTACT_181106]/or Pharmacy personnel having access to the treatment assignment on a 24 -7 basis. If unblinding occurs, it is the responsibility 
of the investigator to promptly document and explain any unblinding and the circumstances that led to it will be reviewed by [CONTACT_329361] .   
 
11 SOURCE DOCUMENTS AN D ACCESS TO SOURCE D ATA/DOCUMENTS  
Every  participating clinical site will maintain appropriate medical and research records for this trial, in 
compliance with ICH E6 and regulatory and institutional requirements for the protection of confidentiality of participants.  Participating clinical sites will also obtain institutional authorization for 
external monitoring by [CONTACT_1034], Data Coordinating Center and the FDA to examine (and when 
permitted by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study safety, progress, and data validity.  
Source data are defined as all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, participant’s memory aids or evaluation checklists, pharmacy dispensing records, recorded audio tapes, recorded data from automated instruments , copi[INVESTIGATOR_652638]                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876325] been reported. The data management plan will describe the front -and back -end edit checks, as well as forms tracking procedures, that will be implemented to 
ensure timely and high -quality data collection.  It will also define the periodic reports that will be shared 
with site coordinators and PIs that summarize site performance.  The clinical monitoring and data management procedures will be consistent with the International Conference on Harmonisation (ICH E6) standards for Good Clinical Practice (GCPs).  
Quality Assurance monitoring for essential study procedures and outcomes will be handled by [CONTACT_652763], Radiology Core, Pharmacy Core and the Biorepository 
Core.  These Core programs will prepare independent man uals of operation and assume responsibility to 
inventory and monitor quality features of every study performed. Core inventory and quality assurance 
reports will be prepared in advance of and included as a component of each DSMB review.  
Monitoring of Prot ocol Compliance  will be carried out as detailed in Section 9.[ADDRESS_876326] twice monthly to review  site monitoring reports  as they become available, enrollment 
and retention reports,  interval AEs and SAEs, drug compliance, protocol compliance including interval 
study withdrawals and treatment failures, delinquincy  reports, regulatory status updates, and interval 
reports from the Core Programs as available .  
 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
 
13.[ADDRESS_876327] with the principles of “Goo d Clinical 
Practice” and in full conformance with the FDA standards for human subject research as codified  in 21 
CFR part 312 (Responsibility of Sponsors and Investigators), 21 CFR part 50 (Protection of Human 
Subjects), and 21 CFR part 56 (Institutional R eview Boards), as well as in a manner compl iant with 
Federal HIPAA Guidelines.  
 
13.[ADDRESS_876328]  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form by [CONTACT_652764]                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876329] for each site before the changes are implemented to the study. All changes to the 
consent form will be IRB approved; a determination will be made regarding whether previously 
consented participants need to be re -consented.  
 
13.[ADDRESS_876330]. The investigators will inform all subjects as to the nature, aims, duration, potential hazards, and procedures to be performed during the study and that his/her medical records and study -related documents may be revi ewed by [CONTACT_1622], NIH or sponsoring 
companies in a manner designed to protect their confidentiality.  This protocol must receive approval by [CONTACT_652765]. Investi gators must also disclose to participants any existing conflicts of interest and explain that 
patients are completely free to refuse to enter the study or to withdraw from it at any time without prejudice to their medical care.  The protocol will be discussed in detail with all potentially eligible patients and the essential components of the informed consent process personally confirmed by a responsible investigator before the consent is signed and countersigned. The participant will sign the 
informed consent document prior to any procedures being done specifically for the study.  All revisions 
of the protocol must be reviewed by [CONTACT_118834]. Patients will receive copi[INVESTIGATOR_652639]. 
 
13.4  SAMPLE INFORMED CONSENT L ANGUAGE   
______________________________________________________________________________________________  
 
DAVID  GEFFEN  SCHOOL  OF MEDICINE AT 
THE UNIVERSITY OF CALIFORNIA LOS ANGELES  
 
CONSENT TO PARTICIPATE IN RESEARCH  
 
 
 
UCLA Site Principal  Investigator: S. Samuel Weigt,  M.D.  
Coordinating Center Principal Investigator:  [INVESTIGATOR_68020]  D. Roth, M.D  
 
INTRODUCTION  Study Title:   Scleroderma Lung Study III (SLS 3):  Combining the anti -fibrotic effects of 
pi[INVESTIGATOR_7735] (PFD) with mycophenolate (MMF) for treating scleroderma-
related interstitial lung disease  
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   97 S. Samuel Weigt, M.D., who is the Principal Investigator [INVESTIGATOR_652640] D. 
Roth, M.D., who is the Principal Investigator [INVESTIGATOR_652641], and their associates from the Pulmonary and Rheumatology Divisions of the Department of Medicine at the University of [LOCATION_004], Los Angeles, are conducting a research study.  
The researchers will explain this study to you. Research studies are voluntary and include  only people 
who choose to take part. Please take your time about deciding whether to participate in this study. Before deciding:  
• You can discuss this study with friends and family.  
• You can also discuss it with your health care doctor or request a second o pi[INVESTIGATOR_1649].  
• If you have any questions, you can ask the researchers for more information before deciding to participate.  
The research team is asking you to participate in this study because you are at least [ADDRESS_876331] been diagnosed with Scleroderma (also called Systemic Sclerosis), your disease is felt to have been active for less than [ADDRESS_876332] lung involvement that includes shortness 
of breath and abnormal lung tests.  
 
WHY IS THIS STUDY BEING DONE?  
This research will use a double -blinded design (meaning that neither you nor the treating doctors will 
know which treatment you are on) to compare the safety and effectiveness of two experimental drug 
treatments for Scleroderma-related lung disease.  One treatment involves taking mycophenolate as the 
only study drug along with a placebo (a sugar capsule that looks the same as pi[INVESTIGATOR_652642]). The other 
treatment involves taking a combination of mycophenolate along with pi[INVESTIGATOR_7735].   
This research is designed to test whether combining pi[INVESTIGATOR_652643] a 
more rapid and possibly greater improvement in lung functio n than occurs when mycophenolate is used 
alone. While both of these drugs have been approved by [CONTACT_941] U.S. Food and Drug Administration (FDA) to treat other medical conditions, neither drug has been FDA -approved for the treatment of scleroderma -
related lung disease.   
This study is being funded in part by [CONTACT_8229], Inc.  
 HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?  
This study will enroll 150 patients with Scleroderma- related lung disease at research centers nationwide 
with the expectation that up to 20 wil l take part at the UCLA site.   
 WHAT WILL HAPPEN IF I TAKE PART IN THIS STUDY?  
 Before you begin the study: Screening  
In order to determine if you are eligible for the study you will need to undergo a two -part screening 
process.  
In the first part of the  screening, a routine medical history and physical examination will be performed. 
You should bring medical records for review of your history as you would for any new medical 
evaluation. A blood sample will be drawn from your arm to check your blood counts , liver and kidney 
tests .  If you recently completed blood tests (within the past 30 days) you should bring a copy of these 
results with you and, if they meet the requirements of the study, you may not need another blood draw.  
Unless already completed within the prior 30 days and considered to meet the needs of the study,  you  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876333] stage of screening, then you will be asked to 
complete the second part of the screening and undergo a high resolution computerized x -ray 
examination of the lungs (chest HRCT scan). If you recently completed a chest HRCT scan (within the 
past 45 days) you should advise the study physician as it can be considered in place of completing another scan. If it is found to meet all of the required study criteria the study physician will advise you of this and a repeat chest HRCT scan performed specifically for the study will not be necessary . Otherwise, 
to complete this test you will lie still on a table that moves into a large donut -shaped machine and you 
will be asked to take a full deep breath and hold your breath at certain times. A computer will then provide us with very detailed images of your lungs. The process will take [ADDRESS_876334] 
baseline visit.  
Before you begin the study: Washing -out other medications  
If you appear to qualify for the study based on results from the screening described above and you are 
currently (or within the past 30 days) taking either one of the study drugs (mycophenolate or 
pi[INVESTIGATOR_7735]) or another medication that might also act as a treatment for scleroderma-related lung disease (the research team will let you know), then you may  need to stop these treatments and let their 
effects wash -out from your system. While a period of at [ADDRESS_876335] interests after considering your history, lab findings and the potential risks and benefits.  
During the study: 
If you take part in this study, the researcher(s) will assign you to one of the treatment groups, ask yo u to 
undergo several procedures, and you will need to return for a number of study visits and procedures 
over the course of the next [ADDRESS_876336] pa ge of this consent.  
 
Baseline  Visit (Visit 1, Month 0)  
You will return to the clinic within [ADDRESS_876337]:  
• You will review any changes in your health or medication with the study doctor, and answer 
questions about your symptoms.  
• You will complete a set of health questionnaires regarding your shortness of breath, your ability to function, how short of breath you are, symptoms of cough, and how you rate your quality of life in respect to scleroderma and your lung problems. These questionnaires will take [ADDRESS_876338] the right to refuse to answer any question you do 
not wish to answer.  
• You will also complete a questionnaire addressing any gastrointestinal s ymptoms you may 
be experiencing (such as nausea or constipation). This questionnaire will take about [ADDRESS_876339] the right to refuse to answer any question you do not wish 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   99 to answer.  
• You will undergo pulmonary function tests similar to  those performed during the screening.  
• You will give a blood sample (approximately 2 -3 tablespoons drawn from a vein in your arm) 
that will be stored in a repository for use in several different types of research tests 
designed to provide information about  the causes of scleroderma and the mechanisms by 
[CONTACT_652766].  
• You will have a pregnancy test if you are a woman who is able to become pregnant.  
If it is determined that you are eligible for the study, you will be randomly assig ned to one of the 
study groups indicated below and given medication to take home with you. Because some test results may not be available immediately, the determination of eligibility might not occur the day of your visit. If this is the case, the medicati on will be mailed to you or you can come to the clinic to 
pi[INVESTIGATOR_191420].  
 
Treatment Group Assignment  
If you qualify , you will be randomly  assigned (like the flip of a coin)  to one  of the following  
two groups:  
• Mycophenolate, up to a target dose of 1.5 gram  twice daily,  as tolerated, plus placebo 
capsules.  
• Mycophenolate, up to a target dose of 1.5 gram  twice daily,  as tolerated, plus pi[INVESTIGATOR_369251], 
administered up to a target dose of 801 mg three times daily as tolerated.  
‘Target  dose’  means  that we will aim to have  all participants  in each  group on this dose  of the 
drug.  However,  different  people  react  differently  to drugs,  so we may  have to adjust the dose 
for some participants. You have an equal (50/50)  chance  of being  in either  group.   Some participants 
will receive placebo capsules instead of pi[INVESTIGATOR_7735].  A placebo  is a pi[INVESTIGATOR_652644]. The placebo  will make it so that neither you nor the study  doctor 
will know  which  study  group  you are in. However,  this information  can be obtained  if there is an 
emergency or if it is necessary to know for your health.  You won’t  start  the study  taking  the target 
doses; rather your dose will be titrated up (slowly increased) to the indicated doses but it may be held or continued at a lower dose if you do not tolerate.  People  in the mycophenolate plus 
pi[INVESTIGATOR_652645] a placebo.  
 
Regular Follow -up Visits (Visits 3, 5 -9, 12, 15, 18, 21)  
Blood and Urine Testing  
There are a number of potential side effects of the study drugs that may be detected only through regular blood testing. Therefore, you will be required to attend a clinic to give regular blood (1 ½ - 3 
½ teaspoons) for routine lab tests and urine for pregnancy testing, if applicable, throughout the study.  These samples will be collected every month for the first [ADDRESS_876340]. Each assessment will not 
necessarily be completed at each visit, so the timing for each one is indicated below.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   100 • You will review any changes in your health or medication with the study doctor, and answer 
questions a bout your symptoms.  
- This will occur at every visit (Visits 3, 5 -9, 12, 15, 18, 21).  
• You will have a targeted physical exam in order to assess the extent of your scleroderma.  
- This will occur at every visit (Visits 3, 5 -9, 12, 15, 18, 21).  
• You will be asked to maintain a study medication calendar and keep all of the bottles of 
study drugs that are supplied to you. You will need to bring the completed calendar and all bottles and containers of medication, whether completely or partially used (or not used  at 
all) to every visit. A study coordinator will review the calendar and your use of medications at every visit.  
- These will be checked at every visit (Visits 3, 5 -9, 12, 15, 18, 21).  
• You will complete breathing tests to measure how deep of a breath you can take, how easily 
you can blow out air from the lungs, and how well your lungs work at taking up oxygen into the bloodstream.  
- This testing will occur at 3 month intervals (Visits 6, 9, 12, 15, 18, 21). Breathing tests will take approximately 30 -45 minute s to complete.  
• You will complete health- related questionnaires.  
- Questionnaires directly assessing your breathing and the impact of shortness of breath on your activity will need to be completed at 3 month intervals (Visits 6, 9, 12, 15, 18, 21). These qu estionnaires will take [ADDRESS_876341] to your scleroderma will need to be completed at 6 month intervals (Visits 9, 15, 21). These 
questionnaires will take [ADDRESS_876342] the right to refuse to 
answer any question you do not wish to answer.  
Interval Phone Visits (Visits 2, 4, 10 -11, 13- 14, 16- 17, 19- 20) 
Some of the regular monitoring for this study will occur over the phone and will not require that you 
present to the clinic (or study center) for an in- person visit. At a pre -arranged date and time, t he 
study team will contact [CONTACT_652767], ask you whether any changes to your health or use of medications has occurred, ask you to report any side effects or adverse health events, and to review the use of your study dr ugs.  
Extra Follow -up Safety Visits (if needed)  
If you should get a side effect that requires adjustment to your dose of study medication, you may 
be required to attend the clinic to provide blood samples for routine lab safety tests every [ADDRESS_876343] is resolved or until a proper dose of medication is identified.  
Visit 15  (Month 12 = 336 days, +/ - 14 days)  
In addition to testing completed at the Regular Follow -up Visits described above, the following will 
take place:  
• You will give a blood sample (approximately 2 -3 tablespoons) that will be stored in a 
repository for use in several different types of research tests designed to provide 
information about the causes of scleroderma and the mechanisms by [CONTACT_652768] l ungs. This will be taken at the same time as your other blood sample and will 
not require an extra needle -stick.  
• You will have a more extensive history and physical examination with the study physician 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   101 that will include an overall assessment of your health  in addition to issues specifically 
related to Scleroderma and Scleroderma-related lung disease  
Visit 21  (Month 18 = 504 days, +/ - 14 days)  
In addition to testing completed at the Regular Follow -up Visits described above, the following will 
take place:  
• You will give a blood sample (approximately 2 -3 tablespoons) that will be stored in a 
repository for use in several different types of research tests designed to provide 
information about the causes of scleroderma and the mechanisms by [CONTACT_652766]. This will be taken at the same time as your other blood sample and will not require an extra needle -stick.  
• You will undergo a high resolution CT (HRCT) scan of the chest.  
 
Final Follow -up Telephone Visit (Visit 22 or within 30 days of pe rmanently stoppi[INVESTIGATOR_652646])  
At a pre -arranged date and time, the study team will contact [CONTACT_652769]. 
This might occur one month after completing the entire [ADDRESS_876344].  
• You will review any changes in your health or use of medications  and answer 
questions about your symptoms.  
• You will be asked to report any side effects or adverse health events  
 Additional Visit for those who prematurely discontinue taking the study treatment: 
If you prematurely and permanently stop taking study drugs  for any reason  (i.e. stop both 
pi[INVESTIGATOR_7735]/placebo and mycophenolate) , you will be asked to return to the clinic for the Month [ADDRESS_876345] the right to refuse to complete th e visits. 
However, If only  the pi[INVESTIGATOR_7735]/placebo  study drug is permanently stopped, and you are  approved to 
continue taking mycophenolate according to the protocol, then you may  continue participation in all 
study visits according to the normal study protocol.  
 
Management of Treatment Failures: 
If, after the first 3 months of being on study drug, your lung function markedly decreases, you will be 
asked to stop taking the study drugs ( both the pi[INVESTIGATOR_7735]/placebo capsules and the mycophenolate  
capsules .) If that situation occurs, the study team will work with you and your treating physician to 
revie w your medical condition and develop an alternative treatment plan that is independent from this 
research study. The exact type of treatment that you might receive, including the responsibility for all 
the medications and testing involved, would be up to you and your treating physician to determine. However, regardless of the type of treatment that you receive after stoppi[INVESTIGATOR_35648], we would ask that you return to and complete the Month [ADDRESS_876346] the right to 
refuse to complete th e visits. 
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   102 HOW LONG WILL I BE IN TH IS STUDY?  
This study will last approximately 19 months from the time you are assigned to a specific treatment 
group, which includes the 18 months of active drug therapy and the final telephone follow -up 
approximately 30 days after stoppi[INVESTIGATOR_652647]. Your participation is voluntary and if you should 
decide to do so, you may withdraw at any time in which case your participation would be shorter than 
described.  
In addition to your participation in the study visits described above, you will be asked at the  end of this 
consent form (section on “Signature [CONTACT_652808]”) to indicate whether you are willing (or not) to be contact[CONTACT_652770] [ADDRESS_876347]?  
For your safety, you must tell the study staff about all medications you are taking before you start the 
study, and any changes in your medications while on the study. There may be unknown or 
unforeseeable risks to participation in the study. It is important that you report any and all symptoms or possible reactions to your study doctor, even if you think it isn’t related to your study participation.  
All drugs and testing have the potential for side effects. Although the experimental drug treatments that will be used in this study have been well- tested in laboratory and animal studies, and in patients taking 
them for other reasons, the potential side effects in patients with scleroderma are not completely known at this time. You will be followed closely by [CONTACT_652771] a part of this study. If you experience any side effects from the study, the researchers will provide you with the 
treatment that has the best chance of taking care of the side effects. If you experience any side effects related to the study drugs that continue at th e end of study, we will continue to follow -up with you until 
these effects stabilize or resolve.  
 Known risks and discomforts associated with the study drugs: 
Risk of pregnancy and breast feeding during study treatment: 
Mycophenolate can harm the fetus when administered to a pregnant woman and use of mycophenolate during pregnancy is associated with an increased risk of first  
trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of  
the distal limbs, heart, esophagus, kidney and nervous. There are no adequate and well -controlled 
studies of pi[INVESTIGATOR_652648]. It is 
not known whether or not these drugs are excreted in human breast milk, but many drug are. In 
addition, there may also be other unknown risks of the study drugs and procedures to pregnant women, fetuses, and nursing children. As all study participants will receive m ycophenolate, those 
who are able to become pregnant (those less than age 55, who have not been postmenopausal for at least [ADDRESS_876348] not had surgery to remove the fallopi[INVESTIGATOR_2134], uterus and/or ovaries) and wish to participate will be required t o use approved contraception methods and to be 
monitored with frequent urine pregnancy tests throughout the study. Women who are breastfeeding will not be eligible to participate in this study.  
For this reason, women who are able to become pregnant must agree to either abstinence (to avoid heterosexual intercourse completely) or use two acceptable methods  of birth control throughout 
the study and must have negative urine pregnancy tests in order to continue their participation in 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   103 the study. Acceptable methods of birth control include hormonal contraceptives (oral contraceptive 
pi[INVESTIGATOR_3353], patch, vaginal ring), implantable contraceptives (such as Norplant, levonorgestal IUS), injectable contraceptive (such as Depo -Provera), barrier metho ds (such as male/female condoms, 
diaphragm, cervical cap), spermicides (such as vaginal sponge, spermicidal cream, foam or jelly), 
intrauterine contraceptive devices (IUD), or surgical sterilization (tubal ligation, vasectomy). The 
study staff will discuss  this with you further. If you think you are pregnant or become pregnant, you 
must tell the study doctor immediately. Follow-up information on the outcome of your pregnancy will be requested, such as if there is anything unusual in the progress of your pregnancy or if it ends early. The study doctor may share this information with the sponsor, the funding source (Genentech, Inc.)  and with the IRB (Institutional Review Board).  
Risks of Mycophenolate:  
For the risks of the study drug noted below, the number in  parentheses indicates the percentage of 
patients in whom the side effects have been seen.  
Common risks  experienced by [CONTACT_652772]:  
• Urinary tract infection (37%)  
• Diarrhea (31%), constipation (23%), and nausea (20%)  
• Hypertension (28%)  
• Peripheral edema (swelling of tissues, usually in the lower limbs, 29%)  
• Anemia * (low red blood cells, 26%), leucopenia (low white blood cells, 23%), and 
thrombocytopenia (low blood platelets, 10%)  
*Anemia may cau se easy fatigue or loss of energy; rapid heartbeat, shortness of breath, and 
headache especially during exercise; difficulty concentrating; dizziness; and pale skin.  The effects of anemia may be reduced with treatment like certain dietary supplements.  
• Abdominal (belly) pain (25%), fever (21%), headache (21%) and infection (19%)  
• Respi[INVESTIGATOR_4416] (22%), dyspnea (shortness of breath, 16%), and increased cough (16%)  
• Tremor (shakiness, 11%), insomnia (inability to sleep, 9%), and dizziness (6%)  
• Skin rashes  (8%) and acne (10%)  
• Hypokalemia (low potassium in the blood, usually with no symptoms, 9%)  
• Gastrointestinal hemorrhage (heavy bleeding from the lining of your stomach or intestine, 5%)  
Like all drug treatments that suppresses the immune system, the use o f mycophenolate can increase 
the risk of infections and it is important to use good hygiene, avoid obvious exposures to those with active infections, and to report any concerns about infection as early as possible to your primary doctor and the study team.  Other side effects may be dose-dependent and this study will slowly 
increase the dose of mycophenolate over several months, monitor for any problems, and adjust the 
dosing if necessary to help avoid serious problems.  
 
Rare (infrequent) but serious risks  experienced by [CONTACT_652773]:  
• Progressive multifocal leukoencephalopathy (PML) is a neurologic disorder that can be fatal 
and has been reported in patients that were taking mycophenolate. However, all of the patients receiving mycophenolate for prevention of transplant rejection in whom PML has been reported were receiving other drugs that cause severe immunosuppression at the same time and PML has not previously been reported in patients treated  with 
mycophenolate as the sole immunosuppressive drug.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   104 • BK Virus has been rarely reported when mycophenolate is used in combination with other 
drugs that cause immunosuppression. A large portion of the general population already carries BK Virus with no symptoms, but taking mycophenolate may cause you to develop symptoms, like kidney problems. In general, reactivation of latent (resting) viruses is a 
theoretical risk whenever the immune system has been severely depressed by [CONTACT_8422].  
• Pure red cell aplasia (PRCA) is a type of anemia in which the bone marrow stops producing 
red blood cells, and may cause symptoms like paleness, weakness, and tiredness. Cases of PRCA have been reported in patients treated with mycophenolate when used in combination with other dr ugs that suppress the immune system. PRCA has not previously 
been reported in patients treated with mycophenolate as the sole immunosuppressive drug for scleroderma- related lung disease.  
• Patients receiving immunosuppression that involves a combinations of  drugs, including 
mycophenolate as part of the treatment, are at increased risk of developi[INVESTIGATOR_153201], particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the s pecific use of mycophenolate. As 
usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by [CONTACT_225275] a sunscreen with a high protection factor. Lymphoproliferative disease or lymphoma developed in 0.4% to 1% of patients when they were receiving mycophenolate (2 g or 3 g daily) along with other immunosuppression as part of the treatment for kidney, heart, and liver transplantation. Lymphoma has not previously been reported in pa tients treated with mycophenolate as the 
sole immunosuppressive drug for scleroderma -related lung disease, although there have 
been reports of benign skin cancer.  
Most of the patients in whom the rare but serious side effects noted above were seen were als o 
receiving other drugs known to cause immune suppression and to be associated with these complications. Few serious side effects have been reported in patients receiving mycophenolate for scleroderma- related lung disease and this study has been specifically designed to avoid the use of 
other potent immune suppressive drugs.  
Risks of Pi[INVESTIGATOR_7735]:  
For the risks of the study drug noted below, the number in parentheses indicates the percentage of patients in whom the side effects have been seen.  
Common risks  experienced by [CONTACT_652774][INVESTIGATOR_652649]:  
• Skin rashes (30%), photosensitivity skin reactions (those occurring in sun -exposed skin; 9%), 
and itching (8%)  
• Nausea (36%), Diarrhea (26%), Abdominal discomfort (which can include stomach, upper 
abdomen or lower abdomen; 22%), Indigestion (19%), Vomiting (13%), and gastroesophageal reflux (the feeling that acid is backing up into the esophagus; 11 %),  
• Fatigue (26%)  
• Dizziness (18%), altered taste (6%), Insomni a (10%) 
• Decreased appetite (13%), Weight loss (10%)  
• Achy joints (10%)  
• Elevation of liver enzymes (ALT, AST, GGT, 0.3% - 4% each)  
In most cases (>80%), the common side effects associated with taking pi[INVESTIGATOR_652650], o ccur more frequently when first starting the drug treatment and often 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876349] often respond to a simple over the counter topi[INVESTIGATOR_2855] 1% cortisol cream. Pi[INVESTIGATOR_652651]. This study was also specifically des igned to slowly increase the dose of 
pi[INVESTIGATOR_7735], monitor for any problems, and adjust the dosing if necessary to help avoid serious 
problems.  
Rare (infrequent) but serious risks  experienced by [CONTACT_652774][INVESTIGATOR_652652]:  
• Angioedema (swelling of the face, lips, tongue and throat) has rarely been reported in patients (in the range of 1 in 100 to 1 in 1,000 patients) who recently started pi[INVESTIGATOR_7735], usually occurring in the first 90 days of treatment. This con dition has not been observed in 
any patients involved in clinical trials with pi[INVESTIGATOR_652653], they require immediate medical attention as swelling of the tongue and throat can be serious 
and potentially life -threatening.  
• Usually, the  changes in liver function tests that occur with pi[INVESTIGATOR_652654], but rarely altered liver function is also observed (an elevated bilirubin test). In all 
cases that were observed during prior clinical trials, this has been reversible with holding or 
stoppi[INVESTIGATOR_652655].  However, in 
postmarketing reports, very rare cases of atypi[INVESTIGATOR_261113] -induced liver injury have occurred, 
including severe liver injury  with fatal outcome.  
 
Known risks and discomforts associated with the study tests and assessments: 
Risks associated with randomization:  
You will be assigned to a study group at random (by [CONTACT_3364]). Your assignment is based on chance 
(like a coin flip) rather than a medical decision made by [CONTACT_41314]. The study group you are assigned to might not be the group you would prefer to be in. It might also prove to be less effective or have mo re side effects than the other study group even though information about such an 
outcome is not currently known.  
Loss of confidentiality:  
As this study involves the use of your identifiable, personal information, there is a chance that a loss 
of confident iality will occur. The researchers have procedures in place to lessen the possibility of this 
happening (see “How will my information be kept confidential?” section below).  
Risks associated with questionnaires:  
Questionnaires require that you provide information about your health, how you feel, and how 
different situations impact on your activity and well- being. Sometimes questions of this type can 
cause a person to feel anxious or vulnerable. You have the right to refuse to answer any question you do not wish to answer.  
Blood draw risks:  
Drawing blood may cause temporary pain from the needle stick, bruising or swelling at the site, and rarely, infection or fainting.  
Risks of Breathing Tests:  
Discomfort is unusual during these breathing tests. However, some people experience temporary shortness of breath, cough, chest discomfort, lightheadedness or fainting, or headache while 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876350] scan risks:  
HRCT scans involve exposure to radiation, a form of energy that is known for its potential to cause tissue injury. You are exposed to radiation on a daily basis, both from natural (sun and earth) and 
manmade sources. The estimated radiation dose that you will receive as a participant for this type of research is compared below to the limits allowed for a radiation worker. This limit for radiation workers is low and is set at a level that is not expected to be harmful. The estimated radiation dose that you will receive as a result of each additional CT scan in this study has been calculated to be about 2.4% of the annual limit allowed radiation workers. One HRCT scan is proposed during the screening phase of the study and a second will occur at completion of the study, [ADDRESS_876351] protocol included in this study is relatively brief and the time inside the enclosed portion of the sca nner is usually no more than a few minutes.  
 Unknown risks and discomforts: 
The experimental treatments may have side effects that no one knows about yet.  The researchers will 
let you know if they learn anything that might make you change your mind about  participating in the 
study.  
 
ARE THERE ANY BENEFITS IF I PARTICIPATE?  
Possible benefits to me:  
You may not receive any specific benefits from participation in this study. However, if mycophenolate or 
pi[INVESTIGATOR_652656] -related lung disease, then it could be possible 
that you may receive the benefits of improvement in lung function and possibly even improvement in other organ involvement (that is, other organs that have been affected by [CONTACT_652775]).  
Possible benefits to others or society: 
This study will also help the researchers l earn more about these drug treatments. Hopefully this 
information will help in the treatment of future patients with conditions like yours.  
 
WHAT OTHER CHOICES DO I HAVE IF I DON’T WANT TO PARTICIPATE?  
If you decide not to take part in this study, or if y ou withdraw from this study before it is completed, you 
can still discuss potential alternative treatments with your personal physicians. There is one medication 
approved by [CONTACT_1622] ( nintedanib , brand name [CONTACT_230834]® ) that may slow the rate of decline in some aspects 
of lung function  in patients with scleroderma -related interstitial lung disease . Your physicians  may be 
able to prescribe this medication or a course of treatment based on what they decide is in the best 
interest of your care even if it is not  FDA approved. Alternatively, there may be other research studies 
that offer other forms of experimental therapy that you could consider. Before you decide to take part in this study, you may discuss the benefits and risks of potential alternatives with th e study doctor.  
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   107 CAN THE RESEARCHERS REMOVE ME FROM THIS STUDY?  
The researchers may end your participation in this study for a number of reasons, such as if your safety 
and welfare are at risk, if you do not follow instructions or if you miss scheduled visits. The researchers or the study sponsor might also decide to stop the study at any time.  
If you are asked to permanently discontinue both study drugs for any reason,  the researcher will ask 
you to partake in a close -out telephone interview and return u nused study medication. The data 
collected about you up to the point of withdrawal will remain part of the study and may not be removed from the study database. In addition, you will be asked to return to the clinic for the Month 12 and Month 18 visit s that are described above (see section on, “What will happen if I take part in this study”). 
These additional visit s and the data obtained from them  will help achieve our research goals even if you 
are no longer taking study drug. While we ask that you return for these visits if at all possible, you have 
the right to refuse to complete either one or both of the requested visits . 
 HOW WILL INFORMATION ABOUT ME AND MY PARTICIPATION BE KEPT CONFIDENTIAL?  
The researchers will do their best to make sure that your private information is kept confidential. Information about you will be handled as confidentially as possible, but participating in research may involve a loss of privacy and the potential for a breach in confidentiality. Study data will be physically and electronically secured.  As with any use of electronic means to store data, there is a risk of breach of data security.   
Storage and use of personal information that can identify you: 
When you rece ive hospi[INVESTIGATOR_71089], testing and medical evaluations that are intended for your personal 
medical care, such information will be stored and handled as would any other confidential medical 
records for hospi[INVESTIGATOR_652657]. Information and blood samples that are stored for the 
purposes of the research study will be coded with a unique study identification number to protect your 
identity. Personal identify information, such as name [CONTACT_18131], will not be attached to such 
samples or information. However, the UCLA Principal Investigator [INVESTIGATOR_652658], which is separately located at the University of Michigan School of Public Health, will maintain a link between the code and your personal identifying information. This code will be maintained in a secured and password -protected manner so that only the Principal Director and the Data Coordinating 
Center Director will have access. Other researchers who may use your samples or information obtained about you during the study will not be provided with the link or any personal identifying information.  
People and agencies that will have access to your information: 
The research team, authorized UCLA personnel, the Data Coordinating Center, and regulatory agencies 
such as the Food and Drug Administration (FDA), may have access to study data and records to monitor 
the study.  Genentech, Inc., the manufacturer of pi[INVESTIGATOR_7735]  (Esbriet®) , may also have access to study 
data and records in the event of a required audit or in the course of preparing filings to regulatory 
agencies such as the FDA. Research records provided to authorized, non -UCLA personnel will not contain 
identifiable information about you. Publications and/or presentations that result from this study will not iden tify you by [CONTACT_2300].  
How long information from the study will be kept:  
Research data, records and specimens will be maintained for a period of at least 7 years after the initiation of this research study and may be retained for longer periods if required to a chieve the study 
goals or by [CONTACT_652776].  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   108  
ARE THERE ANY COSTS FOR TAKING PART IN THIS STUDY? 
The study will supply and pay for the cost of supplying and administering the study drugs and extra 
laboratory tests that are carried out  specifically for the research which include the HRCT scan of the 
chest performed during the screening and at the [ADDRESS_876352].  
 WILL I BE PAID FOR MY PARTICIPATION?  
You will not be paid for your participation in this research study.  
 WHAT OTHER THINGS SHOULD I CONSIDER BEFORE PARTICIPATION?  
Use of My Specimens:  
Any specimens (e.g., tissue, blood, urine) obtained for the purposes of this study will become the property of the University of [LOCATION_004]. Once you provide the specimens you will not have access to them. The University may share your specimens in the future with other researchers or outside 
institutions. Information that identifies you will not be shared with anyone outside of UCLA. The specimens will be used for research and such use may result in inventions or discoveries that could become th e basis for new products or diagnostic or therapeutic agents. In some instances, these 
inventions and discoveries may be of potential commercial value and may be patented and licensed by [CONTACT_2374]. You will not receive any money or other benefits derived from any commercial or other products that may be developed from use of the specimens.  
Researcher Financial Interests in this Study:  
[To be updated by [CONTACT_652777]]  
  WHO CAN I CONTACT [CONTACT_8657] I HAVE QUES TIONS ABOUT THIS STUDY?  
The Research Team: 
You may contact [name(s) to be updated by [CONTACT_652778]] at [phone number(s) to be updated by [CONTACT_652778]] with any questions or concerns about the research or your participation in this study. You 
can also call the UCLA Page Operator at (310) 825 -6301 to reach [insert name(s)] 24 hours a day, 7 days 
week.  
UCLA Office of the Human Research Protection Program (O HRPP): 
If you have questions about your rights while taking part in this study, or you have concerns or 
suggestions and you want to talk to someone other than the researchers about the study, you may contact [CONTACT_485149]: (310) 825 -5344; by [CONTACT_133335] l: [EMAIL_3169] or U.S. mail: 
UCLA OHRPP, [ADDRESS_876353]., Suite 211, Box 951694, Los Angeles, CA [ZIP_CODE]- 1694.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   109 Public Information about this Study:  
ClinicalTrials.gov is a website that provides information about federally and privately supported clinical 
trials. A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This website will not include information that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time.  
 
WHAT HAPPENS IF I BELIEVE I AM INJURED BECAUSE I TOOK PART IN THIS STUDY?  
It is important that you promptly tell the researchers if you believe that you have been injured because 
of taking part in this study. Y ou can tell the researcher in person or call him/her at the number(s) listed 
above.  
 If you are injured as a result of being in this study, UCLA will provide necessary medical treatment. The costs of the treatment may be covered by [CONTACT_652779], depending on a number of factors. The University does not normally provide 
any other form of compensation for injury.  For more information about this, you may call the UCLA 
Office of the  Human Research Protection Program at 310 -825-5344 or send an email to 
[EMAIL_3169].  WHAT ARE MY RIGHTS IF I TAKE PART IN THIS STUDY?  
Taking part in this study is your choice. You can choose whether  or not you want to participate. 
Whatever decision you make, there will be no penalty to you and you will not lose any of your regular 
benefits.  
• You have a right to have all of your questions answered before deciding whether to take part.  
• Your decision  will not affect the medical care you receive from UCLA.  
• If you decide to take part, you can leave the study at anytime.  
• If you decide to stop being in this study you should notify the research team right away. The researchers may ask you to complete some procedures in order to protect your safety.  
• If you decide not to take part, you can still get medical care from UCLA.  
 HOW DO I INDICATE MY AGREEMENT TO PARTICIPATE?  
If you agree to participate in this study you should sign and date below. You have been given a copy of this consent form and the Research Participant’s Bill of Rights to keep. You will be asked to sign a separate form authorizing access, use, creation, or disclosure of health information about you.  
 
SIGNATURE [CONTACT_652809]  
 
______________________________________  
Name [CONTACT_2385]  
 ______________________________________  ______________________  
Signature [CONTACT_652810] [CONTACT_652780] 5 years 
after the study:  
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876354] Number  
 ______________________________________  ______________________  
Signature [CONTACT_652811]                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   111 SCHEDULE OF STUDY VISITS AND ASSESSMENTS  
 
 SCREENING AND INITIAL 6 MONTHS  
Type of Visit:  Screen  Baseline  
Phone  Regular  
Phone  Regular  Regular  Regular  Regular  Regular  
Visit #:  S1-2 1 2 3 4 5 6 7 8 9 
Study Month:   [ADDRESS_876355]*  X X  X  X X X X X 
Blood  for storage  
 X         
* For women  who  are able to become pregnant ; require a blood test at screening then urine testing . 
  MONTHS 7 -19 AND (OPTIONAL) EXTRA FOLLOW -UP FOR 5 YEARS  
Type of Visit:  Phone  Regular  
Phone  One 
Year  Phone  Regular  
Phone  18 
Month  Final 
Phone  Extra  
Visit #:  10-11 12 13-14 15 16-17 18 19-20 21 22  
Study Month:  7, [ADDRESS_876356]*   X  X  X  X   
Blood  for storage     X    X   
* For women  who  are able to become pregnant ; require a blood test at screening then urine testing . 
 
  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876357] by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. Therefore, the study 
protocol, documentation, data, and all other information generated will be held in strict confidence. No 
information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
The study monitor, other authorized representatives of the sponsor, representatives of the IRB or pharmaceutical company supplying study product may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such 
records.  
The study participant’s contact [CONTACT_10414]. At the end of t he study, all records will continue to be kept in a secure location for as 
long a period as dictated by [CONTACT_46202].  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the University of Michigan Data Coordinating Center. This will not include direct links to the participant’s contact [CONTACT_1290]. Rather, individual participants 
and their research data will be identified by a  unique study identification number. The study data entry 
and study management systems used by [CONTACT_652781]. At the end of the study  
when all subject follow -up and analysis is complete, verified and secured, all study databases will be de -
identified and archived.  
 
13.6 FUTURE USE OF STORED D ATA AND SPECIMENS   
Data and biological samples collected for this study will be prepared, analy zed and /or stored at the 
University of Michigan Data Coordinating Center and the  UCLA Administrative and Contracting Core, 
respectively, under the direction of their Directors . After specific phases of the  study are completed, as 
appropriate, the de -identi fied, archived data and specimens will be available for use by [CONTACT_72776]. Permission to  use data and specimens for such 
purposes will be provided by [CONTACT_652782] , with such 
use approved by [CONTACT_652783].   
Such data and  samples are intended  for research into the causes of Scleroderma -associated ILD and its 
associated conditions , the natural history and biology of the disease, its progression and its treatment.   
 
[ADDRESS_876358] KEEPI[INVESTIGATOR_1645]  
 
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Comprehensive data coordinating center (DCC) functions for this clinical trial, including clinical 
monitoring, database development, web -based data entry and management, as well as the creation and 
export of study reports for the DSMB will be provided by [CONTACT_652784] (SABER) group.  Housed in the top nationally ranked Department 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   113 of Biostatistics, SABER, in its 17 -year existence, has served as the DCC for over 50 studies, including 
multi ple NIH- sponsored networks.   
The DCC will use OpenClinica® (OpenClinica Clinical Trial Software; OpenClinica, LLC, Waltham, MA), a 
clinical trial software platform for electronic remote (i.e., site -based entry) data capture and clinical data 
management, as the basis for our custom -designed data entry and management system. The majority of 
data will be collected via electronic Case Report Forms (CRFs); however, other data sources, such as laboratory data from the central laboratory, may be used. In these circumstances, the DCC will also utilize electronic data transfer. Protocols for the transfer of data, with careful attention to data integrity, will be written by [CONTACT_652785].   
The DCC has est ablished a set of standard operating procedures (SOPs) governing the processes used to 
ensure patient privacy and data confidentiality, including the use of anonymous participant IDs on CRFs and in reports. OpenClinica® enables compliance with Good Clinical Practice (GCP) and regulatory requirements by [CONTACT_600848], password and user authentication security, electronic signatures, SSL encryption, and comprehensive auditing to record and monitor 
access and data changes.  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  In addition to th e protocol, the DCC will prepare a Manual of Operations will 
provides additional detail on data collection procedures, including source documentation, eCRF completion guidelines, data handling procedures and procedures for data monitoring and quality contr ol 
that ensure these data are accurate, consistent, complete and reliable and in accordance with ICH 36.   
 
14.[ADDRESS_876359]  for the studied purpose. These documents should be retained for  a longer period, however, if 
required by [CONTACT_427]. No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to b e retained . 
 
14.3 PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MOP requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff.    
It is the responsibility of the site to use continuous vigilance to identify and report deviations within 5 
working days of identification of the protocol deviation or scheduled protocol- required activity .  The 
DCC will also assess compliance with the protocol during its monitoring visits.  The DCC will summarize protocol deviations in site performance reports .  As a result of deviations, corrective actions are to be 
developed by [CONTACT_3483].  
 
14.4 PUBLICATION AND DATA SHARING POLICY  
The Faculty of the University of [LOCATION_004] are committed to disseminating its research and scholarship as widely as possible. In particular, as part of a public university system, the Faculty is dedicated to making its scholarship available to the people of [LOCATION_004] and the world. Each Faculty member grants 
S c l e r o d e rm a  L u n g  S t u d y  I I I                                            [ C o n f i d e n t i a l ]  V e r s i o n  2 . 5  
P r o t o c o l  # U C L A -S L S 3  1 1 / 1 7 / 2 1  
F D A  I N D  # :  1 3 5 8 4 8   1 1 4  t o  t h e  U n i v e r s i t y  o f  C a l i f o r n i a  a  n o n e x c l u s i v e ,  i r r e v o c a b l e ,  w o r l d w i d e  l i c e n s e  t o  e x e r c i s e  a n y  a n d  a l l  
r i g h t s  u n d e r  c o p y r i g h t  r e l a t i n g  t o  e a c h  o f  h i s  o r  h e r  s c h o l a r l y  a r t i c l e s ,  i n  a n y  m e d i um ,  a n d  t o  a u t h o r i z e  
o t h e r s  t o  d o  t h e  s am e ,  f o r  t h e  p u r p o s e  o f  m a k i n g  t h e i r  a r t i c l e s  w i d e l y  a n d  f r e e l y  a v a i l a b l e  i n  a n  o p e n  
a c c e s s  r e p o s i t o r y .  T h i s  p o l i c y  d o e s  n o t  t r a n s f e r  c o p y r i g h t  o w n e r s h i p ,  w h i c h  r em a i n s  w i t h  F a c u l t y  a u t h o r s  
u n d e r  e x i s t i n g  U n i v e r s i t y  o f  C a l i f o r n i a  p o l i c y .   
T h e  s t u d y  w i l l  c om p l y  w i t h  S e c t i o n  8 0 1  o f  t h e  F o o d  a n d  D r u g  A dm i n i s t r a t i o n  Am e n dm e n t s  A c t  o f  2 0 0 7 ,  
a n d  t h i s  c l i n i c a l  t r i a l  w i l l  b e  r e g i s t e r e d  i n  C l i n i c a l T r i a l s . g o v ,  a  f r e e l y  a v a i l a b l e  p u b l i c  r e g i s t r y  s p o n s o r e d  b y  
t h e  N a t i o n a l  L i b r a r y  o f  M e d i c i n e .   
I n  a d d i t i o n ,  a n  e x p l i c i t  g o a l  o f  t h i s  s t u d y  i s  t o  p r e s e n t  t h e  p r im a r y  a n d  r e l a t e d  o u t c om e s  o f  t h i s  s t u d y  a t  
S c i e n t i f i c  M e e t i n g s  a n d  t o  p u b l i s h ,  a s  p o s s i b l e ,  i n  pe e r -r e v i e w e d  S c h o l a r l y  J o u r n a l s  t o  a s s u r e  
d i s s em i n a t i o n  o f  t h e  f i n d i n g s .  T h e  a u t h o r i t y  t o  d o  s o  r e s i d e s  w i t h  t h e  p a r t i c i p a n t  i n v e s t i g a t o r s  a n d  n o t  
w i t h  a n y  s p o n s o r .  
A  bi o -s p e c im e n  r e p o s i t o r y  w i l l  b e  c r e a t e d  i n  w h i c h  d e -i d e n t i f i e d  b l o o d  s p e c im e n t s  a n d  l i n k e d  c l i n i c a l  
a n d  r e s e a r c h  d a t a  w i l l  b e  m a d e  a v a i l a b l e  t o  q u a l i f i e d  r e s e a r c h e r s  w h o  s u bm i t  m e r i t o r i o u s  a p p l i c a t i o n s  
f o r  t h e  a c c e s s  a n d  u s e  o f  s u c h  s am p l e s .  O v e r s i g h t  f o r  t h e  r e v i e w  o f  r e q u e s t s  a n d  t h e  d i s s em i n a t i o n  o f  
s t u d y  m a t e r i a l s  w i l l  b e  t h r o u g h  t h e  S t u d y  E x e c u t i v e  a n d  S t e e r i n g  C omm i t t e e s  a n d / o r  a n y  s u b -
c omm i t t e e s  t h a t  t h e y  m a y  a p p o i n t  f o r  t h i s  p r o c e s s .  
 
1 5  S T U D Y  A DM I N I S T R A T I O N  A N D  O V E R S I G H T  
 
1 5 . 1  S T U D Y  L E A D E R S H I P  
T h e  o v e r a l l  m a n a g em e n t  a n d  d a y -t o -d a y  o p e r a t i o n a l  s t r u c t u r e  p r o p o s e d  f o r  t h e  S L S -I I I  s t u d y  i s  o u t l i n e d  
i n  t h e  t w o  o r g a n i z a t i o n a l  c h a r t s  b e l o w  ( F i g u r e s  1 5 . 1 A - B ).   
 
F i g u r e  1 5 . 1 A :  O r g a n i z a t i o n a l  C h a r t  d e p i c t i n g  S t u d y  A dm i n i s t r a t i v e  O v e r s i g h t  a n d  M a n a g em e n t  
 
S c l e r o d e rm a  L u n g  S t u d y  I I I                                            [ C o n f i d e n t i a l ]  V e r s i o n  2 . 5  
P r o t o c o l  # U C L A -S L S 3  1 1 / 1 7 / 2 1  
F D A  I N D  # :  1 3 5 8 4 8   1 1 5  N o t e  t h a t  t h e  E x e c u t i v e  C omm i t t e e  ( i n d i c a t e d  i n  Y e l l o w )  w i l l  s e r v e  a s  t h e  c e n t r a l  b o d y  r e s p o n s i b l e  f o r  
o v e r s i g h t  a n d  m a n a g em e n t  a n d  w i l l  m e e t  e v e r y  1  t o  2  w e e k s  t h r o u g h o u t  t h e  5 - y e a r  c o u r s e  o f  t h e  s t u d y .  
I t  i s  d i r e c t l y  s u p p o r t e d  i n  t h i s  f u n c t i o n  b y  t h e  p r e s e n c e  o f  t w o  C o o r d i n a t i n g  U n i t s ,  T h e  U C L A  
A dm i n i s t r a t i v e  a n d  C o n t r a c t i n g  C o r e  a n d  t h e  U n i v e r s i t y  o f  M i c h i g a n  D a t a  C o o r d i n a t i n g  C e n t e r  
( h i g h l i g h t e d  i n  b l u e ) .  T h e s e  t h r e e  u n i t s  [ E x e c u t i v e  C omm i t t e e ;  A dm i n i s t r a t i v e  C o r e  a n d  D a t a  
C o o r d i n a t i n g  C e n t e r ]  a r e  r e s p o n s i b l e  f o r  i n t e r a c t i n g  w i t h  t h e  f u l l  S t e e r i n g  C omm i t t e e ,  w h i c h  i n c l u d e s  
r e p r e s e n t a t i o n  f r om  e v e r y  p a r t i c i p a t i n g  c l i n i c a l  s i t e ,  a n d  w i t h  t h e  i n d e p e n d e n t  D a t a ,  S a f e t y  a n d  
M o n i t o r i n g  C omm i t t e e .  T h e  U C L A  A dm i n i s t r a t i v e  C o r e  w i l l  h o l d  t h e  s t u d y  I N D  a n d  t h e  o v e r a l l  s t u d y  I R B  
a p p r o v a l  a n d  r e p r e s e n t  t h e  s t u d y  i n  t h o s e  r e s p e c t s .  
 
F i g u r e  1 5 . 1 B :  D a y -t o -D a y  O p e r a t i o n a l  F l o w  C h a r t  
 
N o t e  t h a t  i n  t h e  d a y -t o -d a y  o p e r a t i o n a l  f l o w ,  t h e  P a r t i c i p a t i n g  C l i n i c a l  S i t e s  ( i n d i c a t e d  i n  Y e l l o w )  s e r v e  a s  
t h e  c e n t r a l  b o d y  r e s p o n s i b l e  f o r  t h e  i n t e r a c t i o n  w i t h  s t u d y  p a t i e n t s  a n d  t h e  d a y -t o -d a y  c l i n i c a l  o v e r s i g h t  
o f  b o t h  p a t i e n t  c a r e  a n d  t e s t i n g .  T h e  C l i n i c a l  S i t e s  a r e  d i r e c t l y  s u p p o r t e d  i n  t h e i r  t a s k  b y  t h e  D a t a  
C o o r d i n a t i n g  C e n t e r  ( h i g h l i g h t e d  i n  b l u e ) ,  w h i c h  i s  r e s p o n s i b l e  f o r  t h e  d a t a  c o l l e c t i o n  a n d  m o n i t o r i n g .  
T h e  U C L A  A dm i n i s t r a t i v e  C o r e  ( h i g h l i g h t e d  i n  g r e e n )  o n l y  h a s  a n  i n d i r e c t  r o l e  i n  t h e  d a y -t o -d a y  
o p e r a t i o n s  i n  t h a t  i t  i s  i n  c o n s t a n t  c o n t a c t  w i t h  t h e  D a t a  C o o r d i n a t i n g  C e n t e r  a n d  o v e r s e e s  t h e  6  U C L A  
C o r e  S e r v i c e s  ( a p p e a r  i n  w h i t e )  w h i c h  d i r e c t l y  s u p p o r t  t h e  d a y -t o -d a y  o p e r a t i o n s  o f  t h e  C l i n i c a l  S i t e s .  
S h o u l d  t h e  D a t a  C o o r d i n a t i n g  C e n t e r s  o r  C o r e s  i d e n t i f y  d a y -t o -d a y  i s s u e s  t h a t  r e q u i r e  i n p u t ,  t h e y  a r e  
em p o w e r e d  t o  imm e d i a t e l y  i n t e r a c t  w i t h  t h e  U C L A  A dm i n i s t r a t i v e  C o r e  o r  t o  a d d r e s s  t h o s e  i s s u e s  i n  t h e  
r e g u l a r l y  s c h e d u l e d  E x e c u t i v e  C omm i t t e e  m e e t i n g s .   
 
1 5 . 1 . 1  U C L A  A dm i n i s t r a t i v e  &  C o n t r a c t i n g  C o r e  
Th e  d e s i g n a t e d  P r i n c i p a l  I n v e s t i g a t o r  f o r  S L S  I I I  w i l l  d i r e c t  t h e  U C L A  A dm i n i s t r a t i v e  a n d  C o n t r a c t i n g  
C o r e ,  w h i c h  w i l l  b e  o p e r a t i o n a l l y  r e s p o n s i b l e  f o r  a l l  a s p e c t s  o f  t h e  c l i n i c a l  t r i a l  a n d  c o n t r a c t i n g  w i t h  
p a r t i c i p a t i n g  c l i n i c a l  s i t e s .  T h e  P r i n c i p a l  I n v e s t i g a t o r  w i l l  b e  a s s i s t e d  b y  a  N a t i o n a l  S t u d y  C o o r d i n a t o r  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876360] QIA Imaging Core, Pulmonary Function QA Core, Pharmacy Core, and a Bio -repository Core, all 
of which will develop operational guidelines and oversee the services defined by [CONTACT_652786] . 
 
15.1.2 Data Coordinating Center (DCC)  
The Director of the DCC, housed at the University of Michigan within the Statistical Analysis of 
Biomedical & Educational Research (SABER) Unit of the School of Public Health, will also serve as 
thes Senior Statistician. The DCC staff will include  a Database programmer, Data manager, Statistical 
Analyst, Project Manager, Clinical Monitor, Web Programmer/Designer, and a Research Administrator. In addition, the Co -PI [INVESTIGATOR_652659] -site Clinical Advisor for the DCC in addition to  other responsibilities . 
The DCC plays a pi[INVESTIGATOR_652660], implementation, execution and administration of the study. The DCC will be responsible for randomization, data forms and online reporting systems, preparation of the manual of operations, addressing questions regarding protocol issues, data screening, entry and analysis, monitoring recruitment, follow -up and adherence to protocol, and 
scheduling and arranging meetings of the Executive Committee, Steering Committee, and DSMB. The Clinical Monitor will interact re gularly  with the National Study Coordinator at UCLA and in the 
initial year, will visit all of the clinical sites for on -site monitoring. Subsequent routine monitoring 
will be done remotely, using regularly scheduled web -based meetings for document and protocol 
review. The DCC will also evaluate sites for meeting performance goals, completing documentation, and producing reimbursement documents for the Administrative Core at UCLA. The DCC will prepare 
all of the routine study reports for the Executive Committee, Steering Committee, DSMB, and in support of annual filings with for the IND, etc. The DCC will interact with all of the Cores and send out study notices, including those related to lab alerts, adverse events and SAEs using auto mated 
notification netw orking.  
 
15.1.[ADDRESS_876361] essential information, and to implement modifications related to the clinical trial. Other members of the Executive Committee include an Executive Consultant, Study  co-PI, and the Director of the DCC, the National Coordinator 
and ad hoc representation from the Directors of the named Cores as needed. Each Executive Committee meeting will include a review of enrollment, random ization, retention, drop -outs, AEs, 
SAEs, medication control issues, site performance and problems, Core reports, study compliance issues, an d any interval protocol issues.  
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   117 15.1.4 Steering Committee  
A Steering Committee chaired by [CONTACT_652787]. Voting 
members will include the Chairman, one Pulmonary and one Rheumatology investigator from each 
Clinical Center, the DCC Director, and the Director of each Core. The Steering Committee will be 
responsible for developi[INVESTIGATOR_007] a final protocol and Manual of Operations; approving any changes in these; monitoring recruitment and follow -up at each center; and presenting/publishing r esults from 
the trial. The Committee will meet face-to -face at least once prior to the initiation of the trial and at 
least annually for the duration of the trial. Steering Committee members will also participate in monthly teleconference/web calls for the  duration of the trial. The Steering Committee will also 
have the authority to organize and empower working subcommittees (as needed for the study) including:  
• Recruitment and Patient Issues Committee  
• Quality Control Committee  
• Drug Distribution and Safety Monitoring Committee  
• Ancillary Studies Committee  
• Manuscript Preparation Committee  
 
15.1.5 Data & Safety Monitoring Board (DSMB)  
A 3-member external Data and Safety Monitoring Board (DSMB) will be appointed and composed of 
individuals who have no direct con flicting involvement with the study  or an active salaried 
appointment with any of the participating institutions. The recommended composition of the DSMB will be to include a pulmonologist, a rheumatologist, and a biostatistician  with an expectation that 
each member will have experience in one or more of the following areas:  
• interstitial lung disease  
• idiopathic pulmonary fibrosis  
• systemic sclerosis  
• collagen -vascular disease associated ILD  
• clinical trial design and management  
• data management and statistical analysis  
• patient safety monitoring  
• the ethical conduct of clinical research   
• clinical use of Pi[INVESTIGATOR_331329]/or Mycophenolate  
The DSMB Chair will be appointed by [CONTACT_652788].   
The DSMB will review the protocol and suggest any changes that might be required prior to  its 
implementation.  Once the trial is initiated, the DSMB will review cumulative trial results to evaluate the treatment for beneficial and adverse effects, including the review of all Serious Adverse Events.  The board will also monitor the performance of individual clinics and study performance indicators (drug monitoring and compliance, visit compliance, recruitment, etc.). The DSMB will meet every 6 months by [CONTACT_369390]/or web videoconferencing for the duration of the trial and will interact directly with the Data Coordinating Center for access to study data and interim reports.  
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   118 The DSMB will be charged to provide external oversight concerning the safety and scientific integrity 
of the study for the duration of the clinical trial and produce written reports that will advise the 
sponsor and Executive Committee  as to whether the DSMB recommends that the study continue as 
is, consider specific safety and/or data management changes, or consider early termination due to 
specific safety or ethical management concerns.  
 
15.1.6 Study Cores  
The Study Cores are provided as a centralized resource that will a) develop and disseminate operational guidelines for their areas of expertise; b) provide site training in their areas of expertise; c) deliver key s ervices, d) and provide standardization and quality assurance. The Core Directors will 
be members of the Executive Committee in order to completely integrate these aspects of study services and oversight into the overall flow and oversight of the Clinical Trial. The Study Cores are:  
• Contracting Core : Uniform contracting guidelines and assurances will be developed and 
executed with each of the participating clinical sites to carry out the described clinical trial. With data input from the Data Coordinating Center, the Contracting Core will also approve  
site expenditures and reimbursements for the performance of study services.  
• National Study Coordinator : The National Study Coordinator acts as a core resource to 
liason between the Investigators and Administration of the study and the actual performance o f the clinical trial by [CONTACT_14523]. The National Study Coordinator will 
help to standardize and distribute regulatory documents, including IRB consents and drug safety notifications, and lead regular meetings of the study coordinators from all 
participating sites so that lessons and experiences at each site can be shared with the other 
sites, which is key in the study of an orphan disease where patient numbers and individual 
experience are limiting features. The National Study Coordinator also acts as a readily available resource to field and trouble -shoot day -to-day operational issues that arise in the 
conduct of the study.  
• HRCT QIA Imaging Core : The Imaging  Core will include a Director, research physicist, 
coordinators and staff that are responsible for establishing and overseeing the CT imaging protocol including the development of the manual of operations, interacting with 
radiologists and technicians at each site to categorize, standardize and program their equipment for participation i n the imaging protocol, and will assure that HIPAA compliant 
protocols are in place for data transfer and storage. In addition to these aspects of raw data acquisition, the imaging core will be responsible for carrying out the quantitative image analysis  required for all CT data sets and for assessing and reporting quality assurance and 
compliance with operational guidelines. If imaging problems should arise, they will work with an individual site to identify and resolve these issues.  
• Pulmonary Function QA  Core : In addition to preparing a PFT manual of operations and 
helpi[INVESTIGATOR_652661] , the PFT Core will review all patient test results for completeness, 
compliance with  protocol requirements, and accuracy . If deficiencies should arise, the Core 
Director will work one -on-one with a site to establish the reason and resolution of such 
deficiencies. If repeat testing is required, the PFT Core Director will communicate this information to the Data Coordinating Center and to the site.  
• Pharmacy Core :  The Investigational Drug Unit of the Department of Pharmaceutical 
Services, University of [LOCATION_004] Los Angeles , at the  Ronald Reagan Medical Center will 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   119 serve as the central drug  packaging and distribution site for all participating institutions. 
Responsibilities include drug procurement , storage  and inventory, drug accountability  and 
drug distribution to all participating sites. They will establish the operational procedures by 
[CONTACT_652789], label and distribute drug supply for the study, but each site will 
be responsible for drug inventory control, distribution and disposal at their individual sites after receipt of study drug from the Core.  
• Bio-repository Core : The UCLA Bio -repository  Core will establish standard procedures and 
train sites for the collection, processing, storage and shippi[INVESTIGATOR_652662]. They will provide centralized kits and instructions and also house the returned sampl e in a secure storage system at UCLA for later use. They will track performance and 
provide inventory control and also, when applicable, at the direction of the Executive Committee, distribute samples to individual investigators for analysis . 
 
15.[ADDRESS_876362] the safety of the study patient, or which may alter the scope of the 
investigation, the scientific quality of the study, the study design, dosages, duration of therapy, patient assessments (added evaluation that poses potential risk or inconvenience to the patient), number of 
patients, and/or patient eligibility criteria, may be made only after appropriate consultation between the investigators, the Study Executive Committee  and the DSMB. In dividual sites may not alter the 
protocol without advanced consultation and approval as noted here -in. 
If the consensus is to revise the current protocol, a formal List of Changes will accompany the amended protocol and these will initially be submitted to  the DSMB for review and until their recommendations 
for further modification have been addressed or it is approved. Once DSMB approval has been obtained, 
the revised Protocol and the List of Changes will be submitted to the FDA and to the IRB s at all 
participating clinical sites . Protocol changes will not be implemented until they have been reviewed and 
approved by [CONTACT_652790]/or their consent 
re-obtained if indicated by [CONTACT_652791]/or 
responsible IRB . 
 
[ADDRESS_876363] the reliability of data submitted to FDA, or alternatively  disclose those financial interests and arrangements to the 
agency and identify steps taken to minimize the potential for bias (21 CFR § 54.4(a)).  
 
16.1.1 Disclosable Financial Interests & Arrangements under [ADDRESS_876364] be disclosed (see 21 CFR § 54.4(a)(3), referred to herein as “disclosable financial interests and arrangements”) are described below.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   120 [IP_ADDRESS]  Any compensation made to the investigator by [CONTACT_652792].  
[IP_ADDRESS]  A proprietary interest in the tested product including, but not limited to, a 
paten t, trademark, copyright or licensing agreement.   
[IP_ADDRESS]  Any equity interest in any sponsor of the covered clinical study, i.e., any 
ownership interest, stock options, or other financial interest whose value cannot be 
readily determined through reference to public prices. The requirement applies to interests held during the time the clinical investigator is carrying out the study and for one year following completion of the study.  
[IP_ADDRESS]  Any equity interest in any sponsor of the covered study if the sponsor is a publicly 
held company and the interest exceeds $50,000 in value. The requirement applies to interests held during the time the clinical investigator is carrying out the study and for one year following completion of the study.  
[IP_ADDRESS]  Significant payments of other sorts (SPOOS) are payments that have a cumulative 
monetary value of $25,000 or more and are made by [CONTACT_652793] a covered study to the investigator or the investigator’s institution during the time the clinical investigator is carrying out the study and for one year following completion of the study. This would include payments that support activities of the investigator (e.g., a grant to the investigator or to the institution to fund the investigator’s ongoing research or compensation  in the form of equipment), exclusive of the costs of conducting the 
clinical study or other clinical studies, or to provide other reimbursements such as retainers for ongoing consultation or honoraria. See Section IV, Questions C.4, C.5, and C.6 for addit ional information on SPOOS.  
 
16.1.2 Completion of Forms FDA 3455 & 3454 under 21 CFR part 54  
For each clinical investigator [a “listed or identified investigator or subinvestigator who is 
directly involved in the treatment or evaluation of research subject s,” including the spouse and 
each dependent child of the investigator or subinvestigator] who is not identified as an employee of the sponsor, one of the following must be submitted (21 CFR § 54.4(a)):  
[IP_ADDRESS]  
FORM FDA 3455 Disclosure Statement . Form 3455  shall be completed  for each 
clinical investigator who, or whose spouse or dependent child, had disclosable financial 
interests in and/or arrangements with any sponsor of the covered clinical study. The form should include an attachment with detailed information about those financial interests and arrangements and a description of the steps taken to minimize the potential for bias resulting from the disclosed financial interests and arrangements (21 CFR § 54.4(a)(3)).  
[IP_ADDRESS]  FORM FDA 3454  Certification Fo rm 3454 shall be completed for any clinical 
investigator who has no disclosable financial interests in or arrangements with any sponsor of the covered clinical study (21 CFR § 54.4(a)(1)); the applicant may append a list of investigator names to a single F ORM FDA 3454 for those investigators with no 
disclosable financial interests or arrangements . 
 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   121 16.2  COMPLIANCE WITH  LOCAL STATE AND UNIVERSITY REGULATIONS & POLICY  
In addition to FDA regulations, I nvestigators at the University of [LOCATION_004] Los Angeles will follow UCLA 
Procedure  925.2:  Disclosing Financial Interests in Non -Governmental Sponsors of Contracts, Grants, 
and Material Transfer Agreements for Research. In addition, Investigators at the D ata Coordinating 
Center  and all participating clinical sites will be held to the ir applicable local State and University Conflict 
of Interest Regulations and Policies . Compliance will be certified as a condition of sub -contract  awards . 
 
17   EMERGENCY DISA STER/PANDEMIC MANAGE MENT PLAN  
Emergency disasters, including infectious outbreaks such as the Coronavirus Disease 2019 (COVID -19) 
pandemic, may disrupt patient access or the capacity for institutions to provide usual study care.  
Modifications to normal st udy operations including inclusion and exclusion criteria, screening and 
randomization, handling of study drugs, study visits, testing and site monitoring may be required in order to protect patients and maintain the integrity of the clinical trial.  
The emergency procedures described herein may be activated by [CONTACT_652794], in whole or in part and for an appropriate duration, in order to respond to the specific circumstances imposed by [CONTACT_652795].  
The declaration of an emergency situation and details regarding the exact components of the protocol 
that will be modified in response to the situation, will be codified in the Manual of Operations and 
distributed as Emergency Updates to all participating clinical sites, st udy investigators and staff, and 
study cores.  
Provisions that may be required to immediately protect patient well- being, as determined by [CONTACT_83671], may be immediately implemented. However, activation of an Emergency 
Disaster/Pandemic Management  Plan and the exact details of that plan are to be reported in a timely 
manner to the local IRB, the SLS III DSMB and to the FDA if required by [CONTACT_652796].  
Once activated, the specif ic provisions of the Emergency Disaster/Pandemic Management Plan will 
supercede normal study operations until the emergency is declared over by [CONTACT_19305]. While the Emergency Disaster/Pandemic Management Plan is active, following the provisions of that management plan will be considered consistent with the official Study Protocol and not designated as 
protocol deviations. The Data Coordinating Center will track related compliance and any missing study 
data due to the emergency.  
 
17.1  MODIFICATIONS TO INCLUSION AND EXCLUSION CRITERIA  
During an emergency, protocol -defined inclusion and exclusion criteria (detailed in the Protocol Sections 
5.1 and 5.2) will be reviewed to determine whether modifications are required. Such determinations will be based on the nature of the emergency and a resulting need to assure the safety of study participants and/or the integrity of the study.  
Potential modifications may include the following examples (not intended to be an  exclusive list):  
a) The age of study participants if required to protect the safety of an identified population at risk 
during the emergency.  
b) Testing for exposure to, or the presence of, an infection as may be required in a pandemic situation.  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   122 c) Additional screening blood tests or modification of existing allowable test thresholds (for 
example, allowable liver function or blood counts) as may be required to reduce or eliminate a disaster- specific risk.  
 
17.[ADDRESS_876365] of any emergency guidelines issued by [CONTACT_1622], Center for Disease Control (CDC) or related health advisory organization and determine whether the indications or contraindications for study drugs have changed and whether the nature of the emergency will impact on patient participation in the study.  Patient safety during an emergency will be considered the first priority.  All active study participants will be notified of potential risk to them posed by  [CONTACT_652797]/or their continued participation in the study. If necessary, study drugs 
may be shipped to patients during an emergency when on -site visits are not possible or not advised due 
to the nature of the emergency.  
 
17.2.1 Risk assignment during COVID -19 pandemic  
a) According to the CDC, adults age 65 or older, those with underlying lung disease, heart 
disease or diabetes, and individuals with an identified immune deficit are considered "at high 
risk" for complications from COVID -19 infection.   
b) Due to the presence of underlying lung disease in all study participants and their treatment with a study drug with immunosupressive properties, all active study participants will be 
notified that their underlying condition and its treatment according to the study define them 
as being "at high risk" for infectious complications from COVID -19 according to CDC criteria.  
 
17.2.2 Options for management of study drugs during COVID -19 pandemic  
a) Participants will be encouraged to follow all Center for Disease Control (CDC) and local public health guidelines to reduce exposure risk .  
c) In the absence of evidence that withdrawing treatment for their lung disease is advisable, participant s who are asymptomatic (from infectious perspective) are not recommended to 
stop study medication.  
d) However, subjects will be advised to communicate any fever or cold symptoms such as cough, chills or new shortness of breath with the local study team and their treating physicians as soon as possible.  
e) Section 6.1.5 .2 of the SLSIII protocol will be follow ed for dose management 
recommendations in the event of any signs of active infection. Per protocol and local investigator discretion, MMF may be held during an infection and doing so in this case should be considered in a timely manner.   
f) Study  participants  will be advised, as already noted in their signed study consent, that 
participation in the study is voluntary and participants  may decide to withdraw from drug 
treatment or the entire study at any time.  
g) While we are not advising the prophylactic suspensi on of MMF at this time, study 
participants are allowed to be off MMF for up to 60 days related to potential tolerability or 
toxicity issues and remain in the study (Section [IP_ADDRESS].i ). Any study participant that holds or 
suspends study drugs in this setti ng will be notified of their options and invited to remain in 
the study regardless of their decision about continuing with study drugs (see Protocol Section 7.2.5). 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876366] of COVID -19 on the operation of participating clinical sites and the perceived risk 
for study participants  in attending Medical Center visits during the pandemic, study drugs will be 
shipped as needed to the participant’s  home after compl etion of required "remote visit".  
a) Remote visits are required (as detailed in Section 17.4 below) to assess drug compliance and 
assure the safety of continued drug administration before prescribing.  
b) Shippi[INVESTIGATOR_652663] m easures and verification that study 
drugs were received by [CONTACT_2299].  
 
17.[ADDRESS_876367] OF THE E MERGENCY ON SCREENIN G AND RANDOMIZATION  
During an emergency, the ability to screen or randomize patients may be impaired due a disruption of services offered at a participating clinical site, issues with patient access, or concerns regarding the safety associatd with initiation of therapy during  the emergency. Options to be considered include:  
a) Proceed with screening and/or randomization if, after notification and consultation with the patient, it is determined to be in the patient's best interest to do so and if the participating clinical site can safely proceed and complete all of the study requirements.  
• A remote visit (as detailed in Section 17.4 below) may be utilized for aspects of the screening and randomization visits, but completion of the informed consent, screening vitals and physical examination must be completed in person.  
• Completion of required pulmonary function testing, mRSS test, and thoracic HRCT must be completed in person in order to meet eligibility criteria.  
b) Delay the completion of scheduled screening visits or planned random izations to a later time if 
the patient will be able to complete randomization within the allowed 90 days from the initiation of screening visit #1.  
c) Cancel further screening or randomization visits until such time as resources are available or it is deemed  safe to proceed. Any participant who has their screening or ran domization cancelled 
should be considered for re -screening when the emergency ends, but would be required to 
meet study inclusion and exclusion criteria at that time.  
 
17.4  ALLOWABLE MODIF ICAT IONS TO STUDY VISITS  AND PROCEDURES  
Study operations may be placed on complete hold or suspended during an emergency when institutional closures and/or perceived risk to the study population prohibit the safe conduct of the study. This determination will be made by [CONTACT_652798], who will be provided with a study closure mitigation plan to address participant  notification and referral to alternative care providers if possible under the 
circumstances. An early termination visit will be carried out as per Protocol Section 7.2.4 when possible.  
Alternatively, the study may convert in person (on -site) study visits to “remote study visits” in order to 
compensate for em ergency issues that limit either institutional or patient access.  
 
17.4.1 Conversion from in person to remote study visits  
a) Screening, baseline and follow -up visits, regardless of whether in  person or remote, are to 
be carried out within established visit windows.   
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   124 b) When an in person visit is converted to a remote visit, this may be carried out using a formal 
telemed or video conference system or by [CONTACT_652799].  
• Regardless of the mechanism employed, the rem ote visit encounter must be 
accompanied by [CONTACT_134405].  
• Study records should indicate when an in person visit is converted to a remote visit.  
• Study records should indicate whenever specific components of a study visit cannot be completed remotely due to the activation of the emergency protocol.  
c) Pre-specified phone follow -up visits are to continue as indicated in Section [IP_ADDRESS].  
 
17.4.2 Components of study visits that can be  carried out remotely  
a) Patient history or interim history. 
• Proceed using telemed, video or phone visits  
b) Review of concomitant medications  
• Proceed using telemed, video or phone visits  
c) Assessment of adverse events  
• Proceed using telemed, video or phone visits  
d) Modified study drug reconciliation  
• Proceed using telemed, video or phone visits  
• Review patient drug diary in detail and have patient provide copy for record if possible  
• Have participant  describe available medication supply  
• Direct pi[INVESTIGATOR_652664] 
e) Toxicity monitoring and pregnancy testing utilizing available commercial laboratories  
• Arrange for particpant  to have complete blood count with differential and platelet 
count, comprehensive metabolic panel and pregnancy testing completed at any available clinical laboratory  
• Pregnancy test may be carried out by [CONTACT_652800] 
• All clinical lab results must be collected and retained as source documents  
f) Study drug dispensing 
• Once a remote visit has been carried out and toxi city monitoring reviewed and 
approved, study drug may be shipped to the participant  as detailed in Section 17.2.3  
g) Patient reported outcomes (PROs)  
• Email or mail (with return envelope and postage) visit -specific questionnaires to 
participants to complete and follow -up with them within [ADDRESS_876368] completed and returned  them . 
• If preferred by [CONTACT_652801], questionnaires may be administered over the 
phone with the coordinator asking questions verbatim and stating all potential choices before recording participant  responses.  
• Note that the SHAQ VAS page cannot be completed by [CONTACT_648]; either ma il the DCC 
provided form to the participant  or skip  its administration. 
h) Modified Mahler Transitional Dyspnea Index  
• Complete the Mahler TDI, if required for the visit, by [CONTACT_648]  
i) Physician and Patient Global Assessments  
• Proceed using telemed, video or phone visits  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876369] examination or on -site completion may not be 
available during an emergency due to limitations in institutional or patient access. T hese components 
cannot be carried out remotely (by [CONTACT_652802]) and the inability to complete will 
require deviation from that described in Protocol Section 7.2, Study Schedule. Absence of the 
following test results for a remote visit should be so noted in the study record as due to “COVID -19 
Restrictions”  or other em ergency situation to address this deviation.  Missing assessments may be 
collect out of window or at next on -site study visit, if appropriate.  
a) Physical examination  
b) mRSS  
c) Pulmonary function tests (spi[INVESTIGATOR_023]).  
d) Thoracic HRCT  
e) Blood collection for Biolo gical Specimen Repository   
 
17.4. [ADDRESS_876370] for patients with SSc -ILD and 
required at routine intervals to monitor patients for the state of their lung disease, inter- current 
illnesses and treatment failures that might warrant additional evaluation and/ or management.  
In the setting of prolonged restrictions on travel  or institutional access , or when ongoing safety 
concerns limit the ability  for participating study patients to  complet e these outcome assessments at 
their assigned clinical site, the Executive Committee may allow such testing to be completed at a 
remote facility. Testing at remote facilities should be carried out in accord with ATS standards and 
by [CONTACT_652803] . All requests for remote PFTs must be reviewed and 
approved in advance  by [CONTACT_19305]. Testing will be carried out as a recommended 
standard -of-care clinical assessment  and therefore completed at the discretion of the study 
participant after being informed of the indications and potential financial implications.  Data 
generated from such assessments may be included as official study outcome measures if reviewed 
by [CONTACT_652804] y Function QA Core and determined to  meet minimum quality and reproducibility 
requirements.  
 
17.[ADDRESS_876371] of an emergency situation on institutional resources, study personnel and the capacity  to schedule and travel to visits, the time windows for the completion of study visits (as 
detailed in Protocol Section 7) may be extended by [CONTACT_8622] 30 days at the discretion of the Executive Committee. Decisions regarding the length  of extended visit windo ws will take into account  issues such 
as availability/access for visits, patient safety monitoring, standard -of-care and the presence of 
adequate study drug reserves.
 
 
18  LITERATURE REFERENCE S  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876372] survival while promoting alveolar epi[INVESTIGATOR_652665], CCAAT enhancer -binding homologous protein. Am J Respir Cell Mol Biol.  
2014;50(5):893 -902.  
2. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S. Double -blind, placebo -controlled trial of pi[INVESTIGATOR_530270]. Am J Respir Crit Care Med.  2005 May 1;171(9):1040- 7. 
3. Barnes J, Mayes MD. Epi[INVESTIGATOR_93211]: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Current Opi[INVESTIGATOR_652666] 2012:24(2):165 -170.  
4. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354(25):2667- 76. 
5. Beretta L, Santaniello A, Lemos A, et al.  Validity of the Saint George’s Respi[INVESTIGATOR_652667] -related quality of life in patients with interstitial lung disease secondary 
to systemic sclerosis. Rheumatology 2007; 46(2):296- 301 
6. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with 
systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581 -1586.  
7. Clements PJ, Roth MD, Elashoff R, Tashkin DP, et al. for the Scleroderma Lung Study.  Differences in the presentation and course of patients with limited versus diffuse Systemic sclerosis.  Ann Rheumatic Dis 2007; 66(12):1641 -7 
8. Colic M, Stojic -Vukanic Z, Pavlovic B, et al. Mycophenolate mofetil inhibits differentiation, 
maturation and a llostimulatory function of human monocyte derived dendritic cells. Clin Exper 
Immunol 2003; 134:63 -69. 
9. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis 
(scleroderma). A study of fifty -eight autopsy cases and fifty -eight matched controls. Am J Med. 1969 
Mar;46(3):428- 40. 
10. Denton CP. Scleroderma Lung Study II —clarity or obfuscation?  Lancet Respir Med.  Published online 
ahead of press: 25 July 2016, http://dx.doi.org/10.1016/S2213- 2600(16)[ZIP_CODE]- 6. 
11. Esbriet (pi[INVESTIGATOR_7735]) Investigator’s Brochure (RO0220912), Eleventh Version, F. Hoffmann -La [COMPANY_002] 
Ltd, July 2016.  
12. Esbriet Package Insert, NDA -022535, Genentech Inc., Approved Oct 15, 2014  
13. Fan MH, Feghali -Bostwick CA, Silver RM. Update on scleroderma- associated interstitial lung disease. 
Curr Opin Rheumatol. 2014;26(6):[ADDRESS_876373] DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, Khanna D, Li N, Elashoff R, Schraufnagel DE; Scleroderma Lung Study. Adverse events during the Scleroderma Lung Study. Am J 
Med. 2011; 124(5):459 -67. 
15. Gardner RM, Clausen JL, Epler GR, Hankinson JL, Permutt S, Plummer AL. Pulmonary function laboratory personnel qualifications. Am Rev Respir Dis 1986; 134:623 -4. 
16. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander C R, Ratoff J, 
Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU. Interstitial lung disease in 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   127 systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248 -54. 
doi: 10.1164/rccm.200706- 877OC. Epub 2008 Mar 27.  
17. Hankinson JL, Odencrantz JR, Fedan KB. Spi[INVESTIGATOR_11825] a sample of the general 
US population. Am J Respir Crit Care Med 1999; 159:179 -187.  
17a.  Hankinson  JL, Kawut  SM, Shahar  E, et al. Performance of American Thoracic  Society -
Recommended  Spi[INVESTIGATOR_652668] a Multiethnic Sample of Adults : The Multi -Ethnic 
Study of  Atherosclerosis (MESA) Lung Study . Chest 2010;  137: 138-145. 
18. Hinchcliff ME, Beaumont JL, Carns MA, Podlusky S, Thavarajah K, Varga J, Cella D, Chang RW. 
Longitudinal evaluation of PROMIS -29 and FACIT -dyspnea short forms in systemic sclerosis. J 
Rheumatol. 2015 Jan;42(1):64- 72. doi: 10.3899/jrheum.140143. Epub 2014 Nov 1.  
19. Hoyles RK, Ellis RW, Wellsbury J, et al. Fibrosing Alveolitis in Scleroderma Trial (FAST) – a multi- centre, 
prospective, randomized, double -blind, placebo -controlled trial of treatment with corticosteroids and 
intravenous cyclophosphamide followed by [CONTACT_652805]. Arth Rheum 2006; 54:3962 -70. 
20. Khanna D, Albera C, Fischer A, N. Khalidi, G. Raghu, L. Chung, D. Chen, E. Schiopu, 8, E. Gorina, M. 
Tagliaferri, J. R. Seibold. Safety And Tolerability Of Pi[INVESTIGATOR_652669] -
Associated Interstitial Lung Disease - The Lotuss Study. Am J Respir Crit Care Me d 191;2015:A1175 
21. Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen 
V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2016 Feb;68(2):299 -311. doi: 10.1002/art.[ZIP_CODE].  
22. Khanna D, Furst  DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: 
results of the D -penicillamine study. Ann Rheum Dis 2006;65:[ADDRESS_876374] Instrument. J Rheumatol. 2011 Sep;38(9):1920 -4. doi: 10.3899/jrheum.110225. Epub [ADDRESS_876375] Instrument. Arthritis Rheum. 2009 Sep 15;61(9):1257 -63. doi: 10.1002/art.[ADDRESS_876376] DE, et al. Minimally important differences in the Mahler’s Transition Dyspnoea Index in a large randomized controlled trial —results from the Scleroderma Lung Study. 
Rheumatology (Oxford) 2009;48:1537- 40. 
26. Khanna D, Yan X, Tash kin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold 
JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, F essler B, 
Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health -related quality of life in patients with active scleroderma lung disease: 
results from the scleroderma lung study. Arthritis Rheum. 2007 ; 56:1676- 84. 
27. Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, Strollo DC, Kleerup E, Chong D, Shah SK, Ahmad S, Abtin F, Tashkin DP, Goldin JG. Quantitative texture -based assessment of one -year 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876377] in scleroderma lung disease treated with oral 
cyclophosphamide. Eur Radiol. 2011 Dec;21(12):2455 -65. doi: 10.1007/s00330- 011-2223- 2. Epub 
2011 Sep 17.  
28. Kim HJ, Tashkin DP, Gjertson DW, Brown MS, Kleerup E, Chong S, Belperio JA, Roth MD, Abtin F, 
Elashoff R, Tseng CH, Khanna D, Goldin JG. Transitions to different patterns of interstitial lung 
disease in scleroderma with and without treatment. Ann Rheum Dis. 2016 Jul;75(7):1367 -71. doi: 
10.1136/annrheumdis -[ADDRESS_876378] WZ, C astro -Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins 
PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pi[INVESTIGATOR_652670]. N Engl J Med. 2014 May 29;370(22):2083- 92. 
30. Leconte S, Ferrant D, Dory V, Degryse J. Validated methods of cough assessment: a systematic review of the literature. Respi[INVESTIGATOR_1516]. 2011;81(2):161 -74. doi: 10.1159/000321231. Epub 2010 Nov 
13. Review.  
31. Little RJA. (1993). Pattern -mixture models for multivariate incomplete data.  Journal of the American 
Statistical Association 88:[ADDRESS_876379];22(10):1876 -
83. 
33. MacIntyre N, Crapo RO, Viegi G, et al. Standarisation of the single -breath determination of carbon 
monoxide uptake in the lung. (ATS/ERS Task Force: Standardisation of Lung Function Testing). Eur Respir J 2005; 26:720 -735.  
34. Miller MR, Hankinson J, Brusasco V, et al. Standadisation of spi[INVESTIGATOR_038]. (ATS/ERS Task Force: 
Standar disation of Lung Function Testing). Eur Respir J 2005; 26:319 -338.  
35. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, By[CONTACT_119980] J, Sahhar J, Roddy J, Gabbay E, 
Youssef P, Nash P, Zochling J, Proudman SM, Stevens W, Nikpour M. Extent of disease on high -
resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis -
related interstitial lung disease. Rheumatology (Oxford). 2013;52(1):155 -60.  
36. Nagai S, Hamada K. Shigematsu M, et al. 2002. Open -label compassionate use one -year treatment 
with pi[INVESTIGATOR_652671]. Intern Med 41: 1118 -1123.  
37. Neas LM, Schwartz J. The determinants of pulmonary diffusing capacity in a national sample of US adults. Am J Respir Crit Care Med 1996; 153:656 -64. 
38. Nikpo ur M, Baron M. Mortality in systemic sclerosis: lessons learned from population -based and 
observational cohort studies. Curr Opin Rheumatol 2014; 26(2):[ADDRESS_876380] WZ. et al. 2011. Pi[INVESTIGATOR_652672]): Two randomised trials. Lancet 377: 1760 -1769.  
40. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of Systemic Sclerosis. Front Immunol 2015; 6:272.  
41. Pellegrino R, Viegi G, Brusasco  V, Crapo RO, et al.  Interpretative strategies for lung function tests. 
(ATS/ERS Task Force: Standardisation of Lung Function Testing). Eur Respir J 2005; 26:948 -68. 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876381]. 1990;97(1):75 -83 
43. Raghu G1, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a 
new antifibrotic agent, pi[INVESTIGATOR_7735]: results of a prospective, ope n-label Phase II study.Am J Respir 
Crit Care Med. 1999 Apr;159(4 Pt 1):[ADDRESS_876382] DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM; Scleroderma Lung Study Research Group. Predicting treatmen t outcomes 
and responder subsets in scleroderma -related interstitial lung disease. Arthritis Rheum. 2011; 
63(9):2797- 808.  
45. Rubin D. (1976).  Inference and missing data (with discussion).  Biometrika 63:581- 592.  
46. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994 ; 37: 1283- 1289.  
47. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000 Nov;43(11):2437- 44. 
48. Steen VD, Medsger TA. Chan ges in causes of death in systemic sclerosis, 1997 –2002. Ann Rheum Dis 
2007; 66:940 –944.  
49. Taniguchi H, Ebina M, Kondoh Y, et al. 2010. Pi[INVESTIGATOR_260408]. Eur Respir J. 35:821- 829.  
50. Tashkin DP, Elashoff R, Clements PJ, et al. for t he Scleroderma Lung Study (SLS) Research Group. 
Effects of 1 -year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung 
disease. Am J Respir Crit Care Med 2007 177(10): 1026.  
51. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furs t DE, Arriola E, Silver R, Strange C, 
Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M for the 
Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung 
disease. N Engl J Med 2006; 354:[ADDRESS_876383] DE, Khanna D, MD, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R , Wigley F, Mayes M, Riley DJ, Hussain S, 
Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga, MD J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T , Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng C -H, Elashoff RM, 
for the Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma -related interstitial lung disease (SLS II): a randomised cont rolled, 
double -blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708 -19. 
53. Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. 2012 Sep;142(3):614- 21. 
54. Tyndall AJ, Bannert B, Vonk M, Airò P , Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller- Ladner U, 
Distler O, Iannone F, Pellerito R, Pi[INVESTIGATOR_652673] M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, R ozman 
B, Ton E, Kumánovics G, Coleiro B, Feierl E, Szucs G, Von Mühlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kötter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, 
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: 135848   130 Rednic S, Stork J, Morovic- Vergles J, Walker UA. Causes and risk factors for death in systemic 
sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum 
Dis. 2010; 69(10):1809- 15.  
55. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci -Cerinic M, Naden 
RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal- Bielecka O, 
Müller- Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, 
Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of 
rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747- 55. 
56. Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis. 2008;66(3):198 -202.  
57. White B. Pulmonary fibrosis and pulmonary vascular involvement in systemic sclerosis. 9a. Pulmonary fibrosis in systemic sclerosis. In Systemic Sclerosis, 2nd edition (PJ Clements, DE Furst, edit). Lippi[INVESTIGATOR_10354], 
Williams, & Wilkins, [LOCATION_001], NY. 2004:[ADDRESS_876384] HR, Ryerson CJ. Predictors 
of mortality and progression in scleroderma- associated interstitial lung disease: a systematic review. 
Chest. 2014;146(2):422- 36.  
 
  
Scleroderma Lung Study III                                           [Confidential]  Version 2.5  
Protocol #UCLA -SLS3  11/17/21  
FDA IND #: [ADDRESS_876385]  
 
Version  Date  Description  Significant Revisions  
1.0 04/25/17  App #A: Study Questionnaires   
     1.1 07/2019  App #B: Drug Packaging Inserts  Pi[INVESTIGATOR_7735] (Esbriet) drug packaging 
insert updated  
 
 